US20190082678A1 - Compositions and methods for tissue preservation at ambient or subnormothermic temperatures - Google Patents
Compositions and methods for tissue preservation at ambient or subnormothermic temperatures Download PDFInfo
- Publication number
- US20190082678A1 US20190082678A1 US15/735,089 US201615735089A US2019082678A1 US 20190082678 A1 US20190082678 A1 US 20190082678A1 US 201615735089 A US201615735089 A US 201615735089A US 2019082678 A1 US2019082678 A1 US 2019082678A1
- Authority
- US
- United States
- Prior art keywords
- somah
- composition
- hearts
- storage
- organ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 199
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000004321 preservation Methods 0.000 title description 47
- 210000000056 organ Anatomy 0.000 claims abstract description 177
- 210000002216 heart Anatomy 0.000 claims description 368
- 239000000243 solution Substances 0.000 claims description 138
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 86
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 78
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 76
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 76
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 76
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 75
- 235000002639 sodium chloride Nutrition 0.000 claims description 68
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 63
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 57
- 239000012266 salt solution Substances 0.000 claims description 56
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 56
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 52
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 51
- 239000008103 glucose Substances 0.000 claims description 49
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 44
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 44
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 44
- 108090001061 Insulin Proteins 0.000 claims description 43
- 102000004877 Insulin Human genes 0.000 claims description 43
- 229940125396 insulin Drugs 0.000 claims description 43
- 108010087806 Carnosine Proteins 0.000 claims description 42
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 41
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 40
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 40
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 40
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 39
- 229960005305 adenosine Drugs 0.000 claims description 39
- 239000001103 potassium chloride Substances 0.000 claims description 38
- 235000011164 potassium chloride Nutrition 0.000 claims description 38
- DROVUXYZTXCEBX-WCCKRBBISA-N (2s)-2-amino-5-(carbamoylamino)pentanoic acid;2-hydroxybutanedioic acid Chemical compound OC(=O)C(O)CC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=O DROVUXYZTXCEBX-WCCKRBBISA-N 0.000 claims description 35
- 229960002173 citrulline Drugs 0.000 claims description 35
- 229940120124 dichloroacetate Drugs 0.000 claims description 35
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 35
- 229910001414 potassium ion Inorganic materials 0.000 claims description 35
- 108010024636 Glutathione Proteins 0.000 claims description 34
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 33
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 33
- 238000002054 transplantation Methods 0.000 claims description 32
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 30
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 30
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 29
- 235000013477 citrulline Nutrition 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 28
- 239000004475 Arginine Substances 0.000 claims description 27
- 229960003180 glutathione Drugs 0.000 claims description 27
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 27
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 26
- 235000010323 ascorbic acid Nutrition 0.000 claims description 26
- 239000011668 ascorbic acid Substances 0.000 claims description 26
- 229960005070 ascorbic acid Drugs 0.000 claims description 26
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 26
- 235000011009 potassium phosphates Nutrition 0.000 claims description 26
- 239000001488 sodium phosphate Substances 0.000 claims description 26
- 235000011008 sodium phosphates Nutrition 0.000 claims description 26
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 24
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 23
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 23
- 239000001110 calcium chloride Substances 0.000 claims description 23
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 23
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 22
- 229940044199 carnosine Drugs 0.000 claims description 22
- 229960003624 creatine Drugs 0.000 claims description 22
- 239000006046 creatine Substances 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 229960005010 orotic acid Drugs 0.000 claims description 22
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 22
- 235000011148 calcium chloride Nutrition 0.000 claims description 21
- 229960004203 carnitine Drugs 0.000 claims description 21
- 235000011147 magnesium chloride Nutrition 0.000 claims description 21
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 21
- 235000000346 sugar Nutrition 0.000 claims description 20
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 19
- 239000001630 malic acid Substances 0.000 claims description 19
- 235000011090 malic acid Nutrition 0.000 claims description 19
- 229940099690 malic acid Drugs 0.000 claims description 19
- 238000001356 surgical procedure Methods 0.000 claims description 19
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 18
- 239000008121 dextrose Substances 0.000 claims description 13
- 210000004072 lung Anatomy 0.000 claims description 8
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 7
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 abstract description 23
- 239000011575 calcium Substances 0.000 abstract description 14
- 229910052791 calcium Inorganic materials 0.000 abstract description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 12
- 239000011777 magnesium Substances 0.000 abstract description 7
- 239000011734 sodium Substances 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052700 potassium Inorganic materials 0.000 abstract description 4
- 239000011591 potassium Substances 0.000 abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 2
- 230000007102 metabolic function Effects 0.000 abstract description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000004898 mitochondrial function Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 108700004900 Somah Proteins 0.000 description 280
- 238000003860 storage Methods 0.000 description 272
- 210000001519 tissue Anatomy 0.000 description 109
- 210000004185 liver Anatomy 0.000 description 104
- 230000010410 reperfusion Effects 0.000 description 90
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 88
- 210000003734 kidney Anatomy 0.000 description 76
- 229960001031 glucose Drugs 0.000 description 74
- 108700027941 Celsior Proteins 0.000 description 65
- 230000010412 perfusion Effects 0.000 description 52
- -1 ammonium ions Chemical class 0.000 description 47
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 46
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 46
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 44
- 235000001727 glucose Nutrition 0.000 description 42
- 230000001965 increasing effect Effects 0.000 description 40
- 230000000670 limiting effect Effects 0.000 description 37
- 229910019142 PO4 Inorganic materials 0.000 description 36
- 230000000747 cardiac effect Effects 0.000 description 36
- 235000021317 phosphate Nutrition 0.000 description 36
- 238000009472 formulation Methods 0.000 description 34
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 102000004420 Creatine Kinase Human genes 0.000 description 28
- 108010042126 Creatine kinase Proteins 0.000 description 28
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 229960004826 creatine monohydrate Drugs 0.000 description 27
- 235000009697 arginine Nutrition 0.000 description 25
- 230000008859 change Effects 0.000 description 25
- 230000004060 metabolic process Effects 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 230000006378 damage Effects 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- 230000002631 hypothermal effect Effects 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 235000003969 glutathione Nutrition 0.000 description 22
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 22
- ROOICMQQLCQCBE-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2,4-dioxo-1h-pyrimidine-6-carboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)C1=CC(=O)NC(=O)N1 ROOICMQQLCQCBE-UHFFFAOYSA-N 0.000 description 21
- 241000605059 Bacteroidetes Species 0.000 description 20
- 229960002337 magnesium chloride Drugs 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 238000010009 beating Methods 0.000 description 17
- 238000001574 biopsy Methods 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 16
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 16
- 210000000709 aorta Anatomy 0.000 description 16
- 230000002503 metabolic effect Effects 0.000 description 16
- 210000003470 mitochondria Anatomy 0.000 description 16
- 230000007423 decrease Effects 0.000 description 15
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 14
- 210000004413 cardiac myocyte Anatomy 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 14
- 239000010452 phosphate Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 13
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 13
- 229960005069 calcium Drugs 0.000 description 13
- 235000001465 calcium Nutrition 0.000 description 13
- 229940100084 cardioplegia solution Drugs 0.000 description 13
- 230000004087 circulation Effects 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 238000013175 transesophageal echocardiography Methods 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 230000002861 ventricular Effects 0.000 description 12
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 11
- 108090000371 Esterases Proteins 0.000 description 11
- 230000004075 alteration Effects 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 210000000941 bile Anatomy 0.000 description 11
- 229910001424 calcium ion Inorganic materials 0.000 description 11
- 230000008602 contraction Effects 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 150000004688 heptahydrates Chemical class 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 11
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 210000003492 pulmonary vein Anatomy 0.000 description 11
- 210000005084 renal tissue Anatomy 0.000 description 11
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- 229930064664 L-arginine Natural products 0.000 description 10
- 235000014852 L-arginine Nutrition 0.000 description 10
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 10
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 10
- 229960003121 arginine Drugs 0.000 description 10
- 230000005779 cell damage Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 210000005003 heart tissue Anatomy 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 10
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 10
- 239000003761 preservation solution Substances 0.000 description 10
- 230000000451 tissue damage Effects 0.000 description 10
- 230000035899 viability Effects 0.000 description 10
- 206010063837 Reperfusion injury Diseases 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 238000001493 electron microscopy Methods 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000002407 ATP formation Effects 0.000 description 8
- 102000003951 Erythropoietin Human genes 0.000 description 8
- 108090000394 Erythropoietin Proteins 0.000 description 8
- 208000010496 Heart Arrest Diseases 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 210000005242 cardiac chamber Anatomy 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 238000002845 discoloration Methods 0.000 description 8
- 229940105423 erythropoietin Drugs 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 238000003306 harvesting Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 8
- 239000000162 organ preservation solution Substances 0.000 description 8
- 230000036284 oxygen consumption Effects 0.000 description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 8
- 210000001147 pulmonary artery Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000036962 time dependent Effects 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 7
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 7
- 230000003385 bacteriostatic effect Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000013194 cardioversion Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000001952 enzyme assay Methods 0.000 description 7
- 238000013401 experimental design Methods 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 239000001272 nitrous oxide Substances 0.000 description 7
- 239000000082 organ preservation Substances 0.000 description 7
- 230000010287 polarization Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 230000002123 temporal effect Effects 0.000 description 7
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
- 229930182837 (R)-adrenaline Natural products 0.000 description 6
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 208000021709 Delayed Graft Function Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000002592 echocardiography Methods 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 229960005139 epinephrine Drugs 0.000 description 6
- 230000010247 heart contraction Effects 0.000 description 6
- 230000004217 heart function Effects 0.000 description 6
- 210000002989 hepatic vein Anatomy 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000002427 irreversible effect Effects 0.000 description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 6
- 229940099563 lactobionic acid Drugs 0.000 description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 241000218691 Cupressaceae Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000000013 bile duct Anatomy 0.000 description 5
- 230000002425 cardiocirculatory effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010835 comparative analysis Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 210000002767 hepatic artery Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000000297 inotrophic effect Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 210000001700 mitochondrial membrane Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- 210000001631 vena cava inferior Anatomy 0.000 description 5
- 238000011265 2D-echocardiography Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 206010049993 Cardiac death Diseases 0.000 description 4
- 102000009193 Caveolin Human genes 0.000 description 4
- 108050000084 Caveolin Proteins 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 206010011906 Death Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 208000003591 Hepatoerythropoietic Porphyria Diseases 0.000 description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 4
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 230000010001 cellular homeostasis Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 230000005786 degenerative changes Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000004116 glycogenolysis Effects 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 229940049920 malate Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000010627 oxidative phosphorylation Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 210000003240 portal vein Anatomy 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium peroxide Inorganic materials [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 4
- 238000002731 protein assay Methods 0.000 description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 208000037816 tissue injury Diseases 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 102000010825 Actinin Human genes 0.000 description 3
- 108010063503 Actinin Proteins 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000013534 Troponin C Human genes 0.000 description 3
- 102000013394 Troponin I Human genes 0.000 description 3
- 108010065729 Troponin I Proteins 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000006538 anaerobic glycolysis Effects 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 238000007675 cardiac surgery Methods 0.000 description 3
- YXSLJKQTIDHPOT-LJCJQEJUSA-N cisatracurium Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1[N@+](CCC(=O)OCCCCCOC(=O)CC[N@+]2(C)[C@@H](C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-LJCJQEJUSA-N 0.000 description 3
- 238000013075 data extraction Methods 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 150000004687 hexahydrates Chemical class 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 3
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 229960002378 oftasceine Drugs 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 150000004686 pentahydrates Chemical class 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 230000036316 preload Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000007388 punch biopsy Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004926 tubular epithelial cell Anatomy 0.000 description 3
- 230000002477 vacuolizing effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- 229960001600 xylazine Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229910001369 Brass Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000002585 Contractile Proteins Human genes 0.000 description 2
- 108010068426 Contractile Proteins Proteins 0.000 description 2
- 241000270722 Crocodylidae Species 0.000 description 2
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 2
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 2
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 238000012752 Hepatectomy Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- QZNPNKJXABGCRC-LFRDXLMFSA-N L-fuculose Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)C(=O)CO QZNPNKJXABGCRC-LFRDXLMFSA-N 0.000 description 2
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000036586 afterload Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000010951 brass Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 230000001101 cardioplegic effect Effects 0.000 description 2
- 230000037198 cardiovascular physiology Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960000358 cisatracurium Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000000222 hyperoxic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 2
- 150000002581 ketopentoses Chemical class 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010291 membrane polarization Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000010016 myocardial function Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000037000 normothermia Effects 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 229960004134 propofol Drugs 0.000 description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- 230000002488 pyknotic effect Effects 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960003394 remifentanil Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940052907 telazol Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000028973 vesicle-mediated transport Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- WCLKSQYCWXZMGX-UHFFFAOYSA-N 1,2,3,4-tetrabromo-5,6-dimethoxybenzene Chemical compound COC1=C(Br)C(Br)=C(Br)C(Br)=C1OC WCLKSQYCWXZMGX-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- SIWNEELMSUHJGO-UHFFFAOYSA-N 2-(4-bromophenyl)-4,5,6,7-tetrahydro-[1,3]oxazolo[4,5-c]pyridine Chemical compound C1=CC(Br)=CC=C1C(O1)=NC2=C1CCNC2 SIWNEELMSUHJGO-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- PGYDGBCATBINCB-UHFFFAOYSA-N 4-diethoxyphosphoryl-n,n-dimethylaniline Chemical compound CCOP(=O)(OCC)C1=CC=C(N(C)C)C=C1 PGYDGBCATBINCB-UHFFFAOYSA-N 0.000 description 1
- MVXMNHYVCLMLDD-UHFFFAOYSA-N 4-methoxynaphthalene-1-carbaldehyde Chemical compound C1=CC=C2C(OC)=CC=C(C=O)C2=C1 MVXMNHYVCLMLDD-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- RMBBSOLAGVEUSI-UHFFFAOYSA-H Calcium arsenate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-][As]([O-])([O-])=O.[O-][As]([O-])([O-])=O RMBBSOLAGVEUSI-UHFFFAOYSA-H 0.000 description 1
- 239000004154 Calcium bromate Substances 0.000 description 1
- 239000005997 Calcium carbide Substances 0.000 description 1
- CBOCVOKPQGJKKJ-UHFFFAOYSA-L Calcium formate Chemical compound [Ca+2].[O-]C=O.[O-]C=O CBOCVOKPQGJKKJ-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 239000004151 Calcium iodate Substances 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- 239000004343 Calcium peroxide Substances 0.000 description 1
- 239000006009 Calcium phosphide Substances 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010070589 Ischaemic contracture of the left ventricle Diseases 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 229910020451 K2SiO3 Inorganic materials 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 229910021055 KNH2 Inorganic materials 0.000 description 1
- 229910021135 KPF6 Inorganic materials 0.000 description 1
- RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229910021322 Mg2Al3 Inorganic materials 0.000 description 1
- 229910019752 Mg2Si Inorganic materials 0.000 description 1
- 229910020056 Mg3N2 Inorganic materials 0.000 description 1
- 229910020073 MgB2 Inorganic materials 0.000 description 1
- 229910020101 MgC2 Inorganic materials 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010064966 Myocardial oedema Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 229910003424 Na2SeO3 Inorganic materials 0.000 description 1
- 229910020293 Na2Ti3O7 Inorganic materials 0.000 description 1
- 229910020344 Na2Zn Inorganic materials 0.000 description 1
- 229910003252 NaBO2 Inorganic materials 0.000 description 1
- 229910018954 NaNH2 Inorganic materials 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241001325280 Tricardia watsonii Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 239000012840 University of Wisconsin (UW) solution Substances 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- CWVZGJORVTZXFW-UHFFFAOYSA-N [benzyl(dimethyl)silyl]methyl carbamate Chemical compound NC(=O)OC[Si](C)(C)CC1=CC=CC=C1 CWVZGJORVTZXFW-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000000758 acidotic effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910001617 alkaline earth metal chloride Inorganic materials 0.000 description 1
- 229910000316 alkaline earth metal phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- NGLMYMJASOJOJY-UHFFFAOYSA-O azanium;calcium;nitrate Chemical compound [NH4+].[Ca].[O-][N+]([O-])=O NGLMYMJASOJOJY-UHFFFAOYSA-O 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000000404 calcium aluminium silicate Substances 0.000 description 1
- 235000012215 calcium aluminium silicate Nutrition 0.000 description 1
- WNCYAPRTYDMSFP-UHFFFAOYSA-N calcium aluminosilicate Chemical compound [Al+3].[Al+3].[Ca+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O WNCYAPRTYDMSFP-UHFFFAOYSA-N 0.000 description 1
- 229940078583 calcium aluminosilicate Drugs 0.000 description 1
- 229940103357 calcium arsenate Drugs 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- UETLMBWMVIQIGU-UHFFFAOYSA-N calcium azide Chemical compound [Ca+2].[N-]=[N+]=[N-].[N-]=[N+]=[N-] UETLMBWMVIQIGU-UHFFFAOYSA-N 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- LVGQIQHJMRUCRM-UHFFFAOYSA-L calcium bisulfite Chemical compound [Ca+2].OS([O-])=O.OS([O-])=O LVGQIQHJMRUCRM-UHFFFAOYSA-L 0.000 description 1
- 235000019397 calcium bromate Nutrition 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- YALMXYPQBUJUME-UHFFFAOYSA-L calcium chlorate Chemical compound [Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O YALMXYPQBUJUME-UHFFFAOYSA-L 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 229940092124 calcium citrate malate Drugs 0.000 description 1
- HAUBPZADNMBYMB-UHFFFAOYSA-N calcium copper Chemical compound [Ca].[Cu] HAUBPZADNMBYMB-UHFFFAOYSA-N 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 239000004221 calcium diglutamate Substances 0.000 description 1
- 235000013921 calcium diglutamate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- BLORRZQTHNGFTI-ZQGCMTCUSA-L calcium erythorbate Chemical compound [Ca+2].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZQGCMTCUSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 229940095626 calcium fluoride Drugs 0.000 description 1
- 229940044172 calcium formate Drugs 0.000 description 1
- 235000019255 calcium formate Nutrition 0.000 description 1
- 239000004281 calcium formate Substances 0.000 description 1
- 229960002283 calcium glubionate Drugs 0.000 description 1
- YPCRNBPOUVJVMU-LCGAVOCYSA-L calcium glubionate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YPCRNBPOUVJVMU-LCGAVOCYSA-L 0.000 description 1
- 229960002562 calcium glucoheptonate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 229940041134 calcium glycerylphosphate Drugs 0.000 description 1
- KAFMRSAFJZENBN-GWTDSMLYSA-L calcium guanylate Chemical compound [Ca+2].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O KAFMRSAFJZENBN-GWTDSMLYSA-L 0.000 description 1
- 239000004244 calcium guanylate Substances 0.000 description 1
- 235000013900 calcium guanylate Nutrition 0.000 description 1
- 235000010260 calcium hydrogen sulphite Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- ZLHWLLPKQPKYJD-MCDZGGTQSA-L calcium inosinate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 ZLHWLLPKQPKYJD-MCDZGGTQSA-L 0.000 description 1
- 239000004197 calcium inosinate Substances 0.000 description 1
- 235000013893 calcium inosinate Nutrition 0.000 description 1
- UHWJJLGTKIWIJO-UHFFFAOYSA-L calcium iodate Chemical compound [Ca+2].[O-]I(=O)=O.[O-]I(=O)=O UHWJJLGTKIWIJO-UHFFFAOYSA-L 0.000 description 1
- 235000019390 calcium iodate Nutrition 0.000 description 1
- 229940046413 calcium iodide Drugs 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- PWKNEBQRTUXXLT-ZBHRUSISSA-L calcium lactate gluconate Chemical compound [Ca+2].CC(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O PWKNEBQRTUXXLT-ZBHRUSISSA-L 0.000 description 1
- 229940041131 calcium lactate gluconate Drugs 0.000 description 1
- 229910000099 calcium monohydride Inorganic materials 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229940087373 calcium oxide Drugs 0.000 description 1
- 229960003144 calcium pangamate Drugs 0.000 description 1
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 description 1
- 235000019402 calcium peroxide Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 229910021346 calcium silicide Inorganic materials 0.000 description 1
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
- 235000010244 calcium sorbate Nutrition 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- JGIATAMCQXIDNZ-UHFFFAOYSA-N calcium sulfide Chemical compound [Ca]=S JGIATAMCQXIDNZ-UHFFFAOYSA-N 0.000 description 1
- GBAOBIBJACZTNA-UHFFFAOYSA-L calcium sulfite Chemical compound [Ca+2].[O-]S([O-])=O GBAOBIBJACZTNA-UHFFFAOYSA-L 0.000 description 1
- 235000010261 calcium sulphite Nutrition 0.000 description 1
- GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 description 1
- 239000001427 calcium tartrate Substances 0.000 description 1
- 235000011035 calcium tartrate Nutrition 0.000 description 1
- AOWKSNWVBZGMTJ-UHFFFAOYSA-N calcium titanate Chemical compound [Ca+2].[O-][Ti]([O-])=O AOWKSNWVBZGMTJ-UHFFFAOYSA-N 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
- JWLAOERSRUNGEF-JQVJEGKNSA-L calcium;(2r,3s,4r,5r)-6-[2-(dimethylamino)acetyl]oxy-2,3,4,5-tetrahydroxyhexanoate Chemical compound [Ca+2].CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O JWLAOERSRUNGEF-JQVJEGKNSA-L 0.000 description 1
- UMVAYAXXQSFULN-QHTZZOMLSA-L calcium;(2s)-2-aminopentanedioate;hydron Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O UMVAYAXXQSFULN-QHTZZOMLSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 description 1
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- LUYGICHXYUCIFA-UHFFFAOYSA-H calcium;dimagnesium;hexaacetate Chemical compound [Mg+2].[Mg+2].[Ca+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O LUYGICHXYUCIFA-UHFFFAOYSA-H 0.000 description 1
- BCFSVSISUGYRMF-UHFFFAOYSA-N calcium;dioxido(dioxo)chromium;dihydrate Chemical compound O.O.[Ca+2].[O-][Cr]([O-])(=O)=O BCFSVSISUGYRMF-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 1
- 230000001959 cardiohemodynamic effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229910001914 chlorine tetroxide Inorganic materials 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003624 condensation of chromatin Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- GTSMOYLSFUBTMV-UHFFFAOYSA-N ethidium homodimer Chemical compound [H+].[H+].[Cl-].[Cl-].[Cl-].[Cl-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2C(C)=[N+]1CCCNCCNCCC[N+](C1=CC(N)=CC=C1C1=CC=C(N)C=C11)=C1C1=CC=CC=C1 GTSMOYLSFUBTMV-UHFFFAOYSA-N 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052839 forsterite Inorganic materials 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000037183 heart physiology Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 230000003494 hepatotrophic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002895 hyperchromatic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052909 inorganic silicate Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000010872 live dead assay kit Methods 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- 229910012375 magnesium hydride Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Inorganic materials [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 1
- QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 description 1
- 229960000407 magnesium orotate Drugs 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- VPJZAANERLRQHG-UHFFFAOYSA-K magnesium potassium hydrogen phosphate chloride Chemical compound [Mg+2].[Cl-].[K+].P(=O)(O)([O-])[O-] VPJZAANERLRQHG-UHFFFAOYSA-K 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- OUZIIFOEMPAZKX-UHFFFAOYSA-N n-[2-(2-chlorophenyl)sulfanylethyl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]sulfonylpropanamide Chemical compound C=1C=C(C(F)(F)F)C=NC=1S(=O)(=O)C(C)(C)C(=O)NCCSC1=CC=CC=C1Cl OUZIIFOEMPAZKX-UHFFFAOYSA-N 0.000 description 1
- 229910021527 natrosilite Inorganic materials 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 229940035480 nimbex Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 1
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- VBKNTGMWIPUCRF-UHFFFAOYSA-M potassium;fluoride;hydrofluoride Chemical compound F.[F-].[K+] VBKNTGMWIPUCRF-UHFFFAOYSA-M 0.000 description 1
- GVPLVOGUVQAPNJ-UHFFFAOYSA-M potassium;hydron;trioxido(oxo)-$l^{5}-arsane Chemical compound [K+].O[As](O)([O-])=O GVPLVOGUVQAPNJ-UHFFFAOYSA-M 0.000 description 1
- UMPKMCDVBZFQOK-UHFFFAOYSA-N potassium;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[K+].[Fe+3] UMPKMCDVBZFQOK-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910001388 sodium aluminate Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 1
- NVIFVTYDZMXWGX-UHFFFAOYSA-N sodium metaborate Chemical compound [Na+].[O-]B=O NVIFVTYDZMXWGX-UHFFFAOYSA-N 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- CLZWAWBPWVRRGI-UHFFFAOYSA-N tert-butyl 2-[2-[2-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-5-bromophenoxy]ethoxy]-4-methyl-n-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]anilino]acetate Chemical compound CC1=CC=C(N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)C(OCCOC=2C(=CC=C(Br)C=2)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)=C1 CLZWAWBPWVRRGI-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- VLCLHFYFMCKBRP-UHFFFAOYSA-N tricalcium;diborate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]B([O-])[O-].[O-]B([O-])[O-] VLCLHFYFMCKBRP-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000010153 Šidák test Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0236—Mechanical aspects
- A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
- A01N1/0247—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components for perfusion, i.e. for circulating fluid through organs, blood vessels or other living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Definitions
- This invention relates, inter alia, to compositions and methods to preserve biological tissues and organs over relatively long periods of time at ambient temperatures.
- compositions and methods described herein represent a significant improvement and advantage over existing methods for organ storage and/or preservation of organs from Beating Heart Donors (BHD), marginal, and Donation after Cardiac Death (DCD) donors.
- BHD Beating Heart Donors
- DCD Donation after Cardiac Death
- the improved storage/preservation solutions e.g., improved Somali (iSomah)
- Exposure of an organ, e.g., a heart, to hypothermia leads to injury and even damage to the organ.
- the concentration of potassium ions and magnesium ions in the solutions described herein are increased (compared to other storage or cardioplegia solutions) to induce temporary paralysis of the heart tissue during subnormothermic storage (e.g., 10-25° C.)), while simultaneously maintaining HEP synthesis, cellular homeostasis, nitric oxide generation (additionally by chelating toxic ammonium ions generated from transaminase reactions; see FIG. 33 ). This results in increased activity of the nitric oxide synthetic pathway in all tissues and organs and accompanying physiological control of edema.
- Cardioplegia is an intentional and temporary cessation of cardiac activity. Such a temporary arresting of the heartbeat is carried out by any of various methods such as by injection or infusion of chemical substances such as a cardioplegia solution. For example, the heart is stopped in such a manner for cardiac surgery. Such surgeries include bypass surgery, heart valve replacement, aorta repair surgery, and heart transplantation etc.
- the solutions provide other advantages such as reduced cost, potentially reduced need for immunosuppression following transplantation because of minimal endothelial and tissue damage to the heart, reduced need for inotropic support (e.g., drugs are not required to increase heart contraction) and incessant electroversions to maintain sinus cardiac function, decreased CPB time, as well as stay in the ICU and hospital (hence, decreased costs). Additionally, use of the organ preservation solutions provided herein result in decreased patient morbidity and improved long-term outcomes and thus most importantly improved quality of life of the patients.
- the solution is flushed out of the heart tissue during surgery. The organ then goes into sinus conversion and resumes beating upon reperfusion with blood and rewarming, in vitro; or upon release of cross-clamp upon transplantation and during rewarming the patient to normothermia.
- compositions, methods, and kits for preserving or resuscitating biological tissues or organs at ambient temperatures are provided herein, inter aliu.
- compositions for preserving or resuscitating biological tissue or organs comprising: a physiological salt solution, glucose (or other sugars such as lactose, maltose, and/or ribose) at concentrations of any of about 5-10 mM, such as about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM), and one or more of glutathione, ascorbic acid, arginine, citrulline malate (or, optionally, citrulline or salts thereof and/or malic acid or salts thereof), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereolf), orotic acid (or salts thereof) carnosine (such as, L-carnosine), carnitine (such as, L-carnitine), orotic acid, and/or dichloroacetate at concentrations of between 0 mM to about 5 mM),
- organ storage solutions described herein containing at least 20 mM potassium ions and/or at least 37 mM magnesium ions exhibit superior properties with respect to protecting and preserving organs during storage and during procedures such as cardioplegia over a more varied range of storage conditions (for example, temperature) compared to previously described organ storage solutions (see U.S. Pat. No. 8,211,628, the disclosure of which is incorporated by reference herein).
- the storage solutions disclosed herein are referred to as “improved Somah” (iSomah).
- compositions for preserving mammalian organs comprising: a physiological salt solution, and one or more of a five or six carbon sugar (such as, ribose, glucose or dextrose), glutathione, ascorbic acid, arginine, citrulline (such as, citrulline malate), malic acid, adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), carnosine (such as, L-carnosine), carnitine (such as, L-carnitine), orotic acid, and/or dichloroacetate, wherein the composition or the organ is maintained at a temperature of 21 ⁇ 4° C.
- a physiological salt solution such as, ribose, glucose or dextrose
- glutathione such as, ascorbic acid
- citrulline such as, citrulline malate
- malic acid such as, adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), carnosine
- the composition or the organ is maintained at a temperature of 21 ⁇ 4° C.
- the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions.
- the composition further comprises insulin.
- insulin is added to the composition just prior to use.
- the physiological salt solution comprises one or more salts selected from the group consisting of potassium phosphate, potassium chloride, sodium chloride, sodium bicarbonate, calcium chloride, sodium phosphate, magnesium chloride, magnesium sulfate.
- the composition comprises 0.44-10 mM of potassium phosphate. In some embodiments of any of the embodiments disclosed herein, the composition comprises 4-65 mM of potassium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 80-135 mM sodium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 2-25 mM sodium bicarbonate. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0-1.5 mM calcium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0.15-30 mM sodium phosphate. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0.5-45 mM magnesium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0.5-1.5 mM magnesium sulfate.
- the physiologically-compatible solutions (modified Somah) described herein are useful as a cardioplegia solution for arresting hearts over a temperature range encountered during open heart surgery and for donor and recipient hearts for and during transplantation.
- the solution contains 20 mM potassium ions, e.g., 20 mM KCl, final concentration; at 10-25° C., the solution contains 20 mM potassium ions. e.g., 20 mM KCl and 37 mM magnesium ions, e.g., 37 mM MgCl 2 , final concentration; at 25-37° C. the solution contains 45 mM potassium ions.
- the solution contains 25 mM potassium ions, e.g., 25 mM KCl, and 37 mM Magnesium ions, e.g., 37 mM MgCl 2 .
- organ arrest e.g., heart cardioplegia
- organ storage e.g., heart, lung, or other organ storage ex vivo
- potassium ion and magnesium ion concentrations e.g., concentrations of KCl and MgCl 2
- hearts are arrested with Somah cardioplegia containing 20 mM KCl (range 4.0-65 mM) and 37 mM MgCl 2 (range 1.5-45 mM) at 4-37° C. and preserved in the same solution at 4-37° C. for transplant.
- lungs are preserved in modified Somah containing 7.5 mM KCl and 2 mM MgCl 2 at 4-37° C. as well as in Somah containing 20 mM KCl (range 4.0-65 mM) and 37 mM MgCl 2 (range 1.5-45 mM) at 4-37° C. for transplant.
- kits for storing, preserving or resuscitating a biological tissue or organ comprising bringing said biological tissue or organ into contact with any of the compositions disclosed herein or above.
- the composition is maintained at a temperature of 10-21 ⁇ 4° C.
- the biological tissue or organs are stored or preserved for 24-72 hours.
- the biological tissue or organ is selected from the group consisting of heart, kidney, liver, stomach, spleen, skin, pancreas, lung, brain, eye, intestines, and bladder.
- the amount of high energy phosphates are higher in the biological tissue or organ following preservation or resuscitation compared to biological tissue or organs not contacted with the composition.
- the organ is a heart.
- coronary blood flow is higher in the biological tissue or organ following preservation or resuscitation compared to biological tissue or organs not contacted with the composition.
- one or more of percent fractional area change, ejection fraction, and/or stroke volume and cardiac output is increased in hearts following preservation or resuscitation compared to hearts not contacted with the composition.
- a composition for storing, preserving or resuscitating biological tissue or organs comprising combining a physiological salt solution and one or more of glucose (11-25 mM), glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof (0.5-10 mM)), orotic acid (0.5-2.5 mM), carnosine (such as, L-carnosine), carnitine (such as, L-carnitine), and/or dichloroacetate, wherein the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions.
- the method further comprises combining the composition with insulin.
- insulin is combined just prior to use.
- the composition is maintained at a temperature of 10-21 ⁇ 4° C.
- the physiological salt solution comprises one or more salts selected from the group consisting of potassium phosphate, potassium chloride, sodium chloride, sodium bicarbonate, calcium chloride, sodium phosphate, magnesium chloride, magnesium sulfate.
- the physiological salt solution comprises 0.44-10 mM of potassium phosphate.
- the physiological salt solution comprises 4-65 mM of potassium chloride.
- the physiological salt solution comprises 80-135 mM sodium chloride. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 2-25 mM sodium bicarbonate. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0-1.5 mM calcium chloride. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0.15-30 mM sodium phosphate. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0.5-45 mM magnesium chloride. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0.5-1.5 mM magnesium sulfate.
- kits comprising: a physiological salt solution and one or more of glucose, glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), carnosine (such as, L-carnosine), orotic acid, carnitine (such as, L-carnitine), dichloroacetate, and/or insulin, wherein the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions.
- the physiological salt solution comprises one or more salts selected from the group consisting of potassium phosphate, potassium chloride, sodium chloride, sodium bicarbonate, calcium chloride, sodium phosphate, magnesium chloride, magnesium sulfate.
- the kit comprises 0.4-10 mM of potassium phosphate.
- the kit comprises 4-65 mM of potassium chloride.
- the kit comprises 80-135 mM sodium chloride.
- the kit comprises 2-25 mM sodium bicarbonate.
- the kit comprises 0-1.5 mM calcium chloride. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0.15-030 mM sodium phosphate. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0.5-45 mM magnesium chloride. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0.5-1.5 mM magnesium sulfate.
- compositions for storing, preserving, or resuscitating biological tissue or organs comprising: 7 mM potassium chloride, 0.44 mM potassium phosphate (monobasic), 0.5 magnesium chloride (hexahydrate), 0.5 mM magnesium sulfate (heptahydrate), 125 mM sodium chloride, 5 mM sodium bicarbonate, 1.3 mM calcium chloride, 0.19 mM sodium phosphate (dibasic; heptahydrate), 11 mM D-glucose, 1.5 mM glutathione (reduced), 1 mM ascorbic acid, 5 mM L-arginine, 1 mM L-citrulline malate, 2 mM adenosine, 0.5 mM creatine orotate, 2.0 mM creatine monohydrate or salts thereof, 10 mM L-carnosine, 10 mM L-carnitine, and 0.5 mM dichloroacetate.
- Advantages of the improved organ storage preservation solutions described herein include: (1) preservation of hearts at hypothennia (4° C.) is superior to current clinically used solutions Celsior and UWS; (2) preserves hearts in fully functional state at ambient temperatures, while the clinically used solutions (such as Celsior and UWS) cannot; (3) preserves heart in excellent condition over the temperature range of 4-25° C.; others cannot (heart metabolism and homeostasis in preserved or accentuated over this temperature range but not in other solutions; (4) hearts require minimal stimulatory interventions for reanimation due to preservation and synthesis of high energy phosphates over the temperature range of storage; hearts in other solutions cannot; (5) facilitates functional preservation of (Beating Heart Donor) BHD and (Donation after Cardiac Death) DCD hearts for 24 hours and other organs for over 72 hours at over the temperature range; while other solutions cannot.
- FIG. 1 depicts the Somah Device, a custom-built apparatus specifically designed for extracorporeal reanimation of hearts was used. Two circuits were prepared, first for the antegrade perfusion of coronaries through aorta during initial reperfusion of the hearts, and second for the perfusion of hearts through PVs in a working heart. Briefly, in Circuit 1 (green), the perfusate was pumped from heart chamber to the oxygenator-heat-exchanger system, and eventually into the aorta for perfusion of coronaries. The return of perfusate to the heart chamber through PA completed this circuit.
- a CDI monitor was incorporated into the system in addition to the oxygenator-heat-exchanger system for real-time monitoring of changes in perfusate pH, temperature, PO 2 , PCO 2 , K + and HCO 3 ⁇ .
- Pressures and flows were recorded at various points in the two circuits.
- the pressure and flow data were acquired and monitored in real time using a computer and HMI software specifically written for the Somah device (Comdel, Inc., Wahpeton, N. Dak.).
- FIG. 2 depicts a flow diagram showing the experimental design.
- the illustration shows the general experimental design of this study, starting from intra-operative cardioplegia for cardiac arrest to the end of the ex vivo heart reperfusion experiment.
- FIG. 3 depicts high-energy phosphates during storage.
- the graph shows the alterations in HEP levels during 5-hour storage in Somah, Celsior and UWS group hearts. Asterisk: significantly higher than controls; dagger: significantly lower than controls.
- FIG. 4A , and FIG. 4B depict cardiac enzymes upon reperfusion.
- Graphs showing the release of the cardiac enzymes creatine kinase and troponin I into the ex vivo circulation upon reperfusion of hearts with the Somah device are depicted in FIG. 4A and FIG. 4B , respectively.
- Asterisk significantly higher versus the other groups.
- FIG. 5A and FIG. 5B depict the metabolic shift upon reperfusion.
- Graphs showing alterations in myocardial oxygen consumption and lactate ratio in hearts within 30 minutes of reperfusion in the Somah, Celsior and UWS groups are depicted in FIG. 5A and FIG. 5B , respectively.
- Asterisk significantly higher than baseline.
- FIG. 6A , FIG. 6B , FIG. 6C , and FIG. 6D depict two-dimensional echocardiographic analysis during extracorporeal perfusion showing functional parameters. Percent fractional area change is depicted in FIG. 6A ; ejection fraction is depicted in FIG. 6 B; and stroke volume is depicted in FIG. 6C .
- the findings are deduced from 2D echocardiography on the Somah, Celsior and UWS group hearts.
- FIG. 6 D depicts alteration in left ventricular anterior wall and septal wall thicknesses upon reperfusion of hearts in the Somah. Celsior and UWS groups. Asterisk: significantly lower than in the Somah group.
- FIG. 7 depicts a flow diagram of the experimental design. Illustration shows the general experimental design of this study, starting from intraoperative cardioplegia for cardiac arrest to the end of ex vivo heart reperfusion experiment.
- FIG. 8 depicts an assessment of edema during 5-h heart storage.
- Heart biopsies were obtained for evaluation of edema and ischemic changes by electron microscopy (EM) (upper panels; magnification—8000 ⁇ ; inset in the first EM image shows a cardiomyocyte nuclei representative of reversible change seen in all the three groups, demonstrating partial condensation of chromatin material below the nuclear membrane) and histopathology (middle panels; magnification-400 ⁇ ) in the 4° C. (left), 13° C. (center) and 21° C. (right) group hearts; representative images.
- the lower graphs show the alteration in heart weights after storage, from prior at harvest weights in the three groups.
- M mitochondria
- SR sarcoplasmic reticulum
- G glycogen granules.
- FIG. 9A and FIG. 9B depict cardiac metabolism in working hearts.
- Myocardial O 2 consumption (MVO 2 ) is depicted in FIG. 9A and lactate ratio is depicted in FIG. 9B upon perfusion of hearts stored at 4° C. 13° C. and 21° C.
- MVO 2 and lactate ratios were determined from the differences in the respective parameters in the outflow and inflow perfusate samples.
- ⁇ Significant change Celsior versus Somah groups at corresponding time points; * Significant change from baseline (p ⁇ 0.05).
- FIG. 10A and FIG. 10B depict release of creatine kinase (CK) and cardiac troponin-I (cTnI) upon reperfusion.
- CK creatine kinase
- cTnI cardiac troponin-I
- FIG. 11 depicts a two-dimensional echocardiography (2D Echo) image procured during in vitro experiments using trans-esophageal echocardiography (TEE) probe.
- FIG. 12B , and FIG. 12C depict viability evaluation of stored hearts.
- Cardiac biopsies were taken either immediately on procurement (as depicted in FIG. 12A ; controls) or before (as depicted in FIG. 12B ) or after (as depicted in FIG. 12C ) reperfusion of hearts donated after cardiocirculatory death preserved in Somah for 24 hours at 4° C., 10° C., 21° C., or 37° C.
- Green fluorescence indicates cell viability; red fluorescence (upper panels), compromised cardiomyocytes.
- a robust green fluorescence of live cells was apparent in all temperature groups. The red fluorescence was noted at 4° C., 10° C., and 37° C. Representative images of independent experiments; magnification 320 ⁇ .
- FIG. 13B , FIG. 13C , FIG. 13D , and FIG. 13E depict mitochondrial membrane polarization in stored hearts.
- Mitochondrial membrane polarization in controls is depicted in FIG. 13A ; hearts donated after cardiocirculatory death preserved in Somah for 24 hours at different temperatures is depicted in FIG. 13B ; or after reperfusion is depicted in FIG. 13C .
- FIG. 14A and FIG. 14B depict high-energy phosphate syntheses in stored hearts.
- Graphs show adenosine triphosphate (ATP; depicted in FIG. 14A ) and Creatine phosphate (CP; depicted in FIG. 14B ) concentration in hearts donated after cardiocirculatory death at procurement (control), after preservation in Somah for 24 hours at different temperatures and upon simulated reperfusion.
- ATP adenosine triphosphate
- CP Creatine phosphate
- FIG. 15 depicts Structural and contractile components of cardiomyocytes.
- Hearts donated after cardiocirculating death were preserved in Somah for 24 hours at 4° C., 10° C., 21° C., or 37° C. prior to reperfusion.
- Left ventricular biopsies were taken before (pre) and after (post) simulated reperfusion. Resolution of myosin heavy (H) and light (L), actinin, actin, and troponin C was investigated.
- Control biopsies were taken immediately after procurement of the hearts.
- Structural and contractile proteins were well preserved at 21° C. but were differentially lost in other temperature groups. Upon reperfusion in the 21° C. group, the myosin light chain protein migrated to a higher level than normal, possibly indicative of phosphorylation.
- FIG. 16 depicts a flow diagram of experimental design. Illustration shows the general experimental design of this study, starting from intraoperative cardioplegia for cardiac arrest to the end of ex vivo heart reperfusion experiment.
- FIG. 17A , FIG. 17B , and FIG. 17C are graphs depicting high energy phosphate levels in hearts arrested and stored in SOMAH. Cardiac tissue biopsies from left ventricle were obtained for determination of HEP including ATP and CP levels in 4 and 21° C. SOMAH cardioplegia group hearts pre and post 5-hour storage. There was a temperature of cardioplegia arrest dependent increase in HEP concentrations in the hearts.
- FIG. 17A depicts Control;
- FIG. 17AB depicts 5 hour storage; and
- FIG. 18A , FIG. 18B , and FIG. 18C are graphs depicting release of creatine kinase and cardiac troponin-I upon reperfusion.
- CK depicted in FIG. 18A .
- AST depicted in FIG. 18B
- cTnI depicted in FIG. 8C
- FIG. 19A and FIG. 19B are bar graphs depicting cardiac metabolism in working hearts.
- FIG. 19A depicts myocardial O 2 consumption while FIG. 19B depicts lactate ratio (B) upon perfusion of 4 and 21° C. cardioplegia hearts.
- FIG. 21 depicts histopathology of livers at 6, 24 and 72 hrs stored in University of Wisconsin (UWS) and Somah solutions. Note that bile ductules show mucosal ulceration and disorganized, heaped, condensed nuclei in livers stored in UWS. These changes were seen as early as 6 hrs. In contrast, livers stored in Somah for 72 hrs showed normal appearing bile ductules in the portal region with clear, rounded uniform lumen and intact mucosa with regular basal nuclei.
- periportal hepatocytes show ballooning degeneration and apoptotic nuclei (arrows), while periportal hepatocytes showed normal cellular boundaries and heterochromatic, open-faced nuclei with nucleoli in livers stored in Somah (arrows).
- Asterisks indicate bile ducts and ductules of different calibers (all images, ⁇ 200).
- FIG. 22 depicts a high power view ( ⁇ 400) of bile ductules obtained from livers cold-stored in UWS and Somah at 6 hrs. Note the regularly arranged basal nuclei and clear lumen in a medium sized bile ductule seen at 0 hr (arrow, left panel). In contrast, note the polychromatic appearance of the ductular nuclei, including some condensed nuclei and reactive (proliferative) nuclear changes in the 3 o'clock position of liver stored in UWS. Note the sloughed material obstructing the ductular lumen and non-uniformly stained and ragged appearance of the mucosa.
- FIG. 23A and FIG. 23B are bar graphs depicting changes in pH, lactate and glucose levels in livers during storage. Graphs show time-dependent alterations in pH (upper panel), lactate (middle panel) and glucose (lower panel) levels in UWS ( FIG. 23A ) and Somah ( FIG. 23B ) solutions during extracorporeal storage of DCD livers. Metabolic parameters were temporally assessed in the storage solution during extracorporeal storage of DCD livers in UWS and Somah for 72 hours at 4° C.
- FIG. 24A and FIG. 24B depict oxygen consumption and co 2 production in Stored Livers.
- FIG. 24A shows the extent of oxygen consumption and
- FIG. 24B shows CO 2 production during extracorporeal storage of livers in UWS and Somah solutions at 0, 6, 24 and 72 hour time points. *Significant change from baseline levels in Somah.
- FIG. 25 depicts graphs showing total phosphates in stored livers. Graphs show time-dependent changes in ATP, CP and total phosphate levels in liver tissue during long-term extracorporeal storage of DCD livers in UWS (upper) and Somah (lower). *p ⁇ 0.05, Compared with 1 Hour.
- FIG. 26 depicts graphs showing release of liver enzymes during organ storage. Release of liver enzymes during extra-corporeal preservation of DCD livers was determined in the respective UWS or Somah solutions at time 0, 6, 24 and 72 hours. ALT (upper), AST (middle) and CK (lower) levels were evaluated.
- FIG. 27 depicts bar graphs showing reperfusion induced release of liver enzymes. Release of liver enzymes during extra-corporeal reperfusion of DCD Somah livers was determined in the perfusate (HV) at time 0 (single pass), 0.5 and 2 hours. ALP, GGT, AST, ALT and CK levels were evaluated. Due to intra variability of enzymes in 72-hour stored blood in the reconstituted perfusate, data was normalized to time 0 hour values; mean ⁇ SEM, from independent experiments.
- FIG. 28 depicts a bar graph showing reperfusion induced synthesis and release of albumin by livers stored in Somah for 72-hours. Somah livers temporally synthesized and released albumin in the perfusate (HV). Increase in albumin synthesis was highly significant at 0.5 hour (P ⁇ 0.03) and at 2 hours (P ⁇ 0.01). Values represent mean+SEM from independent experiments.
- FIG. 29A and FIG. 29B depict gross morphology of kidneys stored in UW ( FIG. 29A ) or Somah ( FIG. 29B ).
- Kidneys were stored for 72 hours and images were obtained for gross morphological evaluation and biopsies taken for histopathology at time 0, and 6, 24 and 72 hours of extracorporeal preservation at 4° C.
- Kidneys flushed with UW displayed a mottled appearance with patchy discoloration at all time points (a).
- Kidneys flushed with Somah displayed uniform color and smooth morphology without patchy changes (d).
- FIG. 30A , FIG. 30B , FIG. 30C , FIG. 30D , and FIG. 30E depict bar graphs showing alterations in metabolic parameters in the UW or Somah solutions storing DCD kidneys over a 72-hour period.
- FIG. 30A shows pH;
- FIG. 30B shows glucose;
- FIG. 30C shows lactate;
- FIG. 30D shows pO 2 and
- FIG. 30E shows pCO 2 .
- FIG. 31 depicts line graphs showing alterations in energy metabolism in the UW (left) and Somah (right) stored DCD kidneys during the 72 hour extracorporeal preservation period. *Significantly different from Time 0 (p ⁇ 0.05).
- FIG. 32 depicts bar graphs showing time-dependent alterations in expression of caveolin, endothelial nitric oxide synthase (eNOS), von-Willebrands factor (vWF) and erythropoietin (EPO) proteins in DCD kidneys stored in either UW or Somah solution for 72 hours.
- eNOS endothelial nitric oxide synthase
- vWF von-Willebrands factor
- EPO erythropoietin
- FIG. 33 is a chart depicting ammonia production and utilization in cells exposed to Somah.
- organ preservation storage solution that facilitates preservation of an organ from various groups of donors over a broad subnormothermic temperature range (4-25° C.), thus preventing tissue injury due to storage at extreme hypothermia (4° C.) prior to transplant.
- the components of the solution should preserve cardiac (and other organ) structure and function by providing ionic balance, energy substrates, chelation of ammonia into substrates for nitric oxide synthase, metabolic modulation for generation of high-energy phosphates (HEP), free radical scavenging, anti-oxidants, reducing agents, intra and extracellular H + chelation, and attenuation of edema by modulation of hemichannels and aquaporins during storage.
- HEP high-energy phosphates
- the storage solution should also facilitate attenuation of ischemia-reperfusion injury (IRI) by preloading with selective, synergistic constituents during hypoxic storage to counterbalance the detrimental effects of the initially hyperoxic state post-reperfusion, and consequently prevent reperfusion injury and perpetuate uneventful rapid transition to normoxic state, aerobic metabolism and optimum mechanical function.
- An ideal solution would synergistically 1) preserve the organ during ischemic storage; 2) prime the organ with metabolites for rapid conversion from hyperoxic to normoxic state, for sustained electromechanical work upon reperfusion; and 3) prevent ischemia-reperfusion (IR) injury.
- Such a solution would have the potential to greatly extend temporal storage for extracorporeal preservation of donor organs prior to transplantation into recipients.
- compositions for preserving mammalian organs and tissues as well as methods and kits for utilizing the same. While any mammalian organ or tissue can be preserved in the presently described compositions using the instantly described methods, the benefits of storing extracorporeal hearts are particularly advantageous.
- the compositions and methods of the present invention permit ex vivo storage for 24-72 hours following removal from a donor.
- compositions and methods of the instant invention can be stored at ambient temperatures without accumulation of significant amounts of edema and without the characteristic cold-mediated tissue and cellular damage brought about by cold storage of hearts.
- compositions and methods of the present invention have the potential to permit hearts to reach suitable transplant recipients located at more remote distances than what is currently possible.
- physiological salt refers to any salt which, when in aqueous solution at a given concentration, assists with or is required for a cellular or physiologic function.
- physiological salts include, without limitation, alkaline and alkaline earth metal chlorides, phosphates and sulfates, such as, KCl, NaCl, MgCl 2 , MgSO 4 , and mixtures thereof.
- a “subject” can be a vertebrate, a mammal, or a human. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats. In one aspect, a subject is a human.
- “normothermic temperature” refers to any temperature in the range of about 36.4-37.1° C., e.g., 36.4° C., 36.5° C., 36.6° C., 36.7° C., 36.8° C., 36.9° C., 37° C., or 37.1° C.
- “Ambient temperature” or “subnormnothermic temperature,” as used herein, refers to temperatures in the range of 10-21 ⁇ 4° C., or in other embodiments, temperatures in the range of 21 ⁇ 2° C., such as any of about 6° C., 7° C., 8° C., 9° C., 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C. 17° C., 18° C. 19° C., 20° C., 21° C., 22° C. 23° C., 24° C., or 25° C.
- “Hypothermic temperatures” or “hypothermia” refers to temperatures in the range of about 0° C. to about 5° C., such as any of about 0° C., 1° C., 2° C., 3° C., 4° C., or 5° C.
- transitional term “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
- compositions of the present invention are solutions for preserving or resuscitating biological tissue or organs at temperatures of about 10-21 ⁇ 4° C., such as any of about 4° C. 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 11° C. 12° C. 13° C. 14° C., 15° C., 16° C. 17° C. 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C.
- Tissues or organs can be stored in the compositions described herein for about 24-72 hours, such as any of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72 or more hours, without significant decreases in the amount of cellular high energy phosphates or without significant increases in edema.
- physiological measurements such as coronary blood flow, percent fractional area change, ejection fraction, and/or stroke volume are increased upon reanimation of the heart relative to hearts stored in currently utilized organ preservation solutions.
- any organ or biological tissue can be stored in the compositions described herein, for example any of heart, kidney, liver, stomach, spleen, skin, pancreas, lung, brain, eye, intestines, or bladder.
- the stored organ is a heart.
- compositions of the present invention can be aqueous (i.e. water-based or solid powder based (reconstituted with distilled water prior to use) or combinations thereof solutions that include one or more of a physiological salt solution, glucose, glutathione, ascorbic acid, arginine, citrulline malate, adenosine, creatine orotate, creatine monohydrate or salts thereof, orotic acid, malic acid, carnosine, camitine, and/or dichloroacetate, wherein the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions.
- a physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions.
- the physiological salt solution can include any salt which, when in aqueous solution at a given concentration, assists or is required for a physiologic function such as maintaining ionic concentrations inside and outside of the biological tissue or organ as well as controlling the amount of water that can traverse cellular membranes.
- the components of the physiological salt solution can also help to buffer and maintain a proper pH.
- Particular salts capable of use in the present in invention include, without limitation, potassium chloride, potassium phosphate, magnesium chloride, magnesium sulfate, calcium chloride, sodium chloride, sodium bicarbonate and sodium phosphate.
- the physiological salt solution of any of the compositions disclosed herein can contain a sodium ion source.
- Sodium ions can be added to the physiological salt solution in the form of a sodium salt, such as, for example, one or more sodium salts selected from the group consisting of NaAlO 2 , NaBO 2 , NaCl, NaClO, NaClO 2 , NaClO 3 , NaClO 4 , NaF, Na 2 FeO 4 , NaHCO 3 , NaH 2 PO 4 , NaHSO 3 , NaHSO 4 , NaI, NaMnO 4 , NaNH 2 , NaNO 2 , NaNO 3 , NaOH, NaPO 2 H 2 , NaSH, Na 2 MnO 4 , Na 3 MnO 4 , Na 2 N2O 2 , Na 2 O 2 , Na 2 SO 3 , Na 2 SO 4 , Na 2 S2O 4 .
- sodium ions in the biological tissue and organ storage composition can be at a concentration of between about 80-145 mM, such as about 80 mM, about 81 mM, about 82 mM, about 83 mM, about 84 mM, about 85 mM, about 86 mM, about 87 mM, about 88 mM, about 89 mM, about 90 mM, about 91 mM, about 92 mM, about 93 mM, about 94 mM, about 95 mM, about 96 mM, about 97 mM, about 98 mM, about 99 mM, 100 mM, about 101 mM, about 102 mM, about 103 mM, about 104 mM, about 105 mM, about 106 mM, about 107 mM, about 108 mM, about 109 mM, about 110 mM, about 111 mM, about 112 mM
- the physiological salt solution contains sodium chloride.
- concentration of sodium chloride in the biological tissue and organ storage composition can be between about 80-135 mM, such as about 80 mM, about 81 mM, about 82 mM, about 83 mM, about 84 mM, about 85 mM, about 86 mM, about 87 mM, about 88 mM, about 89 mM, about 90 mM, about 91 mM, about 92 mM, about 93 mM, about 94 mM, about 95 mM, about 96 mM, about 97 mM, about 98 mM, about 99 mM, 100 mM, about 101 mM, about 102 mM, about 103 mM, about 104 mM, about 105 mM, about 106 mM, about 107 mM, about 108 mM, about 109 mM, about 110 mM
- the physiological salt solution contains sodium phosphate.
- concentration of sodium phosphate in the biological tissue and organ storage composition can be between about 0.15-30 mM, such as about 0.15 mM, about 0.16 mM, about 0.17 mM, about 0.18 mM, about 0.19 mM, about 0.2 mM, about 0.21 mM, about 0.22 mM, about 0.23 mM, about 0.24 mM, about 0.25 mM, about 0.5 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about
- the physiological salt solution contains sodium bicarbonate.
- concentration of sodium bicarbonate in the biological tissue and organ storage composition can be between about 2-25 mM, such as about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, including all ranges and numbers falling within these values.
- the biological tissue and organ storage composition can contain about 0.35 g/L sodium bicarbonate.
- the physiological salt solution contains calcium ions (for example, calcium ions supplied by calcium salts such as calcium chloride).
- calcium ions in the biological tissue and organ storage composition can be at a concentration of between about 0-1.5 mM, such as about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 1.1 mM, about 1.2 mM, about 1.3 mM, about 1.4 mM, or about 1.5 mM, including all ranges and numbers falling within these values.
- the physiological salt solution of the compositions disclosed herein contain calcium ions supplied from one or more calcium salts such as, for example, those selected from the group consisting of calcium acetate, calcium aluminates, calcium aluminoferrite, calcium aluminosilicate, calcium ammonium nitrate, calcium arsenate, calcium ascorbate, calcium azide, calcium benzoate, calcium beta-hydroxy-beta-methylbutyrate, calcium bicarbonate, calcium bisulfite, calcium borate, calcium bromate, calcium bromide, calcium carbide, calcium carbonate, calcium chlorate, calcium chromate, calcium citrate, calcium citrate malate, calcium copper titanate, calcium cyanamide, calcium diglutamate, calcium erythorbate, calcium fluoride, calcium formate, calcium funmarate, calcium glubionate, calcium glucoheptonate, calcium gluconate, calcium glycerylphosphate, calcium guanylate, calcium hexaboride, calcium hydroxide
- the physiological salt solution of any of the compositions disclosed herein can contain a potassium ion source.
- Potassium ions can be added to the physiological salt solution in the form of a potassium salt, such as, for example, one or more potassium salts selected from the group consisting of KAsO 2 , KBr, KBrO 3 , KCN, KCNO, KCl, KClO 3 , KClO 4 , KF, KH, KHCO 2 , KHCO 3 , KHF 2 , KHS, KHSO 3 , KHSO 4 , KH 2 AsO 4 , KH 2 PO 3 , KH 2 PO 4 , KI, KlO 3 , KlO 4 , KMnO 4 , KN 3 , KNH 2 , KNO 2 , KNO 3 , KOCN, KOH, KO 2 , KPF 6 , KCH 3 COO, K 2 Al 2 O 4 , K 2 CO 3 , K 2 CrO 4
- potassium ions in the biological tissue and organ storage composition can be at a concentration of between about 4-65 mM, such as about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM
- the physiological salt solution contains potassium phosphate.
- concentration of potassium phosphate in the biological tissue and organ storage composition can be between about 0.4-10 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, or about 10 mM, including all ranges and numbers falling within these values.
- the biological tissue and organ storage composition can contain about 0.06 g/L potassium phosphate. Any form of potassium phosphate can be used in the present invention, including, without limitation, the monobasic form.
- the physiological salt solution contains potassium chloride.
- concentration of potassium chloride in the biological tissue and organ storage composition can be between about 4-65 mM, such as about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38
- the physiological salt solution of any of the compositions disclosed herein can contain a magnesium ion source.
- Magnesium ions can be added to the physiological salt solution in the form of a magnesium salt, such as one or more magnesium salts selected from the group consisting of MgB 2 , MgBr 2 , MgCO 3 , MgC 2 O 4 , MgC 6 H 6 O 7 , MgC 14 H 10 O 4 , MgCl 2 , Mg(ClO 4 ) 2 , MgF 2 , MgH 2 , Mg(HCO 3 ) 2 , MgI 2 , Mg(NO 3 ) 2 , MgO, MgO 2 , Mg(OH) 2 , MgS, MgSO 3 , MgSO 4 , Mg 2 Al 3 , Mg 2 Si, Mg 2 SiO 4 , Mg 2 Si 3 O 8 , Mg 3 N 2 , Mg 3 (PO 4 ) 2 , and Mg 2 (
- magnesium ions in the biological tissue and organ storage composition can be at a concentration of between about 0.5-45 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM, about 31 mM, such as
- the physiological salt solution contains magnesium chloride.
- concentration of magnesium chloride in the biological tissue and organ storage composition can be between about 0.5-45 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29
- the physiological salt solution contains magnesium sulfate.
- concentration of magnesium sulfate in the biological tissue and organ storage composition can be between about 0.5-1.5 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 1.1, about 1.2 mM, about 1.3 mM, about 1.4 mM, or about 1.5 mM including all ranges and numbers falling within these values.
- the biological tissue and organ storage composition can contain about 0.123 g/L magnesium sulfate. Any form of magnesium sulfate can be used in the present invention, including, without limitation, the heptahydrate form.
- compositions of the present invention can also include one or more of glucose, glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate and salts thereof), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), orotic acid, malic acid and salts thereof, carnosine, carnitine, dichloroacetate, and/or insulin.
- citrulline such as citrulline malate and salts thereof
- adenosine such as creatine orotate or creatine monohydrate or salts thereof
- orotic acid malic acid and salts thereof
- carnosine carnitine
- dichloroacetate dichloroacetate
- a sugar for example, a six carbon sugar like glucose (such as D-glucose or dextrose) and/or a five carbon sugar like ribose, can serve as a substrate for the production of high energy phosphates (such as ATP) and can be included in the biological tissue and organ storage composition described herein at concentrations between about 5-25 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, or 25 mM including all ranges and numbers falling within these values.
- the concentration of glucose is about 1.98 g/L.
- glucose is present at a concentration of about 11 mM.
- Reactive oxygen species can be generated during biological tissue and organ storage; however, ascorbic acid and reduced glutathione (i.e. reducing agents) present in the solution can consume oxygen free radicals during storage.
- both ascorbic acid and reduced glutathione can be present in the biological tissue and organ storage composition described herein at concentrations between about 0.5 mM to 3 mM, such as any of about 0.5 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, or 3 mM, including all ranges and numbers falling within these values.
- the concentration of ascorbic acid is about 0.178 g/L.
- ascorbic acid is present at a concentration of about 1 mM.
- the concentration of reduced glutathione is about 0.462 g/L.
- reduced glutathione is present at a concentration of about 1.5 mM.
- TCA tricarboxylic acid
- malate (cleaved from citrulline) enters the TCA cycle to generate more ATP.
- citrulline malate is converted to arginine and fumarate; fumarate enters the TCA cycle to facilitate more ATP production. Both malate and fumarate in TCA cycle leads to more ATP production.
- the organ storage compositions disclosed herein may be able to drive the otherwise toxic ammonium ion into the nitric oxide synthesis pathway in most organs and tissues by inclusion of citrulline (see FIG. 33 ).
- Increased production of NO is extremely beneficial for long term storage of organs. Specifically, as soon as circulation to an organ is interrupted during harvesting and storage, transaminase (and/or protease) reactions accelerate as part of degenerative breakdown of proteins. These enzymes metabolize amino acids, thereby releasing ammonium ions that can build up in the storage solution, potentially causing toxicity and injury to the tissue.
- citrulline malate, and/or salts thereof can provide a counterbalance to this increased ammonium production when included in the organ storage solutions provided herein. Without being bound to theory, is thought that ammonium ions will combine with glutamine present in cells to form carbamoyl phosphate, which is driven into the NO cycle by the formation of L-citrulline (see FIG. 33 ). To keep this cycle going and to prevent citrulline exhaustion citrulline malate can be included in the solution. Citrulline is metabolized to arginine (leading to NO production) and Krebs's cycle intermediates during NO production (see FIG. 33 ).
- the combination of citrulline and arginine synergistically produces a higher amount of nitrous oxide (NO) in organs stored in any of the solutions disclosed herein compared to the amount of NO produced using a storage solution lacking these ingredients.
- NO nitrous oxide
- arginine such as L-arginine
- citrulline such as citrulline malate, for example, L-citrulline malate or salts thereof
- the organ storage composition does not comprise citrulline malate.
- the concentration of arginine is about 1.074 g/L. In another embodiment, arginine is present at a concentration of about 5 mM. In some embodiments, the concentration of citrulline malate is about 0.175 g/l . . . In another embodiment, citrulline malate is present at a concentration of about 1 mM.
- citrulline such as L-citrulline
- malic acid can be added individually to the compositions in ranges of about 1-10 mM citrulline (such as any of about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM, including all ranges and numbers falling within these values) and about 1-5 mM malic acid (such as any of about 1 mM, 2 mM, 3 mM, 4 mM, or 5 mM, including all ranges and numbers falling within these values), respectively.
- the organ storage composition does not comprise citrulline or citrulline malate.
- the organ storage composition comprises malic acid from about 0.001 to about 7 mM, such as any of about 0.001 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM or 7 mM.
- the organ storage solution does not comprise malate or malic acid.
- Adenosine can be present in the compositions disclosed herein at concentrations between about 1-4 mM, such as any of about 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM, or 4 mM, including all ranges and numbers falling within these values. In one embodiment, the concentration of Adenosine is about 0.534 g/L. In another embodiment. Adenosine is present at a concentration of about 2 mM.
- Adenosine also changes the polarization of the heart for rapid arrest; facilitates dialation of coronary vessels facilitating distribution/perfusion of the heart (organ) with the organ storage solution during storage, thereby attenuating hypoxia/ischemia related injury. Adenosine also slows the rate of K + -induced membrane depolarization, and reduces K + -induced intracellular Ca 2+ loading in ventricular myocytes. Without being bound to theory, such findings support the notion that adenosine plays a cardioprotective role in hyperkalemic cardioplegia or during surgery and/or organ harvest by facilitating gentle arrest; especially for use in high K + scenario, thus preventing inherent injury to the heart induced by such action.
- magnesium in addition to its role in high energy phosphate production and ionic homeostasis, magnesium also protects the heart from repeated ischemia and injury via preconditioning, especially during prolonged organ storage as well as protecting against postoperative ventricular arrythemias upon open heart surgery or transplant. Both high potassium and magnesium concentrations also protects against calcium accumulation in mitochondria and subsequent injury to the organ.
- the composition solution contains creatine.
- creatine is present in the form of creatine orotate and/or creatine monohydrate or salts thereof.
- the concentration of creatine in the biological tissue and organ storage compositions can be between about 2-5 mM, such as about 2 mM, about 3 mM, about 4 mM or about 5 mM, including all ranges and numbers falling within these values.
- the biological tissue and organ storage compositions can contain 0.5 mM creatine orotate.
- the biological tissue and organ storage compositions can contain 0.27 g/L creatine orotate.
- the biological tissue and organ storage compositions can contain 2 mM creatine monohydrate or salts thereof. In another embodiment, the biological tissue and organ storage compositions can contain 0.3 g/L creatine monohydrate or salts thereof. In yet another embodiment, the biological tissue and organ storage compositions contains both 0.5 mM creatine orotate and 2 mM creatine monohydrate or salts thereof. Creatine orotate can be difficult to obtain. Hence, in some embodiments, this can be changed to 0.5 mM orotic acid and salts thereof (0.50-2.50 mM) and 2.50 mM creatine monohydrate or salts thereof (2.50-10 mM).
- the composition solution contains a buffer for intracellular acidity, such as carnosine (for example, L-carnosine).
- concentration of carnosine in the biological tissue and organ storage compositions can be between about 5-15 mM, such as about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, or about 15 mM, including all ranges and numbers falling within these values.
- the biological tissue and organ storage compositions can contain 2.3 g/L L-carnosine.
- the solution contains carnitine (for example, L-carnitine), which facilitates a decrease in myocardial lactate production, hence reducing acidity.
- carnitine for example, L-carnitine
- the concentration of carnitine in the biological tissue and organ storage compositions can be between about 5-15 mM, such as about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, or about 15 mM, including all ranges and numbers falling within these values.
- the biological tissue and organ storage compositions can contain 2 g/L L-carnitine.
- Dichloroacetate if present in the biological tissue and organ storage compositions disclosed herein, can control acidity by lowering lactate levels in the preserved organ, and thus the solution.
- concentration of dichloroacetate in the biological tissue and organ storage compositions can be between about 0.1-2.5 mM, such as about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 1.1 mM, about 1.2 mM, about 1.3 mM, about 1.4 mM, about 1.5 mM, about 1.6 mM, about 1.7 mM, about 1.8 mM, about 1.9 mM, about 2 mM, about 2.1 mM, about 2.2 mM, about 2.3 mM, about 2.4 mM, or about 2.5 mM, including all ranges and numbers falling within these
- the biological tissue and organ storage compositions disclosed herein can contain insulin.
- Insulin can be added after the other ingredients are mixed and/or just prior to use of the storage compositions disclosed herein.
- insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours. e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing an organ in the solution.
- about 100 units/L are added to the biological tissue and organ storage compositions.
- the biological tissue and organ storage compositions disclosed herein can be maintained at a neutral or slightly basic pH, such as about pH 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7, including all ranges and numbers falling within these values.
- a neutral or slightly basic pH such as about pH 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7, including all ranges and numbers falling within these values.
- the pH of biological tissue and organ storage compositions is 7.
- the pH of the biological tissue and organ storage compositions is modulated using THAM (Tris-Hydroxymethyl Aminomethane).
- the organ storage composition comprises the following nominal or base ingredients as shown in Table I for activity of iSomah, combined in deionized, distilled, and/or bacteriostatic water:
- the potassium phosphate salt for use in the non-limiting formulation shown in Table I can be potassium phosphate monohasic.
- the magnesium chloride salt for use in the non-limiting formulation shown in Table I can be magnesium chloride hexahydrate.
- the magnesium sulfate salt for use in the non-limiting formulation shown in Table I can be magnesium sulfate heptahydrate.
- the sodium phosphate salt for use in the non-limiting formulation shown in Table I can be sodium phosphate dibasic heptahydrate.
- the glutathione for use in the non-limiting formulation shown in Table I can be reduced glutathione.
- the creatine for use in the non-limiting formulation shown in Table I can be creatine monohydrate or salts thereof.
- the non-limiting formulation shown in Table I can further comprise one or more of arginine (for example, L-arginine) in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM, carnosine (for example, L-carnosine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM (2.26 g/L for 10 mM), carnitine (for example, L-carnitine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 m
- the non-limiting formulation shown in Table I can further comprise insulin at a concentration of 10 mg-100 mg/ml/Liter or 100-1000 Units/L.
- insulin is included in the composition, it is optionally added just prior to use as an organ preservation solution.
- the non-limiting formulation shown in Table I can further comprise a sugar, such as, but not limited to, a six carbon sugar (e.g., allose, altrose, galactose, glucose (including D-glucose (a.k.a. dextrose) and L-glucose), gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose, fucose, fuculose, or rhamnose) or a five carbon sugar (e.g.
- a six carbon sugar e.g., allose, altrose, galactose, glucose (including D-glucose (a.k.a. dextrose) and L-glucose), gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose, fucose, fuculose, or rhamnose
- the non-limiting formulation shown in Table I can optionally comprise 1-10 mM of citrulline (for example, L-citrulline) or a salt thereof in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM.
- citrulline for example, L-citrulline
- a salt thereof in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM.
- the non-limiting formulation shown in Table II can optionally comprise about 0-10 mM malic acid, such as any of about 0 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM.
- the non-limiting formulation shown in Table I can optionally comprise citrulline malate (such as L-citrulline malate) instead of malic acid and/or citrulline in concentrations of about 0 mM to about 10 mM or about 2 mM to about 7 mM, such as any of about 0 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM citrulline malate.
- citrulline malate such as L-citrulline malate
- the biological tissue and organ storage compositions comprise the following ingredients combined in deionized and/or bacteriostatic water as shown in Table II:
- insulin is added after the other ingredients are mixed and/or just prior to use of the storage compositions.
- insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours, e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing an organ in the solution.
- a cardioplegia solution of the present invention can comprise a physiological salt solution containing at least 20 mM potassium ions (such as any of about 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM or more potassium ions, including all values and ranges falling in between these numbers) as well as one or more of a sugar (for example, ribose, glucose or dextrose), glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine
- Cardioplegia solutions containing at least 20 mM potassium ions can be used to arrest hearts between about 4-10° C. (such as any of about 4° C., 5° C. 6° C. 7° C., 8° C., 9° C. or 10° C.).
- the cardioplegia solution of the present invention can comprise a physiological salt solution containing at least 20 mM potassium ions (such as any of about 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM or more potassium ions, including all values and ranges falling in between these numbers) and at least 37 mM magnesium ions (such as any of about 37 mM, 38 mM, 39 mM, 40 mM, 41 mM, 42 mM, 43 mM, 44 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM or
- Cardioplegia solutions containing at least 20 mM potassium ions and at least 37 mM magnesium ions can be used to arrest hearts between about 10-25° C., such as any of about 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C., 17° C. 18° C., 19° C. 20° C., 21° C., 22° C., 23° C., 24° C., or 25° C.
- the cardioplegia solution of the present invention can comprise a physiological salt solution containing at least 25 mM potassium ions (such as any of about 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, 35 mM, 45 mM, 46 mM, 47 mM, 48 mM, 49 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105, 110, 115, 120, 125 or more potassium ions, including all values and ranges falling in between these numbers) and at least 37 mM magnesium ions (such as any of about 37 mM, 38 mM, 39 mM, 40 mM, 41 mM, 42 mM, 43 mM
- Cardioplegia solutions containing at least 25 mM potassium ions and at least 37 mM magnesium ions can be used to arrest hearts between about 25-37° C., such as any of about 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., 33° C., 34° C. 35° C., 36° C., or 37° C.
- cardioplegia solutions for arresting hearts during open heart surgery or for donor hearts for transplant comprising: a physiological salt solution containing between about 4-65 mM potassium ions (such as any of about 4 mM, 5 mM, 6 mM, 7, 8 mM, 9 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 61 mM, 62 mM, 63 mM, 64 mM, or 65 mM potassium ions, including all values and ranges falling in between these numbers) and between about 1.5-45 mM magnesium ions (such as any of about 1.5 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 15 mM, 20 mM, 25 m
- Cardioplegia solutions containing at least 45 mM potassium ions and at least 37 mM magnesium ions can be used to arrest hearts between about 4-37° C., such as any of about 4° C., 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C., 17° C., 18° C., 19° C. 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 26° C., 27° C., 28° C. 29° C., 30° C., 31° C., 32° C., 33° C., 34° C. 35° C., 36° C., or 37° C.
- Biological tissues and organs stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly more high energy phosphates (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75% more high energy phosphates including all ranges and numbers falling within these percentages) compared to biological tissue and organs that are not stored in the solutions disclosed herein.
- Biological tissue and organs stored for prolonged periods of time exhibit significant increases in lactate production, which can negatively affect the pH of the storage media leading to increased tissue and cellular damage.
- Biological tissue and organs stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly less lactate production (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, less lactate production, including all ranges and numbers falling within these percentages) compared to biological tissue and organs that are not stored in the solutions disclosed herein.
- Hearts stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly higher levels of coronary blood flow (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, more coronary blood flow, including all ranges and numbers falling within these percentages) compared to hearts that are not stored in the solutions disclosed herein.
- Hearts stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly higher levels of percent fractional area change, ejection fraction, and/or stroke volume (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, more percent fractional area change, ejection fraction, and/or stroke volume including all ranges and numbers falling within these percentages) compared to hearts that are not stored in the solutions disclosed herein.
- compositions for preserving biological tissue and organs such as any of the compositions disclosed herein.
- the methods encompass mixing one or more of the ingredients described above at the indicated concentrations in distilled, deionized, and/or bacteriostatic water.
- the method encompasses mixing one or more of the ingredients shown in the Table III below in distilled, deionized, and/or bacteriostatic water.
- insulin is added after the other ingredients are mixed and/or just prior to use of the storage compositions.
- insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours, e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing a biological tissue or organ in the solution.
- citrulline malate such as, L-citrulline malate
- 1-10 mM such as any of about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM, including all ranges and numbers falling within these values
- 1-5 mM such as any of about 1 mM, 2 mM, 3 mM, 4 mM, or 5 mM, including all ranges and numbers falling within these values
- the method encompasses mixing one or more of the ingredients shown in the Table IV below in distilled, deionized, and/or bacteriostatic water.
- insulin is added after the other ingredients are mixed and/or just prior to use of the storage compositions.
- insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours, e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing a biological tissue or organ in the solution.
- the potassium phosphate salt for use in producing the non-limiting formulation shown in Table IV can be potassium phosphate monobasic.
- the magnesium chloride salt for use in the non-limiting formulation shown in Table IV can be magnesium chloride hexahydrate.
- the magnesium sulfate salt for use in the non-limiting formulation shown in Table IV can be magnesium sulfate heptahydrate.
- the sodium phosphate salt for use in the non-limiting formulation shown in Table IV can be sodium phosphate dibasic heptahydrate.
- the glutathione for use in the non-limiting formulation shown in Table IV can be reduced glutathione.
- the creatine for use in the non-limiting formulation shown in Table IV can be creatine monohydrate or salts thereof.
- the arginine for use in the non-limiting formulation shown in Table IV can be L-arginine.
- the carnosine for use in the non-limiting formulation shown in Table IV can be L-carnosine.
- the carnitine for use in the non-limiting formulation shown in Table IV can be L-carnitine.
- the method can also include a step of adjusting the pH of the solution to a neutral or slightly basic level, such as about pH 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7, including all ranges and numbers falling within these values.
- a neutral or slightly basic level such as about pH 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7, including all ranges and numbers falling within these values.
- the pH of the biological tissue and organ storage composition is adjusted to 7.5.
- methods for producing an organ preservation composition encompass mixing one or more of the following ingredients at the indicated concentrations in Table V or Table Va in distilled, deionized, and/or bacteriostatic water.
- the potassium phosphate salt for use in the non-limiting formulation shown in Table V or Table Va can be potassium phosphate monobasic.
- the magnesium chloride salt for use in the non-limiting formulation shown in Table V or Table Va can be magnesium chloride hexahydrate.
- the magnesium sulfate salt for use in the non-limiting formulation shown in Table V or Table Va can be magnesium sulfate heptahydrate.
- the sodium phosphate salt for use in the non-limiting formulation shown in Table V or Table Va can be sodium phosphate dibasic heptahydrate.
- the glutathione for use in the non-limiting formulation shown in Table V or Table Va can be reduced glutathione.
- the non-limiting formulation shown in Table V or Table Va can further comprise one or more of arginine (for example, L-arginine) in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM, carnosine (for example, L-carnosine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM (2.26 g/L for 10 mM), carnitine (for example, L-carnitine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM (2.26 g/L for 10 mM), orotic
- the non-limiting formulation shown in Table V can further comprise insulin at a concentration of 10 mg-100 mg/ml/Liter or 100-1000 Units/L.
- insulin is included in the composition, it is optionally added just prior to use as an organ preservation solution.
- the non-limiting formulation shown in Table V or Table Va can further comprise a sugar, such as, but not limited to, a six carbon sugar (e.g., allose, altrose, galactose, glucose (including D-glucose (a.k.a. dextrose) and L-glucose), gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose, fucose, fuculose, or rhamnose) or a five carbon sugar (e.g.
- a six carbon sugar e.g., allose, altrose, galactose, glucose (including D-glucose (a.k.a. dextrose) and L-glucose), gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose, fucose, fuculose, or rhamnose
- the non-limiting formulation shown in Table V or Table Va can optionally comprise 1-10 mM of citrulline (for example, L-citrulline) or a salt thereof in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM.
- citrulline for example, L-citrulline
- a salt thereof in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM.
- the non-limiting formulation shown in Table V or Table Va can optionally comprise citrulline malate (such as L-citrulline malate) instead of malic acid and/or citrulline in concentrations of about 0 mM to about 10 mM or about 2 mM to about 7 mM, such as any of about 0 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM citrulline malate.
- citrulline malate such as L-citrulline malate
- methods for producing an organ preservation composition encompass mixing one or more of the following ingredients at the indicated concentrations in Table VI in distilled, deionized, and/or bacteriostatic water.
- compositions for making the biological tissue and organ storage/resuscitation solutions disclosed herein are optionally packaged in a kit with the ingredients listed below or multiples thereof in amounts necessary to scale up to make 2, 3, 5, 10, 20 times the amount of solution.
- An exemplary kit contains one or more of glutathione, ascorbic acid, adenosine, potassium chloride, potassium phosphate magnesium chloride, magnesium sulfate, sodium chloride, sodium bicarbonate, sodium phosphate, a sugar (such as ribose, glucose or dextrose), arginine, citrulline malate, adenosine, orotic acid, creatine, and dichloroacetate (for example, one or more of about 2.76 g/L Potassium Chloride, 0.06 g/L Potassium phosphate (monobasic), 7.47 g/L Magnesium chloride (hexahydrate), 0.123 g/L Magnesium sulfate (heptahydrate), 7.30 g/L Sodium chlor
- kits can also contain solutions of means for adjusting the pH of the combined biological tissue and organ preservation/storage solution (e.g. THAM).
- THAM means for adjusting the pH of the combined biological tissue and organ preservation/storage solution
- the kit can be packaged or sold with or without the sterile and/or deionized water component.
- Organ edema is prevented by the addition of cellular impermeants such as mannitol and lactobionic acid to Celsior, and lactobionic acid, raffinose and hydroxyethyl starch to UWS.
- cellular impermeants such as mannitol and lactobionic acid to Celsior, and lactobionic acid, raffinose and hydroxyethyl starch to UWS.
- ATP adenosine triphosphate
- HEP cardiomyocyte high-energy phosphates
- Celsior (20 mmol/liter K + ) or UWS (innate 140 mM K + ), was infused at 75 to 100 mm Hg; hearts were excised and stored in Somah, Celsior or UWS for 5 hours at 21 ⁇ 2° C. (ambient temperature).
- Extracorporeal heart storage Hearts were placed inside ziplock bags (with 2 liters of Somah, Celsior or UWS) in a waterjacketed bath at 21 ⁇ 2° C. Because hearts in Somah showed slow contractile movements during storage, Somah's plegia potential was enhanced by supplemental K + (total 20 mmol/liter) and Mg 2+ (37 mmol/liter) (Fukuhiro et al., Circulation 2000; 102(III):319-25). Hearts were weighed beforehand and after 5 hours. Punch biopsies (2 ⁇ 4 mm) were taken from the left ventricular (LV) posterior wall, before and at the end of storage, for HEP assays.
- LV left ventricular
- ATP and creatine phosphate assay Cardiac tissue HEP were measured as described elsewhere (Devillard et al., Mol Cell Bioclhem 2008; 307:149-57; Bessho et al., Anal Biochem 1991; 192:117-24). Briefly, tissue was suspended in cold perchloric acid and homogenized. Homogenate was centrifuged at 0° C., the pellet was dissolved in NaOH for protein quantitation, and the supernatant was neutralized with cold KHCO 3 and again centrifuged before HEP (ATP+CP) measurement using a bioluminescent kit and protocol (Promega GloMax-Multi+Detection System; Sigma-Aldrich).
- Perfusate pH, glucose, K + , Ca 2+ and HCO 3 ⁇ were adjusted for swine blood levels (pH 7.5; 100 mg/dl; 3.7, 1.38 and 32 mmol/liter, respectively), using 10% dextrose, KCl, CaCl 2 and NaHCO 3 , respectively.
- Somah device A custom-built apparatus was used for extracorporeal reanimation of hearts ( FIG. 1 ).
- a CDI monitor (Clinical Documentation Improvement Monitoring System 500; Terumo Cardiovascular Systems Corp., Ann Arbor, Mich.), was used for real-time monitoring of perfusate pH, temperature, PO 2 , PCO 2 , K + and HCO 3 ⁇ . These parameters were also analyzed in inflow/outflow samples using an iSTAT analyzer (Abaxis, Ltd., Union City, Calif.).
- Average duration for post-perfusion assessment in Somah hearts was 180 minutes, in contrast to 60 and 120 minutes, respectively, for Celsior and UWS hearts due to development of myocardial contracture and/or poor performance, even after several minutes of reperfusion upon reaching 37° C. Electroconversion (40 to 50 J) and/or epinephrine (1:50.000 to 1:100,000 in Somah hearts, as per previous experience (Lowalekar et al., Am J Transpl 2014 October; 14(10):2253-62) or 1:10,000 for Celsior/UWS hearts as reported elsewhere (Hill et al., Am Thorac Surg 2005; 79:168-77)) were used if required.
- Inflow (aortic) and outflow (caval) samples were collected at the beginning and then every 30 minutes ( FIG. 2 ).
- Epicardial 2-dimensional (2D) echocardiography was performed using a transesophageal echocardiography (TEE) probe for functional assessment.
- Epicardial echocardiography Two-dimensional echocardiography data (short- and long-axis views for cardiac functional parameters, and LV septal/ventricular wall thicknesses) was acquired intra-operatively and ex vivo (epicardial) with a TEE probe (Cypress system; Acuson, Mountain View, Calif.) once the system temperature reached 37° C., 30 minutes after start of perfusion, and then analyzed with CYPRESS-VIEWER software. Three-lead ECG was recorded during 2D echocardiography using brass crocodile leads immersed in perfusate in the heart chamber. All Somah hearts sustained full workload (PV perfusion) and sinus rhythm, but not all Celsior and UWS hearts could tolerate the switch to full workload.
- Intra-operative cardioplegia All hearts received cardioplegia at 21° C. Cardiac arrest occurred immediately in the UWS group, likely due to very high K+. In contrast, it took 20 to 25 and 30 to 40 seconds in the Somah and Celsior groups, respectively, for complete cardiac arrest.
- HEP levels during storage were significantly enhanced in Somah stored hearts (28.33 ⁇ 5.51; p ⁇ 0.001), significantly decreased in UWS hearts (5.92 ⁇ 1.46; p ⁇ 0.05), but remained unaltered in Celsior hearts (11.57 ⁇ 2.77), as compared with controls (9.95 ⁇ 2.52 nmol/liter per milligram protein) ( FIG. 3 ), and there was a significantly greater build-up of HEP in Somah hearts than in the comparison groups (p ⁇ 0.001).
- Coronary flow upon reperfusion Coronary flow upon reperfusion. Coronary flow upon initial perfusion at 21° C. was significantly greater in Somah hearts than in Celsior or UWS hearts at similar perfusion pressures (Table 2). Somah hearts, but not Celsior/UWS hearts, demonstrated slow contractions immediately upon initiation of reperfusion. With the increase in system temperature to 37° C., coronary flow increased significantly in Somah and UWS hearts but not in Celsior hearts, and was highest and nearly normal in Somah hearts. In the UWS group, there was a drop in coronary circulation pressure alter an initial abrupt rise.
- Somah 40 ⁇ 1 386 ⁇ 68 a 44 ⁇ 2 375 ⁇ 62 a 53 ⁇ 4 579 ⁇ 35 b,c Celsior 39 ⁇ 1 272 ⁇ 35 51 ⁇ 7 199 ⁇ 44 55 ⁇ 5 289 ⁇ 99 UWS 38 ⁇ 3 163 ⁇ 13 53 ⁇ 6 195 ⁇ 44 38 ⁇ 3 443 ⁇ 80 b,c P1, P2, P3: aortic root pressures at respective temperatures; F1, F2, F3: coronary flows at respective temperature. UWS, University of Wisconsin solution. a Significant difference from other groups at same temperature. b Significant difference from 21° C. in the same group. c Significant difference from Celsior group hearts.
- Somah may be the key “solution” for improving prognosis in heart transplant patients. Robust metabolism, superior functional revival upon reanimation, decreased IRI-dependent damage and diminished requirements for stimulatory interventions that hearts stored in Somah at sub-normothermia are more likely to revert rapidly to robust functionality compared with other preservation solutions.
- This Example examines whether recovery of post storage heart functionality is proportionally dependent on the maintenance of the organ's energy state and storage temperature and compares heart preservation in Celsior at 4° C. and in Somah at 4° C., 13° C., and 21° C., respectively.
- Heart procurement surgery, extracorporeal heart storage, ATP and creatine phosphate assays, preparation of hearts for ex vivo resuscitation and functional studies, preparation of blood for ex vivo studies, the Somah device, and functional studies were performed as described in Example 1, above.
- Heart weight and biopsies Heart chambers were emptied prior to weighing at the start of storage and after 5 h. Cardiac punch biopsies (2-4 mm diameter) were taken using punch forceps within 15 min of heart excision (controls) and at the end of 5-h storage from the posterior wall of left ventricle (LV) for histopathology (HP; hematoxylin and eosin staining) and ultrastructure for Somah hearts and HEP assays for Somah and Celsior hearts.
- LV left ventricle
- Inflow (aortic) and outflow (caval) samples were collected for enzyme assays at 5 min and 90 min after start of perfusate perfusion, and at 60 min (baseline) and 90 min (peak performance) for assessment of myocardial O 2 consumption (MVO 2 ) and lactate levels, using Vetscan VS2 or i-Stat System. MVO 2 was calculated. The Vetscan CK assay values obtained during in vitro reperfusion were specific for heart in these isolated heart studies.
- TEE probe was used for 2D Echo evaluation of cardiac function intraoperatively and ex vivo, using Acuson Cypress system (Acuson, Mountain View, Calif.) and images analyzed using Cypress viewer software.
- Acuson Cypress system Acuson, Mountain View, Calif.
- Cypress viewer software a system that analyzes Cypress viewer software.
- heart was connected to Somah Device and suspended in a chamber containing 2 L perfusate covering two-thirds of hearts surface. An electrocardiogram was recorded from beginning and 2D Echo acquisition was begun approximately 45-60 min after perfusion, if and when good cardiac contractions were observed, and repeated at 30-min intervals.
- Probe was placed in direct contact with heart, and angle of the probe and direction of pulse adjusted to obtain short-axis and long-axis views to assess for cardiac functional parameters and ventricular and septal wall thicknesses.
- Lactate production and oxygen consumption during storage Anaerobic lactate production temporally increased from 0.41 at 2 h to 0.75 ⁇ 0.05 mmol/L in 21° C. hearts but was below detection level in hypothermic Somah groups after 5-h storage. However, the pH remained stable at 7.4 ⁇ 0.1 in all groups. Additionally, hearts stored at higher temperatures vigorously utilized oxygen dissolved in Somah (pO 2 210-240 mm Hg) due to relatively active aerobic metabolism. The pO 2 decreased by 7.0 ⁇ 7.6, 17.0 ⁇ 3.51 and 14.0 ⁇ 3.51 mm Hg in Somah at 4° C., 13° C. and 21° C., respectively during storage, corresponding with a parallel increase in HEP synthesis. Lactate and pO2 utilization could not be measured in Celsior during storage.
- Coronary flow Upon initiation of antegrade perfusion, coronary flow was observed in all hearts irrespective of solution or temperature of storage. The 4° C. and 13° C. Somah hearts demonstrated slow irregular four chamber contraction as temperature was raised to 21° C., while slow rhythmic contraction were immediately observed after initiation of perfusion in 21° C. group.
- Celsior hearts demonstrated irregular contractions of atria but not the ventricles. Cardiac contractions and sinus rhythm were enhanced with rising temperature, reaching peak performance at 37° C. approximately 90 min after initiation of perfusion in all Somah groups, but not in the Celsior hearts.
- Initial coronary flow was significantly greater (p ⁇ 0.05) in Somah hearts stored at 21° C. than in hearts stored at 4° C. and 13° C. At 378 C, furthermore, there was a significant parallel increase in coronary flow in Somah groups (p ⁇ 0.05), but not in the Celsior group (Table 2-1). Additionally, coronary flow at 37° C. in Somah groups was significantly greater than in the Celsior hearts (p ⁇ 0.05).
- MVO 2 Cardiac metabolism and enzyme release upon reperfusion in working hearts: MVO 2 remained unaltered between 60 (baseline) and 90 min post perfusion in 4° C. Somah hearts and increased significantly within 13° C. and 21° C. Somah hearts, but there was no difference between the three groups. In contrast, MVO 2 was severely attenuated in Celsior hearts ( FIG. 9A ). Similarly, lactate level in perfusate at baseline was significantly lower in Celsior group (p ⁇ 0.05) than Somah groups. Lactate decreased in all groups at 90 min, but significantly within the 13° C. and 21° C. Somah groups (p ⁇ 0.05), though the difference was insignificant between the groups ( FIG. 9B ).
- Cardioversion Epinephrine Storage (33-40 V; epicardial) ⁇ (0.1 mg bolus) ⁇ temperature times delivered times delivered Celsior 4° C. >7 >5 Somah 4° C. 4-6 3-4 Somah 13° C. 2-5 2-3 Somah 21° C. 1 —
- Celsior hearts were unable to generate synchronous four chamber contractions and were incapable of sustaining any workload, even with multiple stimulatory interventions (Table 2-3), eventually developing stiffness during the experimental period. Therefore, functional data could not be collected from the Celsior hearts. Data obtained at peak performance 90 min into perfusion and full workload in Somah groups was used for comparative analysis. Calculated percentage fractional area change, coronary flow, blood pressure, stroke volume, ejection fraction and cardiac output approached physiological parameters in 21° C. group hearts (Table 2-4).
- DCD hearts taken 30 minutes after cardiocirculatory death (DCD hearts) were studied and stored for 4 to 5 times the current clinical norms. Additionally, the study was designed to determine the ideal temperature for the long-term storage of DCD hearts in Somali, in a functionally viable state for transplantation.
- Somah Solution Preparation and Other Materials. Somah was formulated as described above. Freshly prepared solution was filter sterilized using 0.4 mm filter (VWR International) stored at 4° C. and used within 24 hours of preparation. All chemicals and antibodies were obtained from Sigma Chemical Co (St Louis, Mo., USA), Amersham Biosciences (Piscatway, N.J., USA), Bio-Rad (Hercules, Calif., USA), or DAKO Corp (Carpinteria, Calif., USA), unless otherwise stated.
- JC-1 Assay of Mitochondrial Membrane Potential Cardiomyocytes were labeled with JC-1 dye (Molecular Probes), imaged, and the mitochondrial polarity ratios were determined using multiphoton microscopy.
- LV tissue (20 mg) was cut into 300 pieces, suspended in 200 mL of Lysis buffer (CellLytic MT; Sigma-Aldrich) with a protease inhibitor cocktail, homogenized for 30 seconds before centrifuging at 16.000 g for 10 minutes and the supernatant (total protein) collected and then quantitated using Bio-Rad protein assay kit. Proteins were resolved on 7.5%, 10% or 12% SDS-PAGE and transferred to nitrocellulose membrane.
- Lysis buffer CellLytic MT; Sigma-Aldrich
- Blots were incubated with primary antibodies (1:1000; anti-myosin heavy and light chain, actinin, actin, and troponin C) followed by HRP (horseradish peroxidase) conjugated secondary antibodies and protein expression detected using electrochemiluminescence (GE Hlealthcare).
- primary antibodies (1:1000; anti-myosin heavy and light chain, actinin, actin, and troponin C)
- HRP horseradish peroxidase conjugated secondary antibodies and protein expression detected using electrochemiluminescence (GE Hlealthcare).
- ATP and CP Assays were measured in cardiac tissue after 24-hour storage at 4° C., 10° C., 21° C. or 37° C. and upon reperfusion using spectrofluorometer and bioluminescent assay kit (Perkin Elmer, Waltham, Mass. USA).
- Multiphoton Imaging State-of-the-art multiphoton imaging techniques using BioRad imaging system (MRC 1024ES) coupled with MaiTai mode-locked titanium:sapphire laser (Spectra-Physics, Mountain View, Calif., USA), were used for deep-imaging cardiac biopsies and semiquantitative fluorescence measurements. Images 512 ⁇ 512 pixels were collected in direct detection configuration, at pixel resolution of 0.484 mm. Cardiomyocytes were identified by XYZ axis scanning, and imaged at depths of 50 mm in LV biopsies from the point of excision.
- FIG. 12 Live-dead assays and multiphoton microscopy ( FIG. 12 ) of cardiac biopsies performed immediately after extraction (control; FIG. 12A ) demonstrated robust green fluorescence (indicative of viable cells) but no red nuclear fluorescence (indicative of damaged cells).
- FIG. 12A Live-dead assays and multiphoton microscopy ( FIG. 12 ) of cardiac biopsies performed immediately after extraction (control; FIG. 12A ) demonstrated robust green fluorescence (indicative of viable cells) but no red nuclear fluorescence (indicative of damaged cells).
- the gross morphology of DCD hearts was well preserved at all other temperature groups while the green fluorescence of live-dead assay in these groups was similar to that of controls.
- the red nuclear fluorescence of damaged cells was also enhanced after 24-hour storage ( FIG.
- Esterase Activity Measurement Prior to simulated perfusion, quantum yield of green fluorescence as a function of esterase activity was highest in the hearts stored at 21° C. and lowest at 37° C. (Table 3-1). After reperfusion, the esterase activity was unaltered in hearts stored at 21° C. but was variably decreased in hearts stored at 4° C., 10° C., and 37° C., although not significant in 10° C. group.
- JC-1 Assay for Mitochondrial Polarization In the freshly extracted DCD hearts, the polarized and depolarized states of mitochondria were in equilibrium ( FIG. 13 ). Irrespective of storage temperature, mitochondrial membranes in cardiomyocytes of DCD hearts remained polarized both after 24-hour storage and upon reperfusion, while the polarization ratio was not altered in any group after reperfusion. Furthermore, there was no significant difference in mitochondrial polarization status in the different groups before or after reperfusion.
- This Example evaluates the relative efficacy of Somah at 4 and 21° C. in preservation of optimum heart function after in vitro storage at subnormothermia.
- Extracorporeal storage of heart Hearts were placed in sterile zip-lock bags containing 2 L of SOMAH in water-jacketed water bath at 21 ⁇ 2° C. The temperature of preservation solution was checked regularly during the entire storage period. Hearts were maintained in a non-contractile state by increasing SOMAH's plegia potential by supplementing the solution with 20 mM K+ complemented by 37 mM Mg2+(Fukuhiro Y, Wowk M, Ou R, Rosenfeldt F, Pepe S: Cardioplegic strategies for calcium control: low Ca2+, high Mg2+, citrate, or Na+/H+exchange inhibitor HOE-642 . Circulation.
- ATP and creatine phosphate assay were measured in tissue extracts as described (Thatte H S. Rousou L, Hussaini B E, Lu X G, Treanor P R, Khuri S F: Development and evaluation of a novel solution, Somah, for the procurement and preservation of beating and non-beating donor hearts for transplantation. Circulation. 2009, 120: 1704-1713; Bessho M. Ohsuzu F, Yanagida S, Sakata N, Aosaki N, Tajima T. Nakamura H: Differential extractability of creatine phosphate and ATP from cardiac muscle with ethanol and perchloric acid solution. Anal Biochem.
- tissue biopsies were flash frozen and stored at ⁇ 80° C.; 20 mg of tissue was suspended in 400 ⁇ l of 0.4 M ice-cold perchloric acid and homogenized twice for 30 seconds. Homogenate was centrifuged at 1970 g for 10 minutes at 0° C. An aliquot of supernatant was neutralized with equal volume of ice-cold 0.4 M KHCO 3 and centrifuged as above. The supernatant was stored at ⁇ 80° C. for ATP and CP measurements. The pellet was dissolved in equal volume of 0.1 M NaOH, centrifuged and used for protein assay. ATP and CP were measured using a bioluminescent assay kit (Sigma-Aldrich and GloMax-Multi+Detection System, Promega), according to the protocol provided by the manufacturer.
- Aorta and pulmonary artery (PA) were separated.
- Aorta was cannulated (1 ⁇ 2-3 ⁇ 8inch tubing connector) and coronaries were gently flushed with 100 ml of SOMAH in both 4° C. and 21° C.
- cardioplegia groups at 40-50 mmHg pressure, carefully avoiding entry of air into the aorta.
- Pulmonary veins (PV) were separated and cannulated with 1 ⁇ 2-1 ⁇ 4 inch tubing connector. PA was cannulated for sample collection while superior and inferior vena cavas were ligated.
- the SOMAH device A custom-built apparatus was used for extra-corporeal reanimation of hearts ( FIG. 1 ).
- CDI monitor (Clinical Documentation Improvement monitoring system 500, Terumo cardiovascular systems corporation. Ann Arbor, Mich.), was used for real-time monitoring of perfusate pH, temperature, pO 2 , pCO 2 , K+ and HCO 3 —. These parameters were also analyzed in inflow/outflow samples using i-STAT analyzer (Abaxis Ltd, Union city, CA). Pressures and flows were recorded at various points in the circuits ( FIG. 16 ).
- a trans-esophageal echocardiography (TEE) probe was used to assess the contractile function of heart using the 2D-Echo system.
- Hearts were perfused through aortic root (no workload) until the system temperature reached 37° C., after which PV perfusion (full workload) proceeded until end of experiment.
- Corollary blood flow was determined during the initial antegrade perfusion by the amount of perfusate flowing to the heart through aorta per minute, and in the working heart by the amount of perfusate collected from pulmonary artery (both cavas ligated) per minute.
- Electroconversion 40-50 J and/or epinephrine (1:50,000-1:100,000) were used if required (Lowalekar S K, Cao H, Lu X G, Treanor R, Thatte H S: Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant. 2014).
- Epicardial 2D Echo was performed using TEE probe for functional assessment at 60 minutes (baseline) and at peak performance, approximately 90 minutes after initiation of perfusate perfusion in the two groups with hearts under full workload; and every 30 minutes thereafter. Peak cardiac performance was defined by the maximum contractile activity observed by 2D Echo. The data at peak performance was used for comparisons between the two groups.
- CK cardiac creatine kinase
- AST aspartate aminotransferase
- cTnI troponin-I
- lactate and gases pO 2 /pCO 2
- Inflow (aortic) and outflow (PA) samples were collected for enzyme assays and post perfusion assessment of myocardial O 2 consumption (MVO 2 ) and lactate levels using Vetscan VS2 or i-Stat System, at 5 and 90 minutes for enzyme assays, and at 60 minutes (baseline) and 90 minutes (peak performance) for MVO2 and lactate, after start of perfusate perfusion with Vetscan or iStat.
- MVO2 was calculated as described (Klabunde R: Cardiac function. Cardiovascular Physiology Concepts. 2011, Lippincott Williams & Wilkins, Baltimore, Md. USA, 84-88).
- a trans-esophageal (TEE) probe was used for 2D echo evaluation of cardiac function intra-operatively and ex vivo using the Acuson Cypress system (Acuson, Mountain View, Calif.) and images were analyzed using Cypress viewer software provided with the system.
- Hearts were connected to SOMAH Device and suspended in a chamber containing 2 L of perfusate that covered 2 ⁇ 3rd surface of the heart. ECG was recorded during entire course of the experiment and 2D Echo acquisition was begun approximately 45-60 minute after perfusion, when good cardiac contractions were observed, and repeated at 30-minute intervals.
- Probe was placed in direct contact with heart and angle of probe and direction of pulse were adjusted as to obtain short-axis and long-axis views for calculations of cardiac functional parameters, and ventricular wall and septal thickness.
- Intraoperative cardioplegia Cardiac arrest was dependent on the temperature of cardioplegia and occurred within 10-15 seconds in 4° C. group and 20-25 seconds in the 21° C. group, likely because the hypothermic (4° C.) component of cardiac arrest was deliberately eliminated in the latter.
- Rate of CK. AST and cTnI release increased in 4° C. hearts during the perfusion period ( FIG. 18 ). Both CK and cTnI release increased significantly with the time of perfusion, but the AST did not. In contrast, there was a temporal decrease in release of these three enzymes in the 21° C. hearts during the same period ( FIG. 18 ). However, release of CK and cTnI, but not the AST, was significantly greater by the 21° C. hearts upon initiation of perfusion than by the 4° C. hearts.
- Myocardial edema has been reported in hearts arrested at perfusion pressures of cardioplegia as low as 50 mmHg (Mehlhorn U, Geissler H J, Laine G A, Allen S J: Myocardial fluid balance. Eur J Cardiothorac Surg. 2001, 20: 1220-1230).
- SOMAH cardioplegia provides all the advantages of blood cardioplegia, in terms of protection from cardiac edema and provision of substrates for energy metabolism, and also provides clear surgical field.
- Antegrade perfusion was significantly lower in the 4° C. heart than in 21° C. hearts, and remained diminished, even at higher perfusion pressures until the system temperature stabilized at 37° C. (Table 4-1). Without being bound to theory, it is plausible that sudden shock of encountering 4° C. cardioplegia by the normothermic beating heart leads to profound vasoconstriction that does not resolve during storage and only does so upon initiation of reperfusion and raising of temperature to 37° C. and potentially because of active release of vasodilators nitric oxide and prostacyclins (Thatte H S. Rousou L, Hussaini B E, Lu X G, Treanor P R, Khuri S F: Development and evaluation of a novel solution.
- This Example was designed to evaluate the novel storage solution Somah in its ability to maintain phosphate synthesis of livers and halt progression of long-term static storage-dependent multicellular damage.
- the aim of this current pilot study was to evaluate the comparative efficacy of Somah with the currently clinically used University of Wisconsin solution (UWS) in their ability to preserve and potentiate recovery of DCD porcine livers in vitro during a 72 hour period of hypothermic storage.
- UWS University of Wisconsin solution
- a limited extracorporeal hepatic reperfusion and functional evaluation of Somah-stored livers was also performed to test the feasibility for future transplant studies to evaluate graft function.
- CoStorSol (UWS) (Preservation Solutions Inc, Elkhorn, Wis.) and Somah (Somahlution, LLC, Jupiter, Fla.), Table 5-1, was compared for storage properties. All other chemicals were obtained from Sigma-Aldrich (SL Louis, Mo.). VetScan iStat, VetScan VS2, CG4+, CG8+, Large Animal Profile. Comprehensive Diagnostic Profile cartridges for measuring blood gases, electrolytes, lactate, glucose, aspartate transaminase (AST), alanine transaminase (ALT) and creatine kinase (CK) enzymes were purchased from Abaxis Inc (Union City, Calif.).
- liver storage and procurement of samples The study was conducted in fourteen female swines, each weighing 40-50 Kg in accordance with protocol approved by an Animal Studies Subconunittee (IACUC), VA Boston Healthcare System. The animals were divided into two groups of seven animals each. Whole livers were dissected out 60 ⁇ 10 minutes after cardiac death and extraction of heart. The livers were stored in UWS (UWS livers) or Somah solution (Somah livers) for 72 hours at 4° C. The solutions were not replaced during storage. Liver biopsies were obtained at 0, 6, 24 and 72 hours for imaging and biochemical assessment of viability. UWS and Somah solutions were sampled at 1, 6, 24 and 72 hours for metabolic monitoring and for other assays and compounds relevant to liver function.
- IACUC Animal Studies Subconunittee
- Surgical procedure General anesthesia was induced with i.m. injections of telazol 4-6 mg/kg and xylazine 2 mg/kg. After intubation, animals were maintained with i.v. propofol (10 mg/kg/hour), remifentanyl (40-60 ⁇ g/hr) and nimbex (cisatracurium) 10-20 mg, and mechanically ventilated. Aorta was cross-clamped, heart arrested, and heart-lung block was extracted for other experiments as described ((Lowalekar S K, Cao H, Lu X G, Treanor R, Thatte H S: Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant.
- ATP and creatine phosphate assay were measured in liver tissue extracts.
- 20 mg of hepatic tissue was suspended in 400 ⁇ l of 0.4 M ice-cold perchloric acid and homogenized twice for 30 sec. Homogenate was centrifuged at 1970 g for 10 mins at 0° C. An aliquot of supernatant was neutralized with equal volume of ice-cold 0.4 M KHCO 1 solution and centrifuged as mentioned above. The supernatant was stored at ⁇ 80° C. for ATP and CP measurements. The pellet was dissolved in equal volume of 0.1 M NaOH and centrifuged and used for protein assay. ATP and CP were measured using a bioluminescent assay kit (Sigma-Aldrich and GloMax-Multi+ Detection System, Promega) according to the protocol provided by manufacturer.
- Livers were gently flushed through the portal vein with 2 L of cold Somah, and then connected to Somah device via the hepatic artery (HA) and portal vein (PV).
- the reservoir outlet was diverted into two circuits: in the first circuit, the perfusate drained by gravity into the PV at a pressure of 8-10 mmHg (adjusted by changing the height of the reservoir).
- perfusate was diverted through a pump to the HA (at pressures of 80-100 mmHg) via the oxygenator and heat exchanger. Temperature of perfusate was raised to 37° C.
- HV hepatic veins
- Tissue biopsies of livers stored either in Somah or UWS were taken at 0, 6, 24 and 72 hour storage time points, fixed in 10% formalin and processed for histopathology (10 ⁇ sections; Hematoxylin and Eosin stain).
- the images were acquired and analyzed using Olympus microscope and image analyzer system (BX51TRF; Olympus America Inc, USA). Images were assessed blindly for histopathology by three independent observers.
- Hepatocytes Nuclear chromatin condensation and pyknotic changes of hepatocytes in numerous low power fields were seen in livers stored in UWS but not in Somah. Binucleate and polyploid hepatocytic nuclei were consistently seen in sections obtained from both UWS and Somah-preserved livers. Furthermore, in Somah livers, cellular boundaries between adjacent hepatocytes were visibly intact, and no cholestasis or bile canalicular dilatations were apparent upon careful scan of multiple fields. In sections obtained from UWS livers at 72 hrs, degeneration of hepatocytes associated with extensive vacuolation was evident, but not in Somah livers ( FIG. 21 ).
- Biliary ducts and ductules Nuclei lining both bile ductules and larger bile ducts in the portal triad appeared intensely pyknotic, suggesting apoptosis or necrosis of cholangiocytes in UWS livers. In contrast, the bile ducts and ductules were uniform in appearance with regularly placed nuclei and well preserved nuclear heterogeneity in Somah livers after 72 hrs of storage ( FIG. 21 ).
- HCO 3 concentration decreased from 7.30 to 5.33 mM/L in UWS during the 72 hour storage, which, without being bound to theory, may have contributed to the non-significant increase in pCO 2 that was observed in UWS during the storage period ( FIG. 25 ).
- Another possibility to be considered is that anaerobic glycolysis, through lactate production, may have contributed to the rise of pCO 2 in Somah (as well as the mild rise in UWS stored livers).
- somah livers Functional evaluation of somah livers. Somah stored livers (72 hours) were reperfused with blood (perfusate) for 2 hours at 37° C. for functional evaluation. Oxygen consumption by the reperfused livers increased significantly by 38% and 64% (p ⁇ 0.05) at 30 and 120 min, respectively. Concomitantly, lactate concentration released in the perfusate decreased by 11% and 41% at 30 min and at the end of 2 hours, indicating anaerobic to aerobic metabolic switch.
- the DCA by enhancing oxidative metabolism of pyruvate, also prevents build-up of lactate in Somah stored livers.
- insulin which enhances the entry of glucose into cells, is a hepatotrophic factor and is essential for maintenance of hepatic ultrastructure and regenerative ability. Somah solution exploits this ability of insulin by providing it in a concentration of 100 U/L, 2.5 folds higher than that in UWS.
- the greater lactate accumulation above threshold levels in the absence of DCA and the lower insulin concentration in UWS-livers contributes to the comparative changes in this group.
- Treanor R, Thatte H S Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant. 2014).
- UWS-stored livers were not evaluated for functional recovery because of gross damage to these organs.
- This Example evaluated the ability of novel organ preservation solution Somah compared to University of Wisconsin (UW) solution for extended storage of DCD kidneys.
- Ice cold cardioplegia (20 mM K+) was infused after aortic clamping to stop the heart which was then excised for other experiments as described [6,7]. Time of complete cessation of heart contraction was recorded as the beginning of warm ischemia of other body organs. Post median laparotomy, suprahepatic aorta was cannulated and abdominal organs flushed with 2 L of ice cold UW (CoStorSol; Preservation Solutions Inc., Elkhorn, Wis.) or Somah solution (Somahlution Inc., Jupiter, Fla.), at 100 mmHg pressure and a flow of 300 ml/min, till perfusate returning through inferior vena cava (IVC) was clear.
- ice cold cardioplegia 20 mM K+
- Tissue was fixed in formalin and embedded in paraffin before cutting 10 ⁇ thin sections that were melted onto glass slides for further processing. Tissue sections were dried in sequentially increasing ethanol concentrations and then subjected to hematoxylin and eosin staining after which slides were immersed in xylazine clearing agent, covered with cover slip and examined under microscope. Images were acquired and analyzed using Olympus microscope and image analyzer system (BX51TRF; Olympus America Inc. USA) and assessed in blind fashion by independent observers.
- ATP and creatine phosphate assay were measured in kidney tissue extracts as described [4-7,10].
- 20 mg of renal tissue was suspended in 400 ⁇ l of 0.4 M ice-cold perchloric acid and homogenized twice for 30 secs. Homogenate was centrifuged at 1970 g for 10 mins at 0° C. An aliquot of supernatant was neutralized with equal volume of ice cold 0.4 M KHCO 3 solution and centrifuged as above. Supernatant was stored at ⁇ 80° C. for ATP/CP measurements. The pellet was dissolved in equal volume of 0.1 M NaOH and centrifuged and used for protein assay. ATP/CP was measured using a bioluminescent assay kit (Sigma-Aldrich and GloMax Multi+Detection System. Promega) according to manufacturer's protocol.
- FIGS. 1 b ,1 c ,1 e and 1 f Histomorphology of kidneys. Irrespective of storage solution, there was no evident interstitial edema in all DCD kidneys at observed time-points, with well preserved overall structure of renal tissue ( FIGS. 1 b ,1 c ,1 e and 1 f ).
- the normal amorphous collection in tubular lumen was observed in proximal convoluted tubules (PCT) at all time-points and not increased with storage duration.
- Distal convoluted tubules (DCT) remained mostly clear of any debris at all time-points except at 72 hour where a minimal to moderate epithelial denudation was apparent in both UW and Somah-preserved kidneys ( FIGS. 1 c and 1 f ).
- Renal glomeruli exhibited normal cellularity with normal appearing Bowman's space and continuous parietal epithelium at all time-points, in
- FIGS. 1 c and 1 f A gradual time-dependent loss of tubular epithelial nuclear heterogeneity with increased hyperchromaticity and occasional loss of cellular margins was observed in both UW and Somah-stored kidneys, indicative of tubular epithelial injury ( FIGS. 1 c and 1 f ). However, extent of these changes were significantly greater in UW-stored kidneys (p ⁇ 0.05).
- HES helps to prevent organ edema during storage, it increases solution density that can interfere with perfusion of all parts of the organ. Although gross morphology is not the best indicator of organ viability, it is probable that an uneven perfusion of kidneys during harvesting, despite copious use of solution for perfusion, could have resulted in patchy discoloration of kidneys, due to greater UW viscosity ( FIG. 29 ).
- Renal histopathology showed no gross ultrastructural changes in either cortical or medullary regions of UW or Somah-stored kidneys.
- higher magnifications revealed subtle changes in cellular nuclei, especially in tubular epithelial cells, characterized by loss of nuclear heterochromacity with increased hyperchromacity, significantly greater in UW-stored kidneys. This is consistent with an inadequacy of UW to reach all parts of kidneys (vide supra), while Somah reached effectively and provided necessary nutrients to tissues in their entirety during harvesting and extracorporeal storage, thus avoiding development of minor lesions and may potentially improve the post-transplant outcomes.
- Somah pH was more acidotic, compared to UW, at all time-points. While acidic pH is reported to be constitutively beneficial to hepatocytes, sinusoidal epithelial cells as well as cardiomyocytes (Lemasters J J, Bond J M, Currin R T, Nieminen A L, Caldwell-Kenkel (1993) Reperfusion Injury to Heart and Liver Cell: Protection by acidosis during ischemia and a ‘pH paradox’ during reperfusion. In: Hochachka P W, Lutz P L, Sick TJ, Rosenthal M (eds) Surviving Hypoxia: Mechanisms of Control and Adaptation. CRC Press, Inc, Florida 495-508), this is the first report showing advantage of a relatively acidic environment in extracorporeal kidney preservation.
- Glucose an important energy source for highly metabolic renal tissue, was excluded from kidney preservation solutions used in current practice as it was thought to cause edema by enhanced lactate accumulation, a product of anaerobic metabolism during extracorporeal storage (Kallerhoff M, Holscher M, Kehrer G, Klab G, Bretschneider H J (1985) Effects of preservation conditions and temperature on tissue acidification in canine kidneys. Transplantation 485-489).
- UW a commonly used solution for renal storage, does not contain any glucose either.
- DCA by virtue of its vessel-preservation abilities, may help prevent development of post-transplant renal artery stenosis, and further improve prognosis of transplanted DCD kidneys (Deuse T, Hua X, Wang D, Maegdefessel L. Heeren J, et al. (2014) Dicholoroacetate prevents restenosis in preclinical animal models of vessel injury. Nature 509: 641-644).
- the blood vessels form the bulk of renal cortical tissue while tubular structures predominate in renal medulla. While glomerular tuft collapse within 6 hour storage in Ilistidine-Tryptophan-Ketoglutarate (IITK) solution has been reported (Kallerhoff M, Blech M, Kehrer G, Kleinert H, Langheinrich M, et al. (1987) Effects of glucose in protected ischemic kidneys. Urol Res 15: 215-222), such drastic glomerular change was not observed in either Somah or UW stored kidneys, at any timepoint ( FIG. 29 ).
- IITK Ilistidine-Tryptophan-Ketoglutarate
- This Example provides evidence that use of Somah for static preservation of DCD kidneys may potentially decrease the incidence of DGF, PNF and improve graft life upon transplantation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Thermal Sciences (AREA)
- Mechanical Engineering (AREA)
- Physics & Mathematics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Patent Application No. 62/173,184, filed Jun. 9, 2015, the disclosure of which is incorporated by reference herein in its entirety.
- The invention was made with government support under Merit Award number BX000817-01A1, awarded by the United States Department of Veterans Affairs. The government has certain rights in the present invention.
- This invention relates, inter alia, to compositions and methods to preserve biological tissues and organs over relatively long periods of time at ambient temperatures.
- The major obstacles in organ transplantation are the limited availability of donor organs and the poor quality of donor organs due to deterioration during storage. This is particularly true with donor hearts, which can currently be stored ex vivo for only 4 to 6 hours. Currently utilized solutions for extracorporeal heart storage are based on the prevention of edema and slowing down of metabolism (metabolic degeneration) during hypothermic storage at temperatures at or near 4° C. However, such low temperatures inevitably result in tissue and cellular damage which becomes irreversible after approximately 6 hours of storage.
- The compositions and methods described herein represent a significant improvement and advantage over existing methods for organ storage and/or preservation of organs from Beating Heart Donors (BHD), marginal, and Donation after Cardiac Death (DCD) donors. For example, the improved storage/preservation solutions, e.g., improved Somali (iSomah), permit storage and perfusion of organs at ambient (25° C.) as well as at sub-ambient (>4 and <25° C.). Exposure of an organ, e.g., a heart, to hypothermia leads to injury and even damage to the organ. Moreover, the transition from a beating heart at normothermia (36.4-37.1° C., e.g., 36.4° C. 36.5° C., 36.6° C., 36.7° C. 36.8° C., 36.9° C., 37° C., or 37.1° C.) to a non-beating heart at hypothermic temperatures, e.g., 4° C., is also stressful for cardiac tissue. However, rather than complete stasis observed at 4° C. due to hypothermia, if a heart continues to demonstrate slow contractions or movements in a novel solution that facilitates storage at room temperature, e.g., approximately 20° C. (21° C.±+4° C.) it would deplete cellular high-energy phosphate stores (ATP+CP) and beat to exhaustion leading to associated degenerative changes such as loss of cellular homeostasis, calcium overload and induction of apoptosis and/or necrosis resulting in untransplantable organ known as a “stone heart.” Therefore, the concentration of potassium ions and magnesium ions in the solutions described herein are increased (compared to other storage or cardioplegia solutions) to induce temporary paralysis of the heart tissue during subnormothermic storage (e.g., 10-25° C.)), while simultaneously maintaining HEP synthesis, cellular homeostasis, nitric oxide generation (additionally by chelating toxic ammonium ions generated from transaminase reactions; see
FIG. 33 ). This results in increased activity of the nitric oxide synthetic pathway in all tissues and organs and accompanying physiological control of edema. - Cardioplegia is an intentional and temporary cessation of cardiac activity. Such a temporary arresting of the heartbeat is carried out by any of various methods such as by injection or infusion of chemical substances such as a cardioplegia solution. For example, the heart is stopped in such a manner for cardiac surgery. Such surgeries include bypass surgery, heart valve replacement, aorta repair surgery, and heart transplantation etc.
- In addition to improving/preserving the condition, e.g., reducing tissue damage of the heart organ, the solutions provide other advantages such as reduced cost, potentially reduced need for immunosuppression following transplantation because of minimal endothelial and tissue damage to the heart, reduced need for inotropic support (e.g., drugs are not required to increase heart contraction) and incessant electroversions to maintain sinus cardiac function, decreased CPB time, as well as stay in the ICU and hospital (hence, decreased costs). Additionally, use of the organ preservation solutions provided herein result in decreased patient morbidity and improved long-term outcomes and thus most importantly improved quality of life of the patients. Once the heart is removed from the solution, the solution is flushed out of the heart tissue during surgery. The organ then goes into sinus conversion and resumes beating upon reperfusion with blood and rewarming, in vitro; or upon release of cross-clamp upon transplantation and during rewarming the patient to normothermia.
- Provided herein, inter aliu, are compositions, methods, and kits for preserving or resuscitating biological tissues or organs at ambient temperatures.
- Accordingly, in some aspects, provided herein are compositions for preserving or resuscitating biological tissue or organs comprising: a physiological salt solution, glucose (or other sugars such as lactose, maltose, and/or ribose) at concentrations of any of about 5-10 mM, such as about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM), and one or more of glutathione, ascorbic acid, arginine, citrulline malate (or, optionally, citrulline or salts thereof and/or malic acid or salts thereof), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereolf), orotic acid (or salts thereof) carnosine (such as, L-carnosine), carnitine (such as, L-carnitine), orotic acid, and/or dichloroacetate at concentrations of between 0 mM to about 5 mM), wherein the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions. The organ storage solutions described herein containing at least 20 mM potassium ions and/or at least 37 mM magnesium ions exhibit superior properties with respect to protecting and preserving organs during storage and during procedures such as cardioplegia over a more varied range of storage conditions (for example, temperature) compared to previously described organ storage solutions (see U.S. Pat. No. 8,211,628, the disclosure of which is incorporated by reference herein). As such, the storage solutions disclosed herein are referred to as “improved Somah” (iSomah).
- In other aspects, provided herein are compositions for preserving mammalian organs comprising: a physiological salt solution, and one or more of a five or six carbon sugar (such as, ribose, glucose or dextrose), glutathione, ascorbic acid, arginine, citrulline (such as, citrulline malate), malic acid, adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), carnosine (such as, L-carnosine), carnitine (such as, L-carnitine), orotic acid, and/or dichloroacetate, wherein the composition or the organ is maintained at a temperature of 21±4° C.
- In some embodiments of any of the embodiments disclosed herein, the composition or the organ is maintained at a temperature of 21±4° C. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions. In some embodiments of any of the embodiments disclosed herein, the composition further comprises insulin. In some embodiments of any of the embodiments disclosed herein, insulin is added to the composition just prior to use. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises one or more salts selected from the group consisting of potassium phosphate, potassium chloride, sodium chloride, sodium bicarbonate, calcium chloride, sodium phosphate, magnesium chloride, magnesium sulfate. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0.44-10 mM of potassium phosphate. In some embodiments of any of the embodiments disclosed herein, the composition comprises 4-65 mM of potassium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 80-135 mM sodium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 2-25 mM sodium bicarbonate. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0-1.5 mM calcium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0.15-30 mM sodium phosphate. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0.5-45 mM magnesium chloride. In some embodiments of any of the embodiments disclosed herein, the composition comprises 0.5-1.5 mM magnesium sulfate.
- For example, in addition to a storage and/or preservation solution, the physiologically-compatible solutions (modified Somah) described herein are useful as a cardioplegia solution for arresting hearts over a temperature range encountered during open heart surgery and for donor and recipient hearts for and during transplantation. For such applications at 4-10° C., the solution contains 20 mM potassium ions, e.g., 20 mM KCl, final concentration; at 10-25° C., the solution contains 20 mM potassium ions. e.g., 20 mM KCl and 37 mM magnesium ions, e.g., 37 mM MgCl2, final concentration; at 25-37° C. the solution contains 45 mM potassium ions. e.g., 45 mM KCl. and 37 mM Magnesium ions, e.g., 37 mM MgCl2. In other embodiments, at 25-37° C. the solution contains 25 mM potassium ions, e.g., 25 mM KCl, and 37 mM Magnesium ions, e.g., 37 mM MgCl2.
- Exemplary temperature ranges for organ arrest (e.g., heart cardioplegia) as well as organ storage (e.g., heart, lung, or other organ storage ex vivo) as well as potassium ion and magnesium ion concentrations (e.g., concentrations of KCl and MgCl2) are described below.
- In one embodiment, hearts are arrested with Somah cardioplegia containing 20 mM KCl (range 4.0-65 mM) and 37 mM MgCl2 (range 1.5-45 mM) at 4-37° C. and preserved in the same solution at 4-37° C. for transplant. In another embodiment, lungs are preserved in modified Somah containing 7.5 mM KCl and 2 mM MgCl2 at 4-37° C. as well as in Somah containing 20 mM KCl (range 4.0-65 mM) and 37 mM MgCl2 (range 1.5-45 mM) at 4-37° C. for transplant.
- In other aspects, provided herein are methods for storing, preserving or resuscitating a biological tissue or organ, comprising bringing said biological tissue or organ into contact with any of the compositions disclosed herein or above. In some embodiments, the composition is maintained at a temperature of 10-21±4° C. In some embodiments of any of the embodiments disclosed herein, the biological tissue or organs are stored or preserved for 24-72 hours. In some embodiments of any of the embodiments disclosed herein, the biological tissue or organ is selected from the group consisting of heart, kidney, liver, stomach, spleen, skin, pancreas, lung, brain, eye, intestines, and bladder. In some embodiments of any of the embodiments disclosed herein, the amount of high energy phosphates are higher in the biological tissue or organ following preservation or resuscitation compared to biological tissue or organs not contacted with the composition. In some embodiments of any of the embodiments disclosed herein, the organ is a heart. In some embodiments of any of the embodiments disclosed herein, coronary blood flow is higher in the biological tissue or organ following preservation or resuscitation compared to biological tissue or organs not contacted with the composition. In some embodiments of any of the embodiments disclosed herein, one or more of percent fractional area change, ejection fraction, and/or stroke volume and cardiac output is increased in hearts following preservation or resuscitation compared to hearts not contacted with the composition.
- In further aspects, provided herein are methods for producing a composition for storing, preserving or resuscitating biological tissue or organs comprising combining a physiological salt solution and one or more of glucose (11-25 mM), glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof (0.5-10 mM)), orotic acid (0.5-2.5 mM), carnosine (such as, L-carnosine), carnitine (such as, L-carnitine), and/or dichloroacetate, wherein the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions. In some embodiments, the method further comprises combining the composition with insulin. In some embodiments, insulin is combined just prior to use. In some embodiments of any of the embodiments disclosed herein the composition is maintained at a temperature of 10-21±4° C. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises one or more salts selected from the group consisting of potassium phosphate, potassium chloride, sodium chloride, sodium bicarbonate, calcium chloride, sodium phosphate, magnesium chloride, magnesium sulfate. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0.44-10 mM of potassium phosphate. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 4-65 mM of potassium chloride. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 80-135 mM sodium chloride. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 2-25 mM sodium bicarbonate. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0-1.5 mM calcium chloride. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0.15-30 mM sodium phosphate. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0.5-45 mM magnesium chloride. In some embodiments of any of the embodiments disclosed herein, the physiological salt solution comprises 0.5-1.5 mM magnesium sulfate.
- In another aspect, provided herein are kits comprising: a physiological salt solution and one or more of glucose, glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), carnosine (such as, L-carnosine), orotic acid, carnitine (such as, L-carnitine), dichloroacetate, and/or insulin, wherein the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions. In some embodiments, the physiological salt solution comprises one or more salts selected from the group consisting of potassium phosphate, potassium chloride, sodium chloride, sodium bicarbonate, calcium chloride, sodium phosphate, magnesium chloride, magnesium sulfate. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0.4-10 mM of potassium phosphate. In some embodiments of any of the embodiments disclosed herein, the kit comprises 4-65 mM of potassium chloride. In some embodiments of any of the embodiments disclosed herein, the kit comprises 80-135 mM sodium chloride. In some embodiments of any of the embodiments disclosed herein, the kit comprises 2-25 mM sodium bicarbonate. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0-1.5 mM calcium chloride. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0.15-030 mM sodium phosphate. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0.5-45 mM magnesium chloride. In some embodiments of any of the embodiments disclosed herein, the kit comprises 0.5-1.5 mM magnesium sulfate.
- In still other aspects, provided herein are compositions for storing, preserving, or resuscitating biological tissue or organs comprising: 7 mM potassium chloride, 0.44 mM potassium phosphate (monobasic), 0.5 magnesium chloride (hexahydrate), 0.5 mM magnesium sulfate (heptahydrate), 125 mM sodium chloride, 5 mM sodium bicarbonate, 1.3 mM calcium chloride, 0.19 mM sodium phosphate (dibasic; heptahydrate), 11 mM D-glucose, 1.5 mM glutathione (reduced), 1 mM ascorbic acid, 5 mM L-arginine, 1 mM L-citrulline malate, 2 mM adenosine, 0.5 mM creatine orotate, 2.0 mM creatine monohydrate or salts thereof, 10 mM L-carnosine, 10 mM L-carnitine, and 0.5 mM dichloroacetate. In some embodiments, the compositions further comprise 100 units/L insulin. In some embodiments, the insulin is added to the composition just prior to use. In some embodiments of any of the embodiments provided herein, the composition is maintained at a temperature of 21±4° C.
- Advantages of the improved organ storage preservation solutions described herein include: (1) preservation of hearts at hypothennia (4° C.) is superior to current clinically used solutions Celsior and UWS; (2) preserves hearts in fully functional state at ambient temperatures, while the clinically used solutions (such as Celsior and UWS) cannot; (3) preserves heart in excellent condition over the temperature range of 4-25° C.; others cannot (heart metabolism and homeostasis in preserved or accentuated over this temperature range but not in other solutions; (4) hearts require minimal stimulatory interventions for reanimation due to preservation and synthesis of high energy phosphates over the temperature range of storage; hearts in other solutions cannot; (5) facilitates functional preservation of (Beating Heart Donor) BHD and (Donation after Cardiac Death) DCD hearts for 24 hours and other organs for over 72 hours at over the temperature range; while other solutions cannot.
- Each of the aspects and embodiments described herein are capable of being used together, unless excluded either explicitly or clearly from the context of the embodiment or aspect.
- Throughout this specification, various patents, patent applications and other types of publications (e.g., journal articles, electronic database entries, etc.) are referenced. The disclosure of all patents, patent applications, and other publications cited herein are hereby incorporated by reference in their entirety for all purposes.
-
FIG. 1 depicts the Somah Device, a custom-built apparatus specifically designed for extracorporeal reanimation of hearts was used. Two circuits were prepared, first for the antegrade perfusion of coronaries through aorta during initial reperfusion of the hearts, and second for the perfusion of hearts through PVs in a working heart. Briefly, in Circuit 1 (green), the perfusate was pumped from heart chamber to the oxygenator-heat-exchanger system, and eventually into the aorta for perfusion of coronaries. The return of perfusate to the heart chamber through PA completed this circuit. In Circuit 2 (red), blood pumped from the heart chamber to the oxygenator—heat exchanger system was collected in a pre-load bag from where it drained into the PVs by gravity. The pressures/flows were adjusted by altering the height of the pre-load bag. This circuit was diverted into two components. The first component was the part of perfusate that entered the coronaries and returned to the heart chamber through the PA. The second component was formed by the perfusate that continued through the aorta into the after-load chamber, from where the perfusate was allowed to return to the heart chamber by gravity. A CDI monitor was incorporated into the system in addition to the oxygenator-heat-exchanger system for real-time monitoring of changes in perfusate pH, temperature, PO2, PCO2, K+ and HCO3 −. Pressures and flows were recorded at various points in the two circuits. The pressure and flow data were acquired and monitored in real time using a computer and HMI software specifically written for the Somah device (Comdel, Inc., Wahpeton, N. Dak.). DAS, data acquisition system. Video of the Somah Device and working heart can be seen at https://www.youtube.com/watch?v=PTga7aeuVzk. -
FIG. 2 depicts a flow diagram showing the experimental design. The illustration shows the general experimental design of this study, starting from intra-operative cardioplegia for cardiac arrest to the end of the ex vivo heart reperfusion experiment. -
FIG. 3 depicts high-energy phosphates during storage. The graph shows the alterations in HEP levels during 5-hour storage in Somah, Celsior and UWS group hearts. Asterisk: significantly higher than controls; dagger: significantly lower than controls. -
FIG. 4A , andFIG. 4B depict cardiac enzymes upon reperfusion. Graphs showing the release of the cardiac enzymes creatine kinase and troponin I into the ex vivo circulation upon reperfusion of hearts with the Somah device are depicted inFIG. 4A andFIG. 4B , respectively. Asterisk: significantly higher versus the other groups. -
FIG. 5A andFIG. 5B depict the metabolic shift upon reperfusion. Graphs showing alterations in myocardial oxygen consumption and lactate ratio in hearts within 30 minutes of reperfusion in the Somah, Celsior and UWS groups are depicted inFIG. 5A andFIG. 5B , respectively. Asterisk: significantly higher than baseline. -
FIG. 6A ,FIG. 6B ,FIG. 6C , andFIG. 6D depict two-dimensional echocardiographic analysis during extracorporeal perfusion showing functional parameters. Percent fractional area change is depicted inFIG. 6A ; ejection fraction is depicted inFIG. 6 B; and stroke volume is depicted inFIG. 6C . The findings are deduced from 2D echocardiography on the Somah, Celsior and UWS group hearts.FIG. 6 D depicts alteration in left ventricular anterior wall and septal wall thicknesses upon reperfusion of hearts in the Somah. Celsior and UWS groups. Asterisk: significantly lower than in the Somah group. -
FIG. 7 depicts a flow diagram of the experimental design. Illustration shows the general experimental design of this study, starting from intraoperative cardioplegia for cardiac arrest to the end of ex vivo heart reperfusion experiment. -
FIG. 8 depicts an assessment of edema during 5-h heart storage. Heart biopsies were obtained for evaluation of edema and ischemic changes by electron microscopy (EM) (upper panels; magnification—8000×; inset in the first EM image shows a cardiomyocyte nuclei representative of reversible change seen in all the three groups, demonstrating partial condensation of chromatin material below the nuclear membrane) and histopathology (middle panels; magnification-400×) in the 4° C. (left), 13° C. (center) and 21° C. (right) group hearts; representative images. The lower graphs show the alteration in heart weights after storage, from prior at harvest weights in the three groups. M, mitochondria; SR, sarcoplasmic reticulum; G, glycogen granules. -
FIG. 9A andFIG. 9B depict cardiac metabolism in working hearts. Myocardial O2 consumption (MVO2) is depicted inFIG. 9A and lactate ratio is depicted inFIG. 9B upon perfusion of hearts stored at 4° C. 13° C. and 21° C. MVO2 and lactate ratios were determined from the differences in the respective parameters in the outflow and inflow perfusate samples. Baseline=60 min after reperfusion, at hemodynamic steady state; 30 min=at peak performance, 90 min after reperfusion. Each bar represents mean±SEM of n=6 for each Somah and n=5 for Celsior group, respectively. ‡Significant change, Celsior versus Somah groups at corresponding time points; * Significant change from baseline (p<0.05). -
FIG. 10A andFIG. 10B depict release of creatine kinase (CK) and cardiac troponin-I (cTnI) upon reperfusion. CK (FIG. 10A ) and cTnI (FIG. 10B ) levels were determined in perfusate, 5 min and 90 min (peak performance) after start of reperfusion of hearts stored at 4° C., 13° C., and 21° C.; n=6 for each Somah group, and n=5 Celsior group. Significant change from Celsior (p<0.05). -
FIG. 11 depicts a two-dimensional echocardiography (2D Echo) image procured during in vitro experiments using trans-esophageal echocardiography (TEE) probe. 2D Echo images during ex vivo experiments were acquired using TEE probe. Images show end-diastolic (upper panels) and end-systolic (lower panels) images (short-axis views) acquired with TEE probe at the papillary muscle level of the left ventricle, at peak performance upon in vitro coronary reperfusion of hearts stored either at 4° C. (left column), 13° C. (central column) or 21° C. (right column). Representative images of independent experiments (n=6 for each group). -
FIG. 12A .FIG. 12B , andFIG. 12C depict viability evaluation of stored hearts. Cardiac biopsies were taken either immediately on procurement (as depicted inFIG. 12A ; controls) or before (as depicted inFIG. 12B ) or after (as depicted inFIG. 12C ) reperfusion of hearts donated after cardiocirculatory death preserved in Somah for 24 hours at 4° C., 10° C., 21° C., or 37° C. Green fluorescence (lower panels) indicates cell viability; red fluorescence (upper panels), compromised cardiomyocytes. In hearts preserved in Somah for 24 hours (as depicted inFIG. 12B ), a robust green fluorescence of live cells was apparent in all temperature groups. The red fluorescence was noted at 4° C., 10° C., and 37° C. Representative images of independent experiments; magnification 320×. -
FIG. 13A .FIG. 13B ,FIG. 13C ,FIG. 13D , andFIG. 13E depict mitochondrial membrane polarization in stored hearts. Mitochondrial membrane polarization in controls is depicted inFIG. 13A ; hearts donated after cardiocirculatory death preserved in Somah for 24 hours at different temperatures is depicted inFIG. 13B ; or after reperfusion is depicted inFIG. 13C . The ratio of polarized to depolarized mitochondria (n=3 in each group) after 24-hour storage (as depicted inFIG. 13D ) and upon reperfusion (as depicted inFIG. 13E ) was unaltered between each temperature group as well as upon reperfusion. Mitochondrial polarization was at equilibrium in all temperature groups. Representative images, 320× magnification. -
FIG. 14A andFIG. 14B depict high-energy phosphate syntheses in stored hearts. Graphs show adenosine triphosphate (ATP; depicted inFIG. 14A ) and Creatine phosphate (CP; depicted inFIG. 14B ) concentration in hearts donated after cardiocirculatory death at procurement (control), after preservation in Somah for 24 hours at different temperatures and upon simulated reperfusion. In all temperature groups except 37° C., both ATP and CP synthesis was significantly increased (P<0.005) after 24-hour storage in Somah. Upon reperfusion, hearts stored at 4° C. and 10° C. demonstrated a decrease in ATP synthesis (P<0.005) but CP synthesis was unaltered. In hearts preserved at 21° C. and 37° C., reperfusion resulted in an increase in ATP synthesis (P<0.001) highly significant at 21° C. while CP synthesis was significantly increased only in 21° C. group (P<0.005). Error bars represent standard error of means. *Significant change from control. ‡Significant change from preperfusion (24-hour storage) levels. -
FIG. 15 depicts Structural and contractile components of cardiomyocytes. Hearts donated after cardiocirculating death were preserved in Somah for 24 hours at 4° C., 10° C., 21° C., or 37° C. prior to reperfusion. Left ventricular biopsies were taken before (pre) and after (post) simulated reperfusion. Resolution of myosin heavy (H) and light (L), actinin, actin, and troponin C was investigated. Control biopsies were taken immediately after procurement of the hearts. Structural and contractile proteins were well preserved at 21° C. but were differentially lost in other temperature groups. Upon reperfusion in the 21° C. group, the myosin light chain protein migrated to a higher level than normal, possibly indicative of phosphorylation. -
FIG. 16 depicts a flow diagram of experimental design. Illustration shows the general experimental design of this study, starting from intraoperative cardioplegia for cardiac arrest to the end of ex vivo heart reperfusion experiment. -
FIG. 17A ,FIG. 17B , andFIG. 17C are graphs depicting high energy phosphate levels in hearts arrested and stored in SOMAH. Cardiac tissue biopsies from left ventricle were obtained for determination of HEP including ATP and CP levels in 4 and 21° C. SOMAH cardioplegia group hearts pre and post 5-hour storage. There was a temperature of cardioplegia arrest dependent increase in HEP concentrations in the hearts.FIG. 17A depicts Control;FIG. 17AB depicts 5 hour storage; andFIG. 17C depicts normalized values (5 hours with respect to 0 hour). Each bar represents mean±SEM of n=5 for each group. * Significantly different from 4° C. cardioplegia group hearts. -
FIG. 18A ,FIG. 18B , andFIG. 18C are graphs depicting release of creatine kinase and cardiac troponin-I upon reperfusion. CK (depicted inFIG. 18A ). AST (depicted inFIG. 18B ) and cTnI (depicted inFIG. 8C ) levels were determined in perfusate, 5 min and 90 min (peak performance) after start of reperfusion of 4 and 21° C. cardioplegia hearts; n=5 for each SOMAH group. *Significant change from 5 minutes (p<0.05); * Significantly different from 4° C. cardioplegia group hearts at similar time point. -
FIG. 19A andFIG. 19B are bar graphs depicting cardiac metabolism in working hearts.FIG. 19A depicts myocardial O2 consumption whileFIG. 19B depicts lactate ratio (B) upon perfusion of 4 and 21° C. cardioplegia hearts. MVO2 and lactate ratios were determined from the differences in the respective parameters in the outflow and inflow perfusate samples. Baseline=60 min after reperfusion, at hemodynamic steady state; 90 min=at peak performance. Each bar represents mean+SEM of n=5 for each group. -
FIG. 20 depicts gross appearance of livers stored in UWS or Somah solutions. Morphology of DCD livers. Liver stored in UWS showed significant discoloration within 1 hour of storage. In contrast, livers stored in Somah maintained their color and morphology throughout the 72-hour storage period. All livers were progressively biopsied for further analysis. Representative images: UWS n=7; Somah n=6 -
FIG. 21 depicts histopathology of livers at 6, 24 and 72 hrs stored in University of Wisconsin (UWS) and Somah solutions. Note that bile ductules show mucosal ulceration and disorganized, heaped, condensed nuclei in livers stored in UWS. These changes were seen as early as 6 hrs. In contrast, livers stored in Somah for 72 hrs showed normal appearing bile ductules in the portal region with clear, rounded uniform lumen and intact mucosa with regular basal nuclei. Also note that in the upper panels, some periportal hepatocytes show ballooning degeneration and apoptotic nuclei (arrows), while periportal hepatocytes showed normal cellular boundaries and heterochromatic, open-faced nuclei with nucleoli in livers stored in Somah (arrows). Asterisks indicate bile ducts and ductules of different calibers (all images, ×200). -
FIG. 22 depicts a high power view (×400) of bile ductules obtained from livers cold-stored in UWS and Somah at 6 hrs. Note the regularly arranged basal nuclei and clear lumen in a medium sized bile ductule seen at 0 hr (arrow, left panel). In contrast, note the polychromatic appearance of the ductular nuclei, including some condensed nuclei and reactive (proliferative) nuclear changes in the 3 o'clock position of liver stored in UWS. Note the sloughed material obstructing the ductular lumen and non-uniformly stained and ragged appearance of the mucosa. In contrast, lumina of bile ductules were regular appearing with intact mucosa in Somah stored livers. These changes were uniformly seen in bile ducts of different diameters (asterisks). Green asterisks indicate portal veins/venules (×400). -
FIG. 23A andFIG. 23B are bar graphs depicting changes in pH, lactate and glucose levels in livers during storage. Graphs show time-dependent alterations in pH (upper panel), lactate (middle panel) and glucose (lower panel) levels in UWS (FIG. 23A ) and Somah (FIG. 23B ) solutions during extracorporeal storage of DCD livers. Metabolic parameters were temporally assessed in the storage solution during extracorporeal storage of DCD livers in UWS and Somah for 72 hours at 4° C. -
FIG. 24A andFIG. 24B depict oxygen consumption and co2 production in Stored Livers.FIG. 24A shows the extent of oxygen consumption andFIG. 24B shows CO2 production during extracorporeal storage of livers in UWS and Somah solutions at 0, 6, 24 and 72 hour time points. *Significant change from baseline levels in Somah. -
FIG. 25 depicts graphs showing total phosphates in stored livers. Graphs show time-dependent changes in ATP, CP and total phosphate levels in liver tissue during long-term extracorporeal storage of DCD livers in UWS (upper) and Somah (lower). *p<0.05, Compared with 1 Hour. -
FIG. 26 depicts graphs showing release of liver enzymes during organ storage. Release of liver enzymes during extra-corporeal preservation of DCD livers was determined in the respective UWS or Somah solutions attime -
FIG. 27 depicts bar graphs showing reperfusion induced release of liver enzymes. Release of liver enzymes during extra-corporeal reperfusion of DCD Somah livers was determined in the perfusate (HV) at time 0 (single pass), 0.5 and 2 hours. ALP, GGT, AST, ALT and CK levels were evaluated. Due to intra variability of enzymes in 72-hour stored blood in the reconstituted perfusate, data was normalized totime 0 hour values; mean±SEM, from independent experiments. -
FIG. 28 depicts a bar graph showing reperfusion induced synthesis and release of albumin by livers stored in Somah for 72-hours. Somah livers temporally synthesized and released albumin in the perfusate (HV). Increase in albumin synthesis was highly significant at 0.5 hour (P<0.03) and at 2 hours (P<0.01). Values represent mean+SEM from independent experiments. -
FIG. 29A andFIG. 29B depict gross morphology of kidneys stored in UW (FIG. 29A ) or Somah (FIG. 29B ). Kidneys were stored for 72 hours and images were obtained for gross morphological evaluation and biopsies taken for histopathology attime -
FIG. 30A ,FIG. 30B ,FIG. 30C ,FIG. 30D , andFIG. 30E depict bar graphs showing alterations in metabolic parameters in the UW or Somah solutions storing DCD kidneys over a 72-hour period.FIG. 30A shows pH;FIG. 30B shows glucose;FIG. 30C shows lactate;FIG. 30D shows pO2 andFIG. 30E shows pCO2. -
FIG. 31 depicts line graphs showing alterations in energy metabolism in the UW (left) and Somah (right) stored DCD kidneys during the 72 hour extracorporeal preservation period. *Significantly different from Time 0 (p<0.05). -
FIG. 32 depicts bar graphs showing time-dependent alterations in expression of caveolin, endothelial nitric oxide synthase (eNOS), von-Willebrands factor (vWF) and erythropoietin (EPO) proteins in DCD kidneys stored in either UW or Somah solution for 72 hours. -
FIG. 33 is a chart depicting ammonia production and utilization in cells exposed to Somah. - What is urgently needed in the art is an organ preservation storage solution that facilitates preservation of an organ from various groups of donors over a broad subnormothermic temperature range (4-25° C.), thus preventing tissue injury due to storage at extreme hypothermia (4° C.) prior to transplant. The components of the solution should preserve cardiac (and other organ) structure and function by providing ionic balance, energy substrates, chelation of ammonia into substrates for nitric oxide synthase, metabolic modulation for generation of high-energy phosphates (HEP), free radical scavenging, anti-oxidants, reducing agents, intra and extracellular H+ chelation, and attenuation of edema by modulation of hemichannels and aquaporins during storage. The storage solution should also facilitate attenuation of ischemia-reperfusion injury (IRI) by preloading with selective, synergistic constituents during hypoxic storage to counterbalance the detrimental effects of the initially hyperoxic state post-reperfusion, and consequently prevent reperfusion injury and perpetuate uneventful rapid transition to normoxic state, aerobic metabolism and optimum mechanical function. An ideal solution would synergistically 1) preserve the organ during ischemic storage; 2) prime the organ with metabolites for rapid conversion from hyperoxic to normoxic state, for sustained electromechanical work upon reperfusion; and 3) prevent ischemia-reperfusion (IR) injury. Such a solution would have the potential to greatly extend temporal storage for extracorporeal preservation of donor organs prior to transplantation into recipients.
- The invention described herein provides, inter alia, compositions for preserving mammalian organs and tissues as well as methods and kits for utilizing the same. While any mammalian organ or tissue can be preserved in the presently described compositions using the instantly described methods, the benefits of storing extracorporeal hearts are particularly advantageous. In contrast to currently available compositions and techniques for preserving extracorporeal hearts, prior to transplantation into recipients, the compositions and methods of the present invention permit ex vivo storage for 24-72 hours following removal from a donor. In further contrast to currently available compositions for heart preservation, which require storage at near freezing temperatures, the compositions and methods of the instant invention can be stored at ambient temperatures without accumulation of significant amounts of edema and without the characteristic cold-mediated tissue and cellular damage brought about by cold storage of hearts. The combination of increased storage time and the ability to maintain hearts at ambient temperatures during storage would allow donor hearts to be transported over longer distances over significantly increased periods of time and without the need for cold storage using the presently described compositions. Due to the fact that donor hearts are in short supply, the compositions and methods of the present invention have the potential to permit hearts to reach suitable transplant recipients located at more remote distances than what is currently possible.
- As used herein, the term “physiological salt” refers to any salt which, when in aqueous solution at a given concentration, assists with or is required for a cellular or physiologic function. Examples of physiological salts include, without limitation, alkaline and alkaline earth metal chlorides, phosphates and sulfates, such as, KCl, NaCl, MgCl2, MgSO4, and mixtures thereof.
- A “subject” can be a vertebrate, a mammal, or a human. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats. In one aspect, a subject is a human.
- As used herein, “normothermic temperature” refers to any temperature in the range of about 36.4-37.1° C., e.g., 36.4° C., 36.5° C., 36.6° C., 36.7° C., 36.8° C., 36.9° C., 37° C., or 37.1° C. “Ambient temperature” or “subnormnothermic temperature,” as used herein, refers to temperatures in the range of 10-21±4° C., or in other embodiments, temperatures in the range of 21±2° C., such as any of about 6° C., 7° C., 8° C., 9° C., 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C. 17° C., 18° C. 19° C., 20° C., 21° C., 22° C. 23° C., 24° C., or 25° C. “Hypothermic temperatures” or “hypothermia” refers to temperatures in the range of about 0° C. to about 5° C., such as any of about 0° C., 1° C., 2° C., 3° C., 4° C., or 5° C.
- Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
- As used herein, the singular terms “a.” “an,” and “the” include the plural reference unless the context clearly indicates otherwise.
- The transitional term “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. By contrast, the transitional phrase “consisting of excludes any element, step, or ingredient not specified in the claim. The transitional phrase” consisting essentially of limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention
- Currently available techniques and compositions for storage of organs, such as donor hearts, permit only around 4-6 hours of storage prior to the onset of irreversible cold-mediated tissue and cellular damage. The compositions of the present invention are solutions for preserving or resuscitating biological tissue or organs at temperatures of about 10-21±4° C., such as any of about 4° C. 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 11° C. 12° C. 13° C. 14° C., 15° C., 16° C. 17° C. 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C. or 25° C., including all temperatures and ranges (such as between about 10-25° C.) falling within these values. Tissues or organs can be stored in the compositions described herein for about 24-72 hours, such as any of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72 or more hours, without significant decreases in the amount of cellular high energy phosphates or without significant increases in edema. With respect to hearts stored in the compositions of the present invention prior to transplantation into a subject in need thereof, physiological measurements such as coronary blood flow, percent fractional area change, ejection fraction, and/or stroke volume are increased upon reanimation of the heart relative to hearts stored in currently utilized organ preservation solutions.
- Any organ or biological tissue can be stored in the compositions described herein, for example any of heart, kidney, liver, stomach, spleen, skin, pancreas, lung, brain, eye, intestines, or bladder. In some embodiments, the stored organ is a heart.
- A. Physiological Salt Solutions
- The compositions of the present invention can be aqueous (i.e. water-based or solid powder based (reconstituted with distilled water prior to use) or combinations thereof solutions that include one or more of a physiological salt solution, glucose, glutathione, ascorbic acid, arginine, citrulline malate, adenosine, creatine orotate, creatine monohydrate or salts thereof, orotic acid, malic acid, carnosine, camitine, and/or dichloroacetate, wherein the physiological salt solution comprises at least 20 mM potassium ions and at least 37 mM magnesium ions. The physiological salt solution can include any salt which, when in aqueous solution at a given concentration, assists or is required for a physiologic function such as maintaining ionic concentrations inside and outside of the biological tissue or organ as well as controlling the amount of water that can traverse cellular membranes. The components of the physiological salt solution can also help to buffer and maintain a proper pH. Particular salts capable of use in the present in invention include, without limitation, potassium chloride, potassium phosphate, magnesium chloride, magnesium sulfate, calcium chloride, sodium chloride, sodium bicarbonate and sodium phosphate.
- The physiological salt solution of any of the compositions disclosed herein can contain a sodium ion source. Sodium ions can be added to the physiological salt solution in the form of a sodium salt, such as, for example, one or more sodium salts selected from the group consisting of NaAlO2, NaBO2, NaCl, NaClO, NaClO2, NaClO3, NaClO4, NaF, Na2FeO4, NaHCO3, NaH2PO4, NaHSO3, NaHSO4, NaI, NaMnO4, NaNH2, NaNO2, NaNO3, NaOH, NaPO2H2, NaSH, Na2MnO4, Na3MnO4, Na2N2O2, Na2O2, Na2SO3, Na2SO4, Na2S2O4. Na2SeO3, Na2SeO4, Na2SiO3, Na2Si2O5, Na4SiO4, Na2Ti3O7, Na2Zn(OH)4. NaH2C6H5O7, and Na3PO4. In some embodiments, sodium ions in the biological tissue and organ storage composition can be at a concentration of between about 80-145 mM, such as about 80 mM, about 81 mM, about 82 mM, about 83 mM, about 84 mM, about 85 mM, about 86 mM, about 87 mM, about 88 mM, about 89 mM, about 90 mM, about 91 mM, about 92 mM, about 93 mM, about 94 mM, about 95 mM, about 96 mM, about 97 mM, about 98 mM, about 99 mM, 100 mM, about 101 mM, about 102 mM, about 103 mM, about 104 mM, about 105 mM, about 106 mM, about 107 mM, about 108 mM, about 109 mM, about 110 mM, about 111 mM, about 112 mM, about 113 mM, about 114 mM, about 115 mM, about 116 mM, about 117 mM, about 118 mM, about 119 mM, about 120 mM, about 121 mM, about 122 mM, about 123 mM, about 124 mM, about 125 mM, about 126 mM, about 127 mM, about 128 mM, about 129 mM, about 130 mM, about 131 mM, about 132 mM, about 133 mM, about 134 mM, about 135 mM, about 136 mM, about 137 mM, about 138 mM, about 139 mM, about 140 mM, about 141 mM, about 142 mM, about 143 mM, about 144 mM, or about 145 mM including all ranges and numbers falling within these values.
- In other embodiments of the compositions disclosed herein, the physiological salt solution contains sodium chloride. The concentration of sodium chloride in the biological tissue and organ storage composition can be between about 80-135 mM, such as about 80 mM, about 81 mM, about 82 mM, about 83 mM, about 84 mM, about 85 mM, about 86 mM, about 87 mM, about 88 mM, about 89 mM, about 90 mM, about 91 mM, about 92 mM, about 93 mM, about 94 mM, about 95 mM, about 96 mM, about 97 mM, about 98 mM, about 99 mM, 100 mM, about 101 mM, about 102 mM, about 103 mM, about 104 mM, about 105 mM, about 106 mM, about 107 mM, about 108 mM, about 109 mM, about 110 mM, about 111 mM, about 112 mM, about 113 mM, about 114 mM, 115 mM, about 116 mM, about 117 mM, about 118 mM, about 119 mM, about 120 mM, about 121 mM, about 122 mM, about 123 mM, about 124 mM, about 125 mM, about 126 mM, about 127 mM, about 128 mM, about 129 mM, about 130 mM, about 131 mM, about 132 mM, about 1303 mM, about 134 mM, or about 135 mM, including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage composition can contain about 7.3 g/L sodium chloride.
- In further embodiments of the compositions disclosed herein, the physiological salt solution contains sodium phosphate. The concentration of sodium phosphate in the biological tissue and organ storage composition can be between about 0.15-30 mM, such as about 0.15 mM, about 0.16 mM, about 0.17 mM, about 0.18 mM, about 0.19 mM, about 0.2 mM, about 0.21 mM, about 0.22 mM, about 0.23 mM, about 0.24 mM, about 0.25 mM, about 0.5 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage composition can contain about 0.05 g/L sodium phosphate. Any form of sodium phosphate can be used in the present invention, including, without limitation, the dibasic heptahydrate form.
- In another embodiment of the compositions disclosed herein, the physiological salt solution contains sodium bicarbonate. The concentration of sodium bicarbonate in the biological tissue and organ storage composition can be between about 2-25 mM, such as about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage composition can contain about 0.35 g/L sodium bicarbonate.
- In another embodiment of the compositions disclosed herein, the physiological salt solution contains calcium ions (for example, calcium ions supplied by calcium salts such as calcium chloride). In some embodiments, calcium ions in the biological tissue and organ storage composition can be at a concentration of between about 0-1.5 mM, such as about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 1.1 mM, about 1.2 mM, about 1.3 mM, about 1.4 mM, or about 1.5 mM, including all ranges and numbers falling within these values. In another embodiment, the physiological salt solution of the compositions disclosed herein contain calcium ions supplied from one or more calcium salts such as, for example, those selected from the group consisting of calcium acetate, calcium aluminates, calcium aluminoferrite, calcium aluminosilicate, calcium ammonium nitrate, calcium arsenate, calcium ascorbate, calcium azide, calcium benzoate, calcium beta-hydroxy-beta-methylbutyrate, calcium bicarbonate, calcium bisulfite, calcium borate, calcium bromate, calcium bromide, calcium carbide, calcium carbonate, calcium chlorate, calcium chromate, calcium citrate, calcium citrate malate, calcium copper titanate, calcium cyanamide, calcium diglutamate, calcium erythorbate, calcium fluoride, calcium formate, calcium funmarate, calcium glubionate, calcium glucoheptonate, calcium gluconate, calcium glycerylphosphate, calcium guanylate, calcium hexaboride, calcium hydride, calcium hydroxide, calcium hypochlorite, calcium inosinate, calcium iodate, calcium iodide, calcium lactate, calcium lactate gluconate, calcium magnesium acetate, calcium nmalate, calcium monohydride, calcium monophosphide, calcium morphenate, calcium nitrate, calcium nitride, calcium nitrite, calcium oxalate, calcium oxide, calcium pangamate, calcium perchlorate, calcium permanganate, calcium peroxide, calcium phosphate, calcium phosphide, calcium propanoate, calcium pyrophosphate, calcium silicate, calcium silicate hydrate, calcium silicide, calcium sorbate, calcium stearate, calcium sulfate, calcium sulfate, calcium sulfide, calcium sulfite, calcium tartrate, calcium titanate, calcium chloride, and calcium cyanide.
- The physiological salt solution of any of the compositions disclosed herein can contain a potassium ion source. Potassium ions can be added to the physiological salt solution in the form of a potassium salt, such as, for example, one or more potassium salts selected from the group consisting of KAsO2, KBr, KBrO3, KCN, KCNO, KCl, KClO3, KClO4, KF, KH, KHCO2, KHCO3, KHF2, KHS, KHSO3, KHSO4, KH2AsO4, KH2PO3, KH2PO4, KI, KlO3, KlO4, KMnO4, KN3, KNH2, KNO2, KNO3, KOCN, KOH, KO2, KPF6, KCH3COO, K2Al2O4, K2CO3, K2CrO4, K2Cr2O7, K2FeO4, K2HPO4, K2MnO4, KO2, K2O2, K2S, K2SeO4, K2SO3, K2SO4, KHSO5, K2S2O5, K2S2O7, K2S2O8, K2SiO3, K3[Fe(C2O4)3], K4[Fe(CN)6], K3PO4, and K4Mo2Cl8. In some embodiments, potassium ions in the biological tissue and organ storage composition can be at a concentration of between about 4-65 mM, such as about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM, about 45 mM, about 46 mM, about 47 mM, about 48 mM, about 49 mM, about 50 mM, about 51 mM, about 52 mM, about 53 mM, about 54 mM, about 55 mM, about 56 mM, about 57 mM, about 58 mM, about 59 mM, about 60 mM, about 61 mM, about 62 mM, about 63 mM, about 64 mM, about or 65 mM, including all ranges and numbers falling within these values. In other embodiments of the compositions disclosed herein, the physiological salt solution contains potassium phosphate. The concentration of potassium phosphate in the biological tissue and organ storage composition can be between about 0.4-10 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, or about 10 mM, including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage composition can contain about 0.06 g/L potassium phosphate. Any form of potassium phosphate can be used in the present invention, including, without limitation, the monobasic form.
- In some embodiments of the compositions disclosed herein, the physiological salt solution contains potassium chloride. The concentration of potassium chloride in the biological tissue and organ storage composition can be between about 4-65 mM, such as about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM, about 45 mM, about 46 mM, about 47 mM, about 48 mM, about 49 mM, about 50 mM, about 51 mM, about 52 mM, about 53 mM, about 54 mM, about 55 mM, about 56 mM, about 57 mM, about 58 mM, about 59 mM, about 60 mM, about 61 mM, about 62 mM, about 63 mM, about 64 mM, about or 65 mM including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage composition can contain about 0.522 g/L potassium chloride.
- The physiological salt solution of any of the compositions disclosed herein can contain a magnesium ion source. Magnesium ions can be added to the physiological salt solution in the form of a magnesium salt, such as one or more magnesium salts selected from the group consisting of MgB2, MgBr2, MgCO3, MgC2O4, MgC6H6O7, MgC14H10O4, MgCl2, Mg(ClO4)2, MgF2, MgH2, Mg(HCO3)2, MgI2, Mg(NO3)2, MgO, MgO2, Mg(OH)2, MgS, MgSO3, MgSO4, Mg2Al3, Mg2Si, Mg2SiO4, Mg2Si3O8, Mg3N2, Mg3(PO4)2, and Mg2(CrO4)2. In some embodiments, magnesium ions in the biological tissue and organ storage composition can be at a concentration of between about 0.5-45 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM, or about 45 mM including all ranges and numbers falling within these values.
- In still further embodiments of the compositions disclosed herein, the physiological salt solution contains magnesium chloride. The concentration of magnesium chloride in the biological tissue and organ storage composition can be between about 0.5-45 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, or about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM, or about 45 mM including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage composition can contain about 101.00 g/L magnesium chloride. Any form of magnesium chloride can be used in the present invention, including, without limitation, the hexahydrate form.
- In other embodiments of the compositions disclosed herein, the physiological salt solution contains magnesium sulfate. The concentration of magnesium sulfate in the biological tissue and organ storage composition can be between about 0.5-1.5 mM, such as about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 1.1, about 1.2 mM, about 1.3 mM, about 1.4 mM, or about 1.5 mM including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage composition can contain about 0.123 g/L magnesium sulfate. Any form of magnesium sulfate can be used in the present invention, including, without limitation, the heptahydrate form.
- B. Other Components
- In addition to the physiological salt solution, compositions of the present invention can also include one or more of glucose, glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate and salts thereof), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), orotic acid, malic acid and salts thereof, carnosine, carnitine, dichloroacetate, and/or insulin. The solution is manufactured and sold without insulin. Insulin is added at the specified concentration at the point of use or shortly before use or prior to use. e.g., just prior to (such as any of about 30 seconds, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more minutes prior to) infusion into an organ of a living patient or just before infusion into an ex vivo organ or submersion of the organ into the solution.
- A sugar, for example, a six carbon sugar like glucose (such as D-glucose or dextrose) and/or a five carbon sugar like ribose, can serve as a substrate for the production of high energy phosphates (such as ATP) and can be included in the biological tissue and organ storage composition described herein at concentrations between about 5-25 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, or 25 mM including all ranges and numbers falling within these values. In one embodiment, the concentration of glucose is about 1.98 g/L. In another embodiment, glucose is present at a concentration of about 11 mM.
- Reactive oxygen species can be generated during biological tissue and organ storage; however, ascorbic acid and reduced glutathione (i.e. reducing agents) present in the solution can consume oxygen free radicals during storage. As such, both ascorbic acid and reduced glutathione can be present in the biological tissue and organ storage composition described herein at concentrations between about 0.5 mM to 3 mM, such as any of about 0.5 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, or 3 mM, including all ranges and numbers falling within these values. In one embodiment, the concentration of ascorbic acid is about 0.178 g/L. In another embodiment, ascorbic acid is present at a concentration of about 1 mM. In some embodiments, the concentration of reduced glutathione is about 0.462 g/L. In another embodiment, reduced glutathione is present at a concentration of about 1.5 mM.
- Other components of the biological tissue and organ storage compositions disclosed herein assist in the production of ATP via the tricarboxylic acid (TCA) cycle. In the citrulline malate-arginine cycle, malate (cleaved from citrulline) enters the TCA cycle to generate more ATP. Also, citrulline malate is converted to arginine and fumarate; fumarate enters the TCA cycle to facilitate more ATP production. Both malate and fumarate in TCA cycle leads to more ATP production.
- Additionally, while it is generally known that only the liver detoxifies ammonia in the urea cycle for elimination by the kidneys under normal physiological circumstances, the organ storage compositions disclosed herein may be able to drive the otherwise toxic ammonium ion into the nitric oxide synthesis pathway in most organs and tissues by inclusion of citrulline (see
FIG. 33 ). Increased production of NO is extremely beneficial for long term storage of organs. Specifically, as soon as circulation to an organ is interrupted during harvesting and storage, transaminase (and/or protease) reactions accelerate as part of degenerative breakdown of proteins. These enzymes metabolize amino acids, thereby releasing ammonium ions that can build up in the storage solution, potentially causing toxicity and injury to the tissue. In order to negate this detrimental changecitrulline, citrulline malate, and/or salts thereof can provide a counterbalance to this increased ammonium production when included in the organ storage solutions provided herein. Without being bound to theory, is thought that ammonium ions will combine with glutamine present in cells to form carbamoyl phosphate, which is driven into the NO cycle by the formation of L-citrulline (seeFIG. 33 ). To keep this cycle going and to prevent citrulline exhaustion citrulline malate can be included in the solution. Citrulline is metabolized to arginine (leading to NO production) and Krebs's cycle intermediates during NO production (seeFIG. 33 ). These intermediates, such as succinate, fumarate, and malate enter into Krebs's cycle resulting in generation of additional ATP, thus further contributing to preservation of the energy state in a stored organ. Additionally, the combination of carnosine and carnitine synergistically produces a higher amount of high energy phosphates in organs stored in any of the solutions disclosed herein compared to the amount of HEPs produced using a storage solution lacking these ingredients. In another embodiment, the combination of carnosine, carnitine, glucose, and creatine synergistically produces a higher amount of high energy phosphates in organs stored in any of the solutions disclosed herein compared to the amount of HEPs produced using a storage solution lacking these ingredients. In other embodiments, the combination of citrulline and arginine synergistically produces a higher amount of nitrous oxide (NO) in organs stored in any of the solutions disclosed herein compared to the amount of NO produced using a storage solution lacking these ingredients. The synergism demonstrated by the combination of these components is both unexpected and surprising. - Accordingly, arginine (such as L-arginine) and citrulline (such as citrulline malate, for example, L-citrulline malate or salts thereof) can be present in the biological tissue and organ storage compositions described herein at concentrations between about 0.5 mM to 7 mM, such as any of about 0.5 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, or 7 mM, including all ranges and numbers falling within these values. In some embodiments, the organ storage composition does not comprise citrulline malate. In one embodiment, the concentration of arginine is about 1.074 g/L. In another embodiment, arginine is present at a concentration of about 5 mM. In some embodiments, the concentration of citrulline malate is about 0.175 g/l . . . In another embodiment, citrulline malate is present at a concentration of about 1 mM. Optionally, citrulline (such as L-citrulline) and malic acid can be added individually to the compositions in ranges of about 1-10 mM citrulline (such as any of about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM, including all ranges and numbers falling within these values) and about 1-5 mM malic acid (such as any of about 1 mM, 2 mM, 3 mM, 4 mM, or 5 mM, including all ranges and numbers falling within these values), respectively. In some embodiments, the organ storage composition does not comprise citrulline or citrulline malate. In yet other embodiments, the organ storage composition comprises malic acid from about 0.001 to about 7 mM, such as any of about 0.001 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM or 7 mM. In further embodiments, the organ storage solution does not comprise malate or malic acid.
- Another component useful for maintaining ATP levels is adenosine. Adenosine can be present in the compositions disclosed herein at concentrations between about 1-4 mM, such as any of about 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM, or 4 mM, including all ranges and numbers falling within these values. In one embodiment, the concentration of Adenosine is about 0.534 g/L. In another embodiment. Adenosine is present at a concentration of about 2 mM. Adenosine also changes the polarization of the heart for rapid arrest; facilitates dialation of coronary vessels facilitating distribution/perfusion of the heart (organ) with the organ storage solution during storage, thereby attenuating hypoxia/ischemia related injury. Adenosine also slows the rate of K+-induced membrane depolarization, and reduces K+-induced intracellular Ca2+ loading in ventricular myocytes. Without being bound to theory, such findings support the notion that adenosine plays a cardioprotective role in hyperkalemic cardioplegia or during surgery and/or organ harvest by facilitating gentle arrest; especially for use in high K+ scenario, thus preventing inherent injury to the heart induced by such action. Further, without being bound to theory, in addition to its role in high energy phosphate production and ionic homeostasis, magnesium also protects the heart from repeated ischemia and injury via preconditioning, especially during prolonged organ storage as well as protecting against postoperative ventricular arrythemias upon open heart surgery or transplant. Both high potassium and magnesium concentrations also protects against calcium accumulation in mitochondria and subsequent injury to the organ.
- In some embodiments of the biological tissue and organ storage compositions disclosed herein, the composition solution contains creatine. In some embodiments, creatine is present in the form of creatine orotate and/or creatine monohydrate or salts thereof. The concentration of creatine in the biological tissue and organ storage compositions can be between about 2-5 mM, such as about 2 mM, about 3 mM, about 4 mM or about 5 mM, including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage compositions can contain 0.5 mM creatine orotate. In another embodiment, the biological tissue and organ storage compositions can contain 0.27 g/L creatine orotate. In other embodiments, the biological tissue and organ storage compositions can contain 2 mM creatine monohydrate or salts thereof. In another embodiment, the biological tissue and organ storage compositions can contain 0.3 g/L creatine monohydrate or salts thereof. In yet another embodiment, the biological tissue and organ storage compositions contains both 0.5 mM creatine orotate and 2 mM creatine monohydrate or salts thereof. Creatine orotate can be difficult to obtain. Hence, in some embodiments, this can be changed to 0.5 mM orotic acid and salts thereof (0.50-2.50 mM) and 2.50 mM creatine monohydrate or salts thereof (2.50-10 mM). Both ex vivo and in vivo experiments show a beneficial effect from Mg—Or (magnesium orotate) administration at the onset of reperfusion on myocardial function and IS. In vitro assays showed that Mg—Or significantly delayed mPTP (mitochondrial pore transition) opening after 1/R. Without being bound to theory, this suggests that Mg—Or administered at the very onset of reperfusion may preserve myocardial function and reduce IS. This beneficial effect may be related to a significant reduction of mPTP opening, a usual trigger of cardiac cell death via apoptosis following I/R.
- In some embodiments of the biological tissue and organ storage compositions disclosed herein, the composition solution contains a buffer for intracellular acidity, such as carnosine (for example, L-carnosine). The concentration of carnosine in the biological tissue and organ storage compositions can be between about 5-15 mM, such as about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, or about 15 mM, including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage compositions can contain 2.3 g/L L-carnosine.
- In other embodiments of the biological tissue and organ storage compositions disclosed herein, the solution contains carnitine (for example, L-carnitine), which facilitates a decrease in myocardial lactate production, hence reducing acidity. The concentration of carnitine in the biological tissue and organ storage compositions can be between about 5-15 mM, such as about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, or about 15 mM, including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage compositions can contain 2 g/L L-carnitine.
- Dichloroacetate, if present in the biological tissue and organ storage compositions disclosed herein, can control acidity by lowering lactate levels in the preserved organ, and thus the solution. The concentration of dichloroacetate in the biological tissue and organ storage compositions can be between about 0.1-2.5 mM, such as about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, about 1 mM, about 1.1 mM, about 1.2 mM, about 1.3 mM, about 1.4 mM, about 1.5 mM, about 1.6 mM, about 1.7 mM, about 1.8 mM, about 1.9 mM, about 2 mM, about 2.1 mM, about 2.2 mM, about 2.3 mM, about 2.4 mM, or about 2.5 mM, including all ranges and numbers falling within these values. In another embodiment, the biological tissue and organ storage compositions can contain 0.08 g/L dichloroacetate. In other embodiments, the biological tissue and organ storage compositions contains no dichloroacetate.
- In further embodiments, the biological tissue and organ storage compositions disclosed herein can contain insulin. Insulin can be added after the other ingredients are mixed and/or just prior to use of the storage compositions disclosed herein. For example, insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours. e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing an organ in the solution. In some embodiments, about 100 units/L are added to the biological tissue and organ storage compositions.
- The biological tissue and organ storage compositions disclosed herein can be maintained at a neutral or slightly basic pH, such as about pH 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7, including all ranges and numbers falling within these values. In one embodiment, the pH of biological tissue and organ storage compositions is 7. In another embodiment, the pH of the biological tissue and organ storage compositions is modulated using THAM (Tris-Hydroxymethyl Aminomethane).
- In other embodiments, the organ storage composition comprises the following nominal or base ingredients as shown in Table I for activity of iSomah, combined in deionized, distilled, and/or bacteriostatic water:
-
TABLE I Component Amount Distilled water 1 L Potassium chloride At least 20 mM potassium ions in combination with KPO4* Potassium phosphate At least 20 mM potassium ions in combination with KCl* Magnesium chloride At least 37 mM magnesium ions in combination with MgSO4 Magnesium sulfate At least 37 mM magnesium ions in combination with MgCl* Sodium chloride 100-115 mM Sodium bicarbonate 5-15 mM Sodium phosphate 10-40 mM Glutathione 1.5-5.0 mM Ascorbic acid 1.0-5 mM Adenosine 2-5 mM - In some embodiments, the potassium phosphate salt for use in the non-limiting formulation shown in Table I can be potassium phosphate monohasic. In another embodiment, the magnesium chloride salt for use in the non-limiting formulation shown in Table I can be magnesium chloride hexahydrate. In other embodiments, the magnesium sulfate salt for use in the non-limiting formulation shown in Table I can be magnesium sulfate heptahydrate. In yet other embodiments, the sodium phosphate salt for use in the non-limiting formulation shown in Table I can be sodium phosphate dibasic heptahydrate. In some embodiments, the glutathione for use in the non-limiting formulation shown in Table I can be reduced glutathione. In another embodiment, the creatine for use in the non-limiting formulation shown in Table I can be creatine monohydrate or salts thereof. In other embodiments, the non-limiting formulation shown in Table I can further comprise one or more of arginine (for example, L-arginine) in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM, carnosine (for example, L-carnosine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM (2.26 g/L for 10 mM), carnitine (for example, L-carnitine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM (2.26 g/L for 10 mM), orotic acid, for example, in concentrations of about 0.5-2 mM, such as any of about 0.5, 1, 1.5, or 2 mM, or creatine (for example, creatine monohydrate or salts thereof), in concentrations of about 2-5 mM, such as any of about 2 mM, 3 mM, 4 mM, or 5 mM. In another embodiment, the non-limiting formulation shown in Table I can further comprise insulin at a concentration of 10 mg-100 mg/ml/Liter or 100-1000 Units/L. When insulin is included in the composition, it is optionally added just prior to use as an organ preservation solution.
- In yet other embodiments, the non-limiting formulation shown in Table I can further comprise a sugar, such as, but not limited to, a six carbon sugar (e.g., allose, altrose, galactose, glucose (including D-glucose (a.k.a. dextrose) and L-glucose), gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose, fucose, fuculose, or rhamnose) or a five carbon sugar (e.g. arabinose, lyxose, ribose, xylose, ketopentoses, ribulose, or xylulose) in concentrations from between about 11 mM to about 25 mM, such as any of about 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, or 25 mM sugar.
- In still other embodiments, the non-limiting formulation shown in Table I can optionally comprise 1-10 mM of citrulline (for example, L-citrulline) or a salt thereof in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM. In another embodiment, the non-limiting formulation shown in Table II can optionally comprise about 0-10 mM malic acid, such as any of about 0 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM. In another embodiment, the non-limiting formulation shown in Table I can optionally comprise citrulline malate (such as L-citrulline malate) instead of malic acid and/or citrulline in concentrations of about 0 mM to about 10 mM or about 2 mM to about 7 mM, such as any of about 0 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM citrulline malate.
- In other embodiments, and as a non-limiting example of iSomah, the biological tissue and organ storage compositions comprise the following ingredients combined in deionized and/or bacteriostatic water as shown in Table II:
-
TABLE II Component Amount Distilled water 1 L Potassium chloride 4-65 mM Potassium phosphate (monobasic) 0.44-10 mM Magnesium chloride (hexahydrate) 0.5-65 mM Magnesium sulfate (heptahydrate) 0.5-1.5 mM Sodium chloride 80-135 mM Sodium bicarbonate 2-25 mM Sodium phosphate (dibasic; heptahydrate) 0.15-30 mM Calcium chloride 0-1.5 mM D-Glucose 5-25 mM Glutathione (reduced) 0.5-3 mM Asorbic acid 0.5-3 mM L-Arginine 0.5 mM to 7 mM Malic acid 0 mM to 7 mM (optional) Adenosine 1-4 mM orotic acid 0.5-2 mM Creatine monohydrate 2-5 mM L carnosine 5-15 mM L-carnitine 5-15 mM Dichloroacetate 0.1-2.5 mM Insulin 10 mg-100 mg/ml/Liter or 100-1000 Units/L - In some embodiments, insulin is added after the other ingredients are mixed and/or just prior to use of the storage compositions. For example, insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours, e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing an organ in the solution.
- C. Cardioplegia Solutions
- Cardioplegia solutions for arresting hearts during open heart surgery or for donor hearts for transplant are also provided herein. In one embodiment, a cardioplegia solution of the present invention can comprise a physiological salt solution containing at least 20 mM potassium ions (such as any of about 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM or more potassium ions, including all values and ranges falling in between these numbers) as well as one or more of a sugar (for example, ribose, glucose or dextrose), glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), orotic acid, carnosine (such as L-carnosine), carnitine (such as L-camitine), and/or dichloroacetate. Cardioplegia solutions containing at least 20 mM potassium ions can be used to arrest hearts between about 4-10° C. (such as any of about 4° C., 5° C. 6° C. 7° C., 8° C., 9° C. or 10° C.).
- In another embodiment, the cardioplegia solution of the present invention can comprise a physiological salt solution containing at least 20 mM potassium ions (such as any of about 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM or more potassium ions, including all values and ranges falling in between these numbers) and at least 37 mM magnesium ions (such as any of about 37 mM, 38 mM, 39 mM, 40 mM, 41 mM, 42 mM, 43 mM, 44 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM or more magnesium ions, including all values and ranges falling in between these numbers) as well as one or more of a sugar (for example, ribose, glucose or dextrose), glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), carnosine (such as L-carnosine), orotic acid, carnitine (such as L-carnitine), and/or dichloroacetate. Cardioplegia solutions containing at least 20 mM potassium ions and at least 37 mM magnesium ions can be used to arrest hearts between about 10-25° C., such as any of about 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C., 17° C. 18° C., 19° C. 20° C., 21° C., 22° C., 23° C., 24° C., or 25° C. In yet other embodiments, the cardioplegia solution of the present invention can comprise a physiological salt solution containing at least 25 mM potassium ions (such as any of about 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, 35 mM, 45 mM, 46 mM, 47 mM, 48 mM, 49 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105, 110, 115, 120, 125 or more potassium ions, including all values and ranges falling in between these numbers) and at least 37 mM magnesium ions (such as any of about 37 mM, 38 mM, 39 mM, 40 mM, 41 mM, 42 mM, 43 mM, 44 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM or more magnesium ions, including all values and ranges falling in between these numbers) as well as one or more of a sugar (for example, ribose, glucose or dextrose), glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), orotic acid, carnosine (such as L-carnosine), carnitine (such as L-carnitine), and/or dichloroacetate. Cardioplegia solutions containing at least 25 mM potassium ions and at least 37 mM magnesium ions can be used to arrest hearts between about 25-37° C., such as any of about 25° C., 26° C., 27° C., 28° C., 29° C., 30° C., 31° C., 32° C., 33° C., 34° C. 35° C., 36° C., or 37° C. Other embodiments of cardioplegia solutions for arresting hearts during open heart surgery or for donor hearts for transplant comprising: a physiological salt solution containing between about 4-65 mM potassium ions (such as any of about 4 mM, 5 mM, 6 mM, 7, 8 mM, 9 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 61 mM, 62 mM, 63 mM, 64 mM, or 65 mM potassium ions, including all values and ranges falling in between these numbers) and between about 1.5-45 mM magnesium ions (such as any of about 1.5 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 41 mM, 42 mM, 43 mM, 44 mM, or 45 mM magnesium ions, including all values and ranges falling in between these numbers), as well as one or more of a sugar (for example, ribose, glucose or dextrose), glutathione, ascorbic acid, arginine, citrulline (such as citrulline malate), adenosine, creatine (such as creatine orotate or creatine monohydrate or salts thereof), carnosine (such as L-carnosine), orotic acid, carnitine (such as L-carnitine), and/or dichloroacetate. Cardioplegia solutions containing at least 45 mM potassium ions and at least 37 mM magnesium ions can be used to arrest hearts between about 4-37° C., such as any of about 4° C., 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C., 17° C., 18° C., 19° C. 20° C., 21° C., 22° C., 23° C., 24° C., 25° C., 26° C., 27° C., 28° C. 29° C., 30° C., 31° C., 32° C., 33° C., 34° C. 35° C., 36° C., or 37° C.
- A. Methods for Storing Biological Tissue and Organs
- Effective methods for storing biological tissue and organs using the compositions disclosed herein are also provided by the present invention. Biological tissue and organs can be stored in the solutions disclosed herein at ambient temperatures (for example, 10-21=4° C.). According to the methods provided herein, biological tissue and organs may be stored in the disclosed solutions for 24-72 hours, such as any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72 or more hours, without significant accumulation of storage edema, free radical damage, an/or cellular/tissue damage commonly observed when organs are stored at temperatures at or near freezing.
- Maintenance of high energy phosphate concentrations (such as, ATP) in biological tissue and organs during extended storage is important for the health of tissues and organs once they are transplanted into a donor (or resuscitated in the case of heart transplantation). Biological tissues and organs stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly more high energy phosphates (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75% more high energy phosphates including all ranges and numbers falling within these percentages) compared to biological tissue and organs that are not stored in the solutions disclosed herein.
- Biological tissue and organs stored for prolonged periods of time exhibit significant increases in lactate production, which can negatively affect the pH of the storage media leading to increased tissue and cellular damage. Biological tissue and organs stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly less lactate production (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, less lactate production, including all ranges and numbers falling within these percentages) compared to biological tissue and organs that are not stored in the solutions disclosed herein.
- When hearts are stored extracorporeally, coronary blood flow is often obstructed or decreased following storage and resuscitation. Hearts stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly higher levels of coronary blood flow (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, more coronary blood flow, including all ranges and numbers falling within these percentages) compared to hearts that are not stored in the solutions disclosed herein.
- Additionally, when hearts are stored extracorporeally one or inmore of percent fractional area change, ejection fraction, and/or stroke volume as measured by epicardial 2-dimensional (2D) echocardiography can be decreased following storage and/or resuscitation. Hearts stored in any of the solutions disclosed herein according to the methods disclosed herein exhibit significantly higher levels of percent fractional area change, ejection fraction, and/or stroke volume (such as any of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, more percent fractional area change, ejection fraction, and/or stroke volume including all ranges and numbers falling within these percentages) compared to hearts that are not stored in the solutions disclosed herein.
- B. Methods for Producing Biological Tissue and Organ Storage Compositions
- Provided herein are methods for producing a composition for preserving biological tissue and organs, such as any of the compositions disclosed herein. The methods encompass mixing one or more of the ingredients described above at the indicated concentrations in distilled, deionized, and/or bacteriostatic water. In a further embodiment, and as a non-limiting example of iSomah, the method encompasses mixing one or more of the ingredients shown in the Table III below in distilled, deionized, and/or bacteriostatic water.
-
TABLE III Component mM Potassium Chloride 7.00 Potassium phosphate (monobasic) 0.44 Magnesium chloride (hexahydrate) 0.5 Magnesium sulfate (heptahydrate) 0.503 Sodium chloride 125.00 Sodium bicarbonate 5.00 Sodium phosphate (dibasic; heptahydrate) 0.19 D-Glucose 11.00 Glutathione (reduced) 1.50 Ascorbic acid 1.00 L-Arginine 5.00 L-Citrulline malate 1.00 Adenosine 2.00 Creatine orotate 0.50 Creatine monohydrate 2.00 L carnosine 10.00 L-carnitine 10.00 Dichloroacetate 0.5 Insulin 100 units/L - In some embodiments, insulin is added after the other ingredients are mixed and/or just prior to use of the storage compositions. For example, insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours, e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing a biological tissue or organ in the solution.
- In one embodiment of the methods disclosed herein, rather than adding citrulline malate (such as, L-citrulline malate) to the composition, 1-10 mM (such as any of about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM, including all ranges and numbers falling within these values) of citrulline (such as, L-citrulline) can be added along with 1-5 mM (such as any of about 1 mM, 2 mM, 3 mM, 4 mM, or 5 mM, including all ranges and numbers falling within these values) of malic acid, respectively.
- In other embodiments, and as a non-limiting example of iSomah, the method encompasses mixing one or more of the ingredients shown in the Table IV below in distilled, deionized, and/or bacteriostatic water.
-
TABLE IV Component mM Potassium Chloride 7.00 Potassium phosphate 0.44 Calcium chloride 1.30 Magnesium chloride 0.5 Magnesium sulfate 0.503 Sodium chloride 125.00 Sodium bicarbonate 5.00 Sodium phosphate 0.19 D-Glucose 11.00 Glutathione 1.50 Asorbic acid 1.00 Arginine 5.00 Citrulline 5.00 Malic acid 1.00 Adenosine 2.00 Orotic acid 0.50 Creatine monohydrate 2.50 carnosine 10.00 carnitine 10.00 Dichloroacetate 0.5 Insulin 100 units/L - In some embodiments, insulin is added after the other ingredients are mixed and/or just prior to use of the storage compositions. For example, insulin can be added minutes, e.g., 0.5, 1, 2, 5, minutes to hours, e.g., 0.5, 1, 2, 3, 4, or 5 hours prior to immersing a biological tissue or organ in the solution.
- In some embodiments, the potassium phosphate salt for use in producing the non-limiting formulation shown in Table IV can be potassium phosphate monobasic. In another embodiment, the magnesium chloride salt for use in the non-limiting formulation shown in Table IV can be magnesium chloride hexahydrate. In other embodiments, the magnesium sulfate salt for use in the non-limiting formulation shown in Table IV can be magnesium sulfate heptahydrate. In yet other embodiments, the sodium phosphate salt for use in the non-limiting formulation shown in Table IV can be sodium phosphate dibasic heptahydrate. In some embodiments, the glutathione for use in the non-limiting formulation shown in Table IV can be reduced glutathione. In another embodiment, the creatine for use in the non-limiting formulation shown in Table IV can be creatine monohydrate or salts thereof. In another embodiment, the arginine for use in the non-limiting formulation shown in Table IV can be L-arginine. In another embodiment, the carnosine for use in the non-limiting formulation shown in Table IV can be L-carnosine. In another embodiment, the carnitine for use in the non-limiting formulation shown in Table IV can be L-carnitine.
- The method can also include a step of adjusting the pH of the solution to a neutral or slightly basic level, such as about pH 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7, including all ranges and numbers falling within these values. In one embodiment, the pH of the biological tissue and organ storage composition is adjusted to 7.5.
- In preferred embodiments, and as non-limiting examples of iSomah, methods for producing an organ preservation composition encompass mixing one or more of the following ingredients at the indicated concentrations in Table V or Table Va in distilled, deionized, and/or bacteriostatic water.
-
TABLE V Component mM Potassium Chloride 20 Potassium phosphate 0.44 Calcium chloride 1.30 Magnesium chloride 37 Magnesium sulfate 0.5 Sodium chloride 100.00 Sodium bicarbonate 5.00 Sodium phosphate 30.00 D-Glucose 11.00 Dichloroacetate 0.50 (optional) Malic acid 1.0 Glutathione 1.50 Asorbic acid 1.00 Adenosine 2.00 Orotic acid 0.50 Creatine 2.50 carnosine 10.00 carnitine 10.00 Arginine 5.00 Citrulline 5.00 Insulin 100 units/L
wherein insulin is added just prior to use. -
TABLE Va Component mM Potassium Chloride 20 Potassium phosphate 0.44 Calcium chloride 1.30 Magnesium chloride 37 Magnesium sulfate 0.5 Sodium chloride 100.00 Sodium bicarbonate 5.00 Sodium phosphate 30.00 D-Glucose 11.00 Dichloroacetate 0.50 (optional) Malic acid 1.0 Glutathione 1.50 Asorbic acid 1.00 Adenosine 2.00 Orotic acid 0.50 Creatine 2.50 carnosine 10.00 carnitine 10.00 Arginine 5.00 Citrulline 5.00 - In some embodiments, the potassium phosphate salt for use in the non-limiting formulation shown in Table V or Table Va can be potassium phosphate monobasic. In another embodiment, the magnesium chloride salt for use in the non-limiting formulation shown in Table V or Table Va can be magnesium chloride hexahydrate. In other embodiments, the magnesium sulfate salt for use in the non-limiting formulation shown in Table V or Table Va can be magnesium sulfate heptahydrate. In yet other embodiments, the sodium phosphate salt for use in the non-limiting formulation shown in Table V or Table Va can be sodium phosphate dibasic heptahydrate. In some embodiments, the glutathione for use in the non-limiting formulation shown in Table V or Table Va can be reduced glutathione.
- In further embodiments, the non-limiting formulation shown in Table V or Table Va can further comprise one or more of arginine (for example, L-arginine) in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM, carnosine (for example, L-carnosine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM (2.26 g/L for 10 mM), carnitine (for example, L-carnitine) in concentrations of between about 5 to about 10 mM, such as any of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM (2.26 g/L for 10 mM), orotic acid, for example, in concentrations of about 0.5-2 mM, such as any of about 0.5, 1, 1.5, or 2 mM, or creatine (for example, creatine monohydrate or salts thereof), in concentrations of about 2-5 mM, such as any of about 2 mM, 3 mM, 4 mM, or 5 mM. In another embodiment, the non-limiting formulation shown in Table V can further comprise insulin at a concentration of 10 mg-100 mg/ml/Liter or 100-1000 Units/L. When insulin is included in the composition, it is optionally added just prior to use as an organ preservation solution.
- In yet other embodiments, the non-limiting formulation shown in Table V or Table Va can further comprise a sugar, such as, but not limited to, a six carbon sugar (e.g., allose, altrose, galactose, glucose (including D-glucose (a.k.a. dextrose) and L-glucose), gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose, fucose, fuculose, or rhamnose) or a five carbon sugar (e.g. arabinose, lyxose, ribose, xylose, ketopentoses, ribulose, or xylulose) in concentrations from between about 11 mM to about 25 mM, such as any of about 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, or 25 mM of sugar.
- In still other embodiments, the non-limiting formulation shown in Table V or Table Va can optionally comprise 1-10 mM of citrulline (for example, L-citrulline) or a salt thereof in concentrations of between about 2 to about 10 mM, such as any of about 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM. In another embodiment, the non-limiting formulation shown in Table V or Table Va can optionally comprise citrulline malate (such as L-citrulline malate) instead of malic acid and/or citrulline in concentrations of about 0 mM to about 10 mM or about 2 mM to about 7 mM, such as any of about 0 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM or 10 mM citrulline malate.
- In another embodiment, and as a non-limiting example of iSomah, methods for producing an organ preservation composition encompass mixing one or more of the following ingredients at the indicated concentrations in Table VI in distilled, deionized, and/or bacteriostatic water.
-
TABLE VI Component Amount Distilled water 1 L Potassium chloride 4-65 mM Potassium phosphate 0.44-10 mM Magnesium chloride 0.5-65 mM Magnesium sulfate 0.5-1.5 mM Sodium chloride 80-135 mM Sodium bicarbonate 2-25 mM Sodium phosphate 0.15-30 mM Calcium chloride 0-1.5 mM D-Glucose 5-25 mM Glutathione 0.5-3 mM Asorbic acid 0.5-3 mM Arginine 0.5 mM to 7 mM Malic acid 0 mM to 7 mM (optional) Adenosine 1-4 mM Orotic acid 0.5-2 mM Creatine 2-5 mM carnosine 5-15 mM carnitine 5-15 mM Dichloroacetate 0.1-2.5 mM Insulin 10 mg-100 mg/ml/Liter or 100-1000 Units/L
wherein insulin is added just prior to use. - The compositions for making the biological tissue and organ storage/resuscitation solutions disclosed herein are optionally packaged in a kit with the ingredients listed below or multiples thereof in amounts necessary to scale up to make 2, 3, 5, 10, 20 times the amount of solution. An exemplary kit contains one or more of glutathione, ascorbic acid, adenosine, potassium chloride, potassium phosphate magnesium chloride, magnesium sulfate, sodium chloride, sodium bicarbonate, sodium phosphate, a sugar (such as ribose, glucose or dextrose), arginine, citrulline malate, adenosine, orotic acid, creatine, and dichloroacetate (for example, one or more of about 2.76 g/L Potassium Chloride, 0.06 g/L Potassium phosphate (monobasic), 7.47 g/L Magnesium chloride (hexahydrate), 0.123 g/L Magnesium sulfate (heptahydrate), 7.30 g/L Sodium chloride, 0.35 g/L Sodium bicarbonate, 0.05 g/L Sodium phosphate (dibasic; heptahydrate), 1.98 g/L D-Glucose, 0.462 g/L Glutathione (reduced), 0.18 g/L Asorbic acid, 0.21 g/L Arginine, 0.15 g/L L-Citrulline malate, 0.27 g/L Adenosine, 0.27 g/L Creatine orotate, orotic acid 0.373 g/L, Creatine monohydrate or salts thereof, 2.3 g/L L-carnosine, 2.0 g/L L-carnitine, 0.08 g/L Dichloroacetate, and 100 units/L insulin. The kit may optionally also contain citrulline (such as L-citrulline), and malic acid.
- These ingredients can be packaged together with instructions for use and are mixed in 0.01-2.0 L of distilled water. The kit may also contain solutions of means for adjusting the pH of the combined biological tissue and organ preservation/storage solution (e.g. THAM). The kit can be packaged or sold with or without the sterile and/or deionized water component.
- It is intended that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.
- The invention can be further understood by reference to the following examples, which are provided by way of illustration and are not meant to be limiting.
- In the following Examples, tables are designated using Arabic numbers (e.g. Table 1, Table 2, Table 3, etc.).
- In the last 40 years, notable progress has been made in the preservation of solid organs such as livers and kidneys, allowing for extracorporeal preservation for up to several hours. Unfortunately, the same cannot be ascribed to preservation of hearts, which, even after decades of arduous effort, can be stored ex vivo only for 4 to 6 hours (Churchill T A. Organ preservation for transplantation. In: Storey K B, editor. Functional metabolism: regulation and adaptation. John Wiley-Liss; 2004; 529-55). Major advances include the conceptual development of solutions, such as Celsior and University of Wisconsin solution (UWS; Table 1-1), the formulation of which was based on the prevention of edema during “hypothermic storage at 4° C.”—a concept deeply ingrained in the philosophy of organ preservation that allows for only short-term ex vivo storage. This theory likely exists because, at such extremely low temperatures, there is tissue/cellular damage, rendered irreversible with time (Devillard et al., Mol Cell Biochem 2008; 307:149-57; Belzer et al., Transplantation 1988; 45:673-6; Southard et al., Annu Rev Med 1995; 46:235-47). Organ edema is prevented by the addition of cellular impermeants such as mannitol and lactobionic acid to Celsior, and lactobionic acid, raffinose and hydroxyethyl starch to UWS. Because cellular adenosine triphosphate (ATP) consumption/synthesis is essentially very low at 41° C., there is not much stress on maintenance of cardiomyocyte high-energy phosphates (HEP; such as ATP and creatine phosphate) in the formulation of Celsior and UWS, except for addition of adenosine in UWS.
- In this Example it is shown that by enhancing high energy phosphate (HEP) synthesis, extracorporeal storage of hearts at higher temperatures is possible. Unlike Celsior, porcine hearts stored at 4° C. in Somah demonstrate robust maintenance of organ viability after 4-hour storage (Thatte et al., Circulation 2009; 120:1704-13). In addition, hearts stored at 21° C. in Somah are viably superior to those stored at extreme hypothermia (4° C.) (Lowalekar et al., Transplant Proc 2013; 45:3192-7) and have demonstrated far superior functional revival upon extracorporeal reperfusion (Lowalekar et al., Am J Transpl 2014 October; 14(10):2253-62).
- Materials and Methods
- Heart procurement surgery. Female Yorkshire swine (45 to 54 kg) were used as approved by the animal studies committee in strict accordance with established humane policies. Hearts were extracted as described elsewhere (Thatte et al., Circulation 2009; 120:1704-13) and femoral blood was collected for ex vivo experiments before clamping the aorta at a systolic pressure of <40 mm Hg. Then 1.000-ml cardioplegia at 21° C., with either Somah (20 mmol/liter K+). Celsior (20 mmol/liter K+) or UWS (innate 140 mM K+), was infused at 75 to 100 mm Hg; hearts were excised and stored in Somah, Celsior or UWS for 5 hours at 21±2° C. (ambient temperature).
- Extracorporeal heart storage. Hearts were placed inside ziplock bags (with 2 liters of Somah, Celsior or UWS) in a waterjacketed bath at 21±2° C. Because hearts in Somah showed slow contractile movements during storage, Somah's plegia potential was enhanced by supplemental K+ (total 20 mmol/liter) and Mg2+ (37 mmol/liter) (Fukuhiro et al., Circulation 2000; 102(III):319-25). Hearts were weighed beforehand and after 5 hours. Punch biopsies (2×4 mm) were taken from the left ventricular (LV) posterior wall, before and at the end of storage, for HEP assays.
- ATP and creatine phosphate assay. Cardiac tissue HEP were measured as described elsewhere (Devillard et al., Mol Cell Bioclhem 2008; 307:149-57; Bessho et al., Anal Biochem 1991; 192:117-24). Briefly, tissue was suspended in cold perchloric acid and homogenized. Homogenate was centrifuged at 0° C., the pellet was dissolved in NaOH for protein quantitation, and the supernatant was neutralized with cold KHCO3 and again centrifuged before HEP (ATP+CP) measurement using a bioluminescent kit and protocol (Promega GloMax-Multi+Detection System; Sigma-Aldrich).
-
TABLE 1-1 Composition of Somah, Celsior, and UW solutions Somah (pH 7.5) Potassium phosphate (monobasic) 0.44 Potassium chloride 7.00 Sodium chloride 125.00 Sodium bicarbonate 5.00 Calcium chloride 1.30 Sodium phosphate (dibasic, heptahydrate) 0.19 Magnesium chloride (hexahydrate) 0.50 Magnesium sulfate (heptahydrate) 0.50 D-glucose 11.00 Glutathione (reduced) 1.50 Ascorbic acid 1.00 L-arginine 5.00 L-citrulline malate 1.00 Adenosine 2.00 Creatine orotate 0.50 Creatine monohydrate 2.00 L-carnosine 10.00 L-carnitine 10.00 Dichloroacetate 0.50 Insulin 100 units/liter Celsior (pH 7.3) Mannitol 60.00 Lactobionic acid 80.00 Glutamic acid 20.00 Histidine 30.00 Calcium chloride 0.25 Potassium chloride 15.00 Magnesium chloride 2.64 Sodium hydroxide 100.00 Glutathione SH 3.00 UW solution (pH 7.4) Lactobionic acid 105.00 Potassium dihydrogen phosphate 25.00 Potassium hydroxide (56%) 100.00 Sodium hydroxide (40%) 27.00 Magnesium sulfate (heptahydrate) 5.00 Raffinose (pentahydrate) 30.00 Adenosine 5.00 Glutathione 3.00 Allopurinol 1.00 Hydroxyethyl starch (pentafraction) 50 g/ liter Insulin 40 units/liter aDate expressed in millimoles per liter (mmol/liter), unless specified otherwise. - Preparation of heart for ex vivo resuscitation and functional studies. After separation from adjoining tissue and other vessels, the aorta, pulmonary veins (PVs) and pulmonary artery were cannulated using ½-to ⅜-in., ½-to ¼-in. and ½-to ⅜-in. tubing connectors, respectively, whereas vena cavae were ligated.
- Preparation of blood for ex vivo studies. Systemically heparinized blood was collected intra-operatively, leukodepleted using a sterile leukocyte reduction filler (Pall Lukoguard R S), and stored at 41° C. Perfusate hematocrit was adjusted to 20% using Somah or Plasmalyte (+1.3 mmol/liter calcium) at a 1:1 ratio, to reduce viscous strain on the heart during extracorporeal perfusion. Perfusate pH, glucose, K+, Ca2+ and HCO3 − were adjusted for swine blood levels (pH 7.5; 100 mg/dl; 3.7, 1.38 and 32 mmol/liter, respectively), using 10% dextrose, KCl, CaCl2 and NaHCO3, respectively.
- Somah device. A custom-built apparatus was used for extracorporeal reanimation of hearts (
FIG. 1 ). A CDI monitor (Clinical DocumentationImprovement Monitoring System 500; Terumo Cardiovascular Systems Corp., Ann Arbor, Mich.), was used for real-time monitoring of perfusate pH, temperature, PO2, PCO2, K+ and HCO3 −. These parameters were also analyzed in inflow/outflow samples using an iSTAT analyzer (Abaxis, Ltd., Union City, Calif.). - Ex vivo functional studies. UWS hearts were flushed with saline to clear excess potassium. Upon attachment to the Somah device, Somah and Celsior/UWS hearts were flushed at 40 to 60 mm Hg, with 1.5 liters of Somah (pH 7.5) or Plasma-Lyte A (pH 7.5; clinically used physiologic solution) solutions, respectively, followed by perfusate. Pressure flow data were acquired using HMI software. The system temperature was raised to 37° C. over 30 minutes. Average duration for post-perfusion assessment in Somah hearts was 180 minutes, in contrast to 60 and 120 minutes, respectively, for Celsior and UWS hearts due to development of myocardial contracture and/or poor performance, even after several minutes of reperfusion upon reaching 37° C. Electroconversion (40 to 50 J) and/or epinephrine (1:50.000 to 1:100,000 in Somah hearts, as per previous experience (Lowalekar et al., Am J Transpl 2014 October; 14(10):2253-62) or 1:10,000 for Celsior/UWS hearts as reported elsewhere (Hill et al., Am Thorac Surg 2005; 79:168-77)) were used if required. Inflow (aortic) and outflow (caval) samples were collected at the beginning and then every 30 minutes (
FIG. 2 ). Epicardial 2-dimensional (2D) echocardiography was performed using a transesophageal echocardiography (TEE) probe for functional assessment. - Enzyme assays and blood chemistry. Blood creatine kinase (CK), troponin I (cTnI), lactate and gases (partial pressure of oxygen/partial pressure of carbon dioxide [PO2/PCO2]) were measured using analyzers (Vetscan VS2 and iSTAT; Abaxis), intra-operatively, during storage and at reperfusion. MVO2 was calculated during reperfusion as described elsewhere (Klabunde R. Cardiac function. Cardiovascular physiology concepts. Philadelphia: Lippincott Williams & Wilkins; 84-8).
- Epicardial echocardiography. Two-dimensional echocardiography data (short- and long-axis views for cardiac functional parameters, and LV septal/ventricular wall thicknesses) was acquired intra-operatively and ex vivo (epicardial) with a TEE probe (Cypress system; Acuson, Mountain View, Calif.) once the system temperature reached 37° C., 30 minutes after start of perfusion, and then analyzed with CYPRESS-VIEWER software. Three-lead ECG was recorded during 2D echocardiography using brass crocodile leads immersed in perfusate in the heart chamber. All Somah hearts sustained full workload (PV perfusion) and sinus rhythm, but not all Celsior and UWS hearts could tolerate the switch to full workload.
- Statistical analyses. For each investigation, equal numbers of animals from each group were assigned for comparative analysis. Biopsies and other samples were timed, as shown in
FIG. 2 . Coronary and aortic flow/pressure data were acquired using HMI software. SIGMA-PLOT software was used for statistical analysis. For comparisons between groups, a Kruskal-Wallis 1-way analysis of variance (ANOVA) ranks test was performed, assuming non-parametric data. If normality and equal variance testing passed, further analysis was performed using a Holm-Sidak test or Dunn's test; otherwise, data were compared by 1-way ANOVA. Assuming nonparametric data, to determine significant alterations within the same group, the Mann-Whitney rank-sum test was performed. If normality and equal variance testing passed, Student's t-test was performed. p<0.05 was considered significant. All values are presented as mean±SEM. - Results
- Intra-operative cardioplegia. All hearts received cardioplegia at 21° C. Cardiac arrest occurred immediately in the UWS group, likely due to very high K+. In contrast, it took 20 to 25 and 30 to 40 seconds in the Somah and Celsior groups, respectively, for complete cardiac arrest.
- Gross morphology, heart weights and release of enzymes during storage. All stored hearts presented normal gross morphology without discoloration and were pliable with no signs of rigidity/stiffness. Heart weights were not altered during 5-hour storage, suggesting absence of gross edema. A minimal release of cardiac enzymes (CK/cTnI) was detected in all solutions during storage.
- Cardiac tissue HEP levels during storage. After storage, HEP levels were significantly enhanced in Somah stored hearts (28.33±5.51; p<0.001), significantly decreased in UWS hearts (5.92±1.46; p<0.05), but remained unaltered in Celsior hearts (11.57±2.77), as compared with controls (9.95±2.52 nmol/liter per milligram protein) (
FIG. 3 ), and there was a significantly greater build-up of HEP in Somah hearts than in the comparison groups (p<0.001). - Coronary flow upon reperfusion. Coronary flow upon initial perfusion at 21° C. was significantly greater in Somah hearts than in Celsior or UWS hearts at similar perfusion pressures (Table 2). Somah hearts, but not Celsior/UWS hearts, demonstrated slow contractions immediately upon initiation of reperfusion. With the increase in system temperature to 37° C., coronary flow increased significantly in Somah and UWS hearts but not in Celsior hearts, and was highest and nearly normal in Somah hearts. In the UWS group, there was a drop in coronary circulation pressure alter an initial abrupt rise.
-
TABLE 1-2 Alterations in coronary flow in Somah, Celsior, and UES group hearts, with rise in system temperature of Somah Device. P1-21° C. F1-21° C. P2-30° C. F2-30° C. P3-37° C. F3-37° C. Somah 40 ± 1 386 ± 68a 44 ± 2 375 ± 62a 53 ± 4 579 ± 35b,c Celsior 39 ± 1 272 ± 35 51 ± 7 199 ± 44 55 ± 5 289 ± 99 UWS 38 ± 3 163 ± 13 53 ± 6 195 ± 44 38 ± 3 443 ± 80b,c P1, P2, P3: aortic root pressures at respective temperatures; F1, F2, F3: coronary flows at respective temperature. UWS, University of Wisconsin solution. aSignificant difference from other groups at same temperature. bSignificant difference from 21° C. in the same group. cSignificant difference from Celsior group hearts. - Release of enzymes upon reperfusion. Whereas CK and cTnI release in Somah and Celsior hearts was comparable after 30 minutes of reperfusion, there was a significantly greater release of both by UWS hearts (
FIGS. 4A and B). - Metabolism in reperfused hearts. There was a rapid switch from anaerobic to aerobic metabolism within 30 minutes of reperfusion in Somah hearts, as suggested by the increased MVO2 and lactate ratio reversal (
FIGS. 5A and B). In contrast, although a positive lactate production (unturned lactate ratio) was evident in Celsior and UWS hearts, MVO2 was unaltered in Celsior hearts during the same time period (FIGS. 5A and B). - Functional revival upon reperfusion. Upon reperfusion, immediate spontaneous atrioventricular activity, complemented by rudimentary electrical activity (ECG), was apparent in Somah hearts with further augmentation of ventricular contraction as system temperature was raised to 37° C., and a single cardioversion established sinus rhythm. Somah hearts did not require inotropic support or further electroversions and remained pliabl throughout the investigation. In contrast. Celsior and UWS hearts demonstrated minimally visible spontaneous activity, not detectable electrically, and became progressively firm to the touch, beginning at the LV apex, eventually involving the entire LV and septal walls, and ultimately the RV and atria, suggesting possible initialization of ischemia-reperfusion injury (IRI). Accordingly, perfusate Ca2+ levels also rapidly dropped, suggesting an intracellular shift. Celsior/UWS hearts were not revertible despite several attempts at cardioversion and epinephrine infusion. Thus, functional 2D echocardiographic data could not be procured successfully in every Celsior/UWS heart and the cardiac functional data exemplified significantly lower performance in Celsior/UWS hearts (
FIG. 6A-C ). Moreover, post-perfusion LV anterior/septal wall thicknesses were greatly increased in UWS hearts (FIG. 6D ). - In conclusion, Somah may be the key “solution” for improving prognosis in heart transplant patients. Robust metabolism, superior functional revival upon reanimation, decreased IRI-dependent damage and diminished requirements for stimulatory interventions that hearts stored in Somah at sub-normothermia are more likely to revert rapidly to robust functionality compared with other preservation solutions.
- This Example examines whether recovery of post storage heart functionality is proportionally dependent on the maintenance of the organ's energy state and storage temperature and compares heart preservation in Celsior at 4° C. and in Somah at 4° C., 13° C., and 21° C., respectively.
- Materials and Methods
- Heart procurement surgery, extracorporeal heart storage, ATP and creatine phosphate assays, preparation of hearts for ex vivo resuscitation and functional studies, preparation of blood for ex vivo studies, the Somah device, and functional studies were performed as described in Example 1, above.
- Heart weight and biopsies. Heart chambers were emptied prior to weighing at the start of storage and after 5 h. Cardiac punch biopsies (2-4 mm diameter) were taken using punch forceps within 15 min of heart excision (controls) and at the end of 5-h storage from the posterior wall of left ventricle (LV) for histopathology (HP; hematoxylin and eosin staining) and ultrastructure for Somah hearts and HEP assays for Somah and Celsior hearts.
- Electron microscopy. Somah heart tissue was fixed in glutaraldehyde and processed for ultrastructure studies. Briefly, tissue taken for electron microscopy (EM) studies was immediately fixed in glutaraldehyde and stored at 4° C. After fixation, dehydration and embedding, 70-100 nm sections were cut using ultramicrotome, transferred to grid and examined under JEOL electron microscope (1200EX-80 kV; JEOL USA Inc., Peabody, Mass.) to identify any ultrastructural changes.
- Enzyme assays and blood chemistry. Creatine kinase (CK), cardiac troponin-I (cTnI), lactate and gases (pO2/pCO2) were measured intra-operatively, and in Somah samples taken at 10 min, 2 h, and at end of 5-h heart storage using Vetscan VS2 or iStat (Abaxis Ltd, Union City, Calif.). Components of Celsior interfered with the assays; hence, storage samples could not be assayed. Inflow (aortic) and outflow (caval) samples were collected for enzyme assays at 5 min and 90 min after start of perfusate perfusion, and at 60 min (baseline) and 90 min (peak performance) for assessment of myocardial O2 consumption (MVO2) and lactate levels, using Vetscan VS2 or i-Stat System. MVO2 was calculated. The Vetscan CK assay values obtained during in vitro reperfusion were specific for heart in these isolated heart studies.
- Epicardial echocardiography. TEE probe was used for 2D Echo evaluation of cardiac function intraoperatively and ex vivo, using Acuson Cypress system (Acuson, Mountain View, Calif.) and images analyzed using Cypress viewer software. During ex vivo experiments, heart was connected to Somah Device and suspended in a chamber containing 2 L perfusate covering two-thirds of hearts surface. An electrocardiogram was recorded from beginning and 2D Echo acquisition was begun approximately 45-60 min after perfusion, if and when good cardiac contractions were observed, and repeated at 30-min intervals. Probe was placed in direct contact with heart, and angle of the probe and direction of pulse adjusted to obtain short-axis and long-axis views to assess for cardiac functional parameters and ventricular and septal wall thicknesses.
- Statistical analyses. All values are expressed as mean±SEM. The analyses were focused on comparing
Celsior 4° C. (n=5) withSomah 4° C. heart (n=6), 13° C. (n=6) and 21° C. (n=6) hearts. One-way analysis of variance was performed for all functional measurements (differences in total HEP values in control and at 300 min; MVO2, lactate, CK, cTnI, coronary flow at 60 min [baseline] and 90 min [peak performance], and ventricular and septal wall thickness) using SigmaPlot (Systat Software Inc., San Jose, Calif.). Tukey test was used to identify specific differences between the groups. Since HEPs are significantly increased in Somah stored hearts, three hearts at random per Somah group and five Celsior hearts were selected for HEP analysis. A paired t-test was used to assess the difference in coronary flow attime 0 and at 37° C., in MVO2 and lactate at baseline and 90 min within the four groups. For mitochondrial ischemic scores (MIS), four EM slides (×8000 magnification) with 20 mitochondria per slide in Somah hearts (n=3/group) were used. Statistical significance was accepted at the 95% confidence level (p<0.05). Tissue and blood samples for different investigations were obtained as illustrated (FIG. 7 ). - Results
- Gross morphology, heart weights, HP and EM. Hearts preserved in Celsior and Somah presented normal morphology and did not show any discoloration. Cardiac dema was estimated in Somah groups by comparing EM, HP and heart weights (
FIG. 8 ). EM and HP demonstrated intact organelle membranes, normal intracellular glycogen content and alignment of contractile proteins, the absence of vacuolation and clear spaces between myofiber bundles and lack of contracture bands, indicating paucity of intracellular edema. Differences in heart weights pre- and post-storage were insignificant. Minimal reversible changes in cardiomyocyte nuclei characterized by accumulation of chromatin beneath nuclear membrane were apparent in Somah groups. Density of mitochondrial matrix was well preserved with insignificant ischemia. Mean MIS, on a scale of 0-6 (6 being worst), demonstrated negligible reversible changes in mitochondria and were 0.09±0.02, 0.17-0.03, 0.07±0.02 in 4° C., 13° C. and 21° C. Somah hearts, respectively. Characteristic irreversible damage such as cristolysis, vacuolation and mitochondrial membrane rupture was not seen in any hearts. - Cardiac Metabolism During Storage
- High-energy phosphates: Hearts preserved in Sonmah synthesized HEPs irrespective of storage temperature confirming previous observations. There was a temperature of storage dependent increase in HEP concentration in Somah hearts. Total HEP values of 55.7±5.1, 68.4±11.0 and 81.5±19.8 nM/mg protein in Somah hearts (n=3/group) preserved at 4° C., 13° C. and 21° C. respectively, were significantly greater (p<0.05) than 26.31±1.4 nM/mg protein observed in Celsior hearts (n=5) at end of storage. Control values were not significantly different between the groups.
- Lactate production and oxygen consumption during storage: Anaerobic lactate production temporally increased from 0.41 at 2 h to 0.75±0.05 mmol/L in 21° C. hearts but was below detection level in hypothermic Somah groups after 5-h storage. However, the pH remained stable at 7.4±0.1 in all groups. Additionally, hearts stored at higher temperatures vigorously utilized oxygen dissolved in Somah (pO2 210-240 mm Hg) due to relatively active aerobic metabolism. The pO2 decreased by 7.0±7.6, 17.0±3.51 and 14.0±3.51 mm Hg in Somah at 4° C., 13° C. and 21° C., respectively during storage, corresponding with a parallel increase in HEP synthesis. Lactate and pO2 utilization could not be measured in Celsior during storage.
- Cardiac Functional Studies
- Coronary flow: Upon initiation of antegrade perfusion, coronary flow was observed in all hearts irrespective of solution or temperature of storage. The 4° C. and 13° C. Somah hearts demonstrated slow irregular four chamber contraction as temperature was raised to 21° C., while slow rhythmic contraction were immediately observed after initiation of perfusion in 21° C. group.
- In contrast. Celsior hearts demonstrated irregular contractions of atria but not the ventricles. Cardiac contractions and sinus rhythm were enhanced with rising temperature, reaching peak performance at 37° C. approximately 90 min after initiation of perfusion in all Somah groups, but not in the Celsior hearts. Initial coronary flow was significantly greater (p<0.05) in Somah hearts stored at 21° C. than in hearts stored at 4° C. and 13° C. At 378 C, furthermore, there was a significant parallel increase in coronary flow in Somah groups (p<0.05), but not in the Celsior group (Table 2-1). Additionally, coronary flow at 37° C. in Somah groups was significantly greater than in the Celsior hearts (p<0.05).
-
TABLE 2-1 Alterations in coronary flow (millimeter per minute) in Celsior 4° C., 13° C., and 21° C.group hearts upon reperfusion and increasing system temperature. Heart group Time 0 At 21° C. At 37° C. Celsior 4° C. 323 ± 44 223 ± 40 350 ± 211 Somah 4° C.290 ± 212 299 ± 25 495 ± 381,3 Somah 13° C. 230 ± 132 182 ± 13 439 ± 171,3 Somah 21° C. 312 ± 902 312 ± 90 621 ± 881,3 n = 5 Celsior hearts; n = 6 Somah hearts per temperature group; time 0 = coronary flow immediately upon initial reperfusion.1Celsior versus Somah groups at 37° C. (p < 0.05). 221° C. versus 13° C. and 4° C. group hearts (p < 0.05) at time 0.3 Time 0 versus 37° C. (p < 0.05) - Cardiac metabolism and enzyme release upon reperfusion in working hearts: MVO2 remained unaltered between 60 (baseline) and 90 min post perfusion in 4° C. Somah hearts and increased significantly within 13° C. and 21° C. Somah hearts, but there was no difference between the three groups. In contrast, MVO2 was severely attenuated in Celsior hearts (
FIG. 9A ). Similarly, lactate level in perfusate at baseline was significantly lower in Celsior group (p<0.05) than Somah groups. Lactate decreased in all groups at 90 min, but significantly within the 13° C. and 21° C. Somah groups (p<0.05), though the difference was insignificant between the groups (FIG. 9B ). Energy requirements reached steady state at peak performance in all Somah hearts, independent of storage temperature. Ratios of pre- and post-workload HEP levels in cardiac tissue were comparable (˜0.37) in Somah working hearts, but not in Celsior hearts. CK release was lowest in 21° C. Somah group; however, there was no significant difference between any of the groups (FIG. 10A ). In contrast, cTnI release was significantly lower in Celsior hearts (p<0.05) compared with the Somah groups (FIG. 10B ). - TEE and in vitro 2D Echo imaging: LV anterior wall and septal thicknesses showed no significant change between intraoperative and in vitro reanimation between the four groups (Table 2-2).
-
TABLE 2-2 Comparison of intraoperative and in vitro thickness (end-systolic) of the left ventricular (LV) anterior and septal walls in differentially stored hearts. Temperature Intraoperative In vitro group LV wall thickness (cm) thickness (cm) Celsior Anterior 1.29 ± 0.01 1.43 ± 0.04 4° C. Septal 1.37 ± 0.13 1.54 ± 0.19 Somah Anterior 1.37 ± 0.17 1.40 ± 0.06 4° C. Septal 1.29 ± 0.12 1.36 ± 0.08 Somah Anterior 1.73 ± 0.09 1.56 ± 0.10 13° C. Septal 1.50 ± 0.09 1.44 ± 0.07 Somah Anterior 1.56 ± 0.03 1.55 ± 0.06 21° C. Septal 1.58 ± 0.08 1.71 ± 0.04 In vivo and in vitro groups, Celsior, n = 5; Somah; n = 6/group. - In Somah hearts, 2D Echo visibly demonstrated a temperature-of-storage dependent performance (
FIG. 11 ). In higher temperature groups, a greater degree of wall motion and LV contraction with enhancement of other cardiac functional parameters (FIG. 6 ) was evident, both during preload (antegrade coronary perfusion) and afterload (PV perfusion). Optimal function of hearts was attained in 21° C. group, at a left atrial pressure of 4±2 mm Hg, in contrast to 12±3 mm Hg for 4° C. and 13° C. hearts, requiring differential stimulatory interventions (Table 2-3). -
TABLE 2-3 Numbers of cardioversions and amount of epinephrine required for functional re-instatement of hearts stored at 4° C., 13° C. or 21° C. Cardioversion Epinephrine Storage (33-40 V; epicardial) × (0.1 mg bolus) × temperature times delivered times delivered Celsior 4° C.>7 >5 Somah 4° C.4-6 3-4 Somah 13° C. 2-5 2-3 Somah 21° C. 1 — - In contrast, Celsior hearts were unable to generate synchronous four chamber contractions and were incapable of sustaining any workload, even with multiple stimulatory interventions (Table 2-3), eventually developing stiffness during the experimental period. Therefore, functional data could not be collected from the Celsior hearts. Data obtained at
peak performance 90 min into perfusion and full workload in Somah groups was used for comparative analysis. Calculated percentage fractional area change, coronary flow, blood pressure, stroke volume, ejection fraction and cardiac output approached physiological parameters in 21° C. group hearts (Table 2-4). -
TABLE 2-4 Cardiac functional parameters during surgery and at peak performance upon extracorporeal reperfusion. In vitro In vivo Celsior 4°C. Somah 4° C. Somah 13° C. Somah 21° C. Heart rate (beats/min) 98 ± 12 40 ± 20 113 ± 10 111 ± 10 100 ± 10 LV systolic pressure (mm Hg) 116 ± 8 20 ± 15 75 ± 5 80 ± 10 100 ± 20 LV diastolic pressure (mm Hg) 68 ± 7 5 ± 5 15 ± 5 35 ± 5 40 ± 10 Left atrial pressure (mm Hg) <10 nt 10-15 8-10 0-5 Cardiac output (mL/min) 3300 ± 400 nt 1250 ± 100 2350 ± 3501 2500 ± 3001 2D Echo data analysis % Fractional area change >40 10% 21.7 ± 5.54 40.08 ± 10.281 41.58 ± 12.571 Ejection fraction (%) 65 ± 5 nt 34.0 ± 6.43 56.08 ± 3.721 57.64 ± 3.541 Stroke volume (mL) 29 ± 4 nt 11 ± 3 21 ± 5 25 ± 21 2D Echo, 2-dimensional echocardiography; LV, left ventricular; nt, not tested secondary to lack of predicted function. n = 23, in vivo group; n = 5 Celsior hearts; n = 6 Somah hearts per temperature group. 113° C. and 21° C. versus 4° C. group hearts (p < 0.05). - This is the first report demonstrating rapid revival of hearts into a fully functional state within physiologically relevant cardio-hemodynamic parameters with minimal injury after extracorporeal preservation for 5 h at 21° C. This study suggests that, if hypothermic damage can be prevented while enhancing the energy state of an organ during storage, it is possible to maintain structural integrity, cellular homeostasis, repair and recovery of function. Somah solution meets the fundamental requisites of organ storage namely, prevention of edema, Reactive oxygen species-dependent injuries and enhancement of HEP synthesis, thus, mitigating requirements for extreme hypothermic (4° C.) storage and associated cellular injury.
- In this example, hearts taken 30 minutes after cardiocirculatory death (DCD hearts) were studied and stored for 4 to 5 times the current clinical norms. Additionally, the study was designed to determine the ideal temperature for the long-term storage of DCD hearts in Somali, in a functionally viable state for transplantation.
- Materials and Methods
- Animal Model. Three-month-old male Sprague-Dawley Rats were used strictly in accordance with the protocol approved by an Institutional Animal Studies Subcommittee.
- Somah Solution Preparation and Other Materials. Somah was formulated as described above. Freshly prepared solution was filter sterilized using 0.4 mm filter (VWR International) stored at 4° C. and used within 24 hours of preparation. All chemicals and antibodies were obtained from Sigma Chemical Co (St Louis, Mo., USA), Amersham Biosciences (Piscatway, N.J., USA), Bio-Rad (Hercules, Calif., USA), or DAKO Corp (Carpinteria, Calif., USA), unless otherwise stated.
- Extraction. Storage, and Simulated Reperfusion of the Hearts. Rats rendered unconscious with CO2 were guillotined and the blood was collected in acid-citrate-dextrose tubes for simulated reperfusion of hearts. DCD hearts were extracted 30 minutes after euthanasia and stored in Somah at 4° C.±2° C., 10° C.±2° C., 21° C.±2° C., or 37° C.±2° C. for 24 hours. At the end of 24-hour storage, simulated reperfusion was performed by incubating hearts in perfusate solution (blood:Somah::3:1) at 37° C. for 30 minutes in a shaking water bath. Heart biopsies were taken before and after reperfusion for live-dead and esterase assays, mitochondrial polarization assays, protein expression, and tissue adenosine triphosphate (ATP) and creatine phosphate (CP) levels.
- Live-Dead Viability and Esterase Activity Assays. Viability of cardiomyocytes from Somah DCD hearts was assessed with fluorescence-based live-dead assays and multiphoton microscopy. Heart biopsies, were incubated with calcein AM (acetomethoxy derivative of calcein) and ethidium homodimer dyes (Live-Dead assay kit; Molecular Probes), 10 mmol/L in 1.5 mL HBSS (Hanks Balanced Salt Solution), pH 7.4, for 30 minutes at 21° C., washed with preservation solution and imaged with multiphoton microscope for green (living cells) and/or red (injured/dead cells) fluorescence. Functional integrity of cardiomyocytes was evaluated by semiquantitative measurement of the quantum yield (photon counts) of calcein fluorescence, indicative of esterase activity.
- JC-1 Assay of Mitochondrial Membrane Potential. Cardiomyocytes were labeled with JC-1 dye (Molecular Probes), imaged, and the mitochondrial polarity ratios were determined using multiphoton microscopy.
- Protein Extraction and Western Blotting. LV tissue (20 mg) was cut into 300 pieces, suspended in 200 mL of Lysis buffer (CellLytic MT; Sigma-Aldrich) with a protease inhibitor cocktail, homogenized for 30 seconds before centrifuging at 16.000 g for 10 minutes and the supernatant (total protein) collected and then quantitated using Bio-Rad protein assay kit. Proteins were resolved on 7.5%, 10% or 12% SDS-PAGE and transferred to nitrocellulose membrane. Blots were incubated with primary antibodies (1:1000; anti-myosin heavy and light chain, actinin, actin, and troponin C) followed by HRP (horseradish peroxidase) conjugated secondary antibodies and protein expression detected using electrochemiluminescence (GE Hlealthcare).
- ATP and CP Assays. ATP and CP levels were measured in cardiac tissue after 24-hour storage at 4° C., 10° C., 21° C. or 37° C. and upon reperfusion using spectrofluorometer and bioluminescent assay kit (Perkin Elmer, Waltham, Mass. USA).
- Multiphoton Imaging. State-of-the-art multiphoton imaging techniques using BioRad imaging system (MRC 1024ES) coupled with MaiTai mode-locked titanium:sapphire laser (Spectra-Physics, Mountain View, Calif., USA), were used for deep-imaging cardiac biopsies and semiquantitative fluorescence measurements. Images 512×512 pixels were collected in direct detection configuration, at pixel resolution of 0.484 mm. Cardiomyocytes were identified by XYZ axis scanning, and imaged at depths of 50 mm in LV biopsies from the point of excision.
- Statistical Analysis. Metamorph software (Molecular Devices, Downingtown, Pa., USA) was used for data extraction, quantification, and analysis of fluorescence counts from multiphoton images, in blinded fashion by different members of the lab. Data are expressed as means±standard errors. Differences between groups were determined using Student t test (paired on unpaired) or 1-way analysis of variance where applicable. Statistical significance was accepted at the 95% confidence level (P<0.05). Data was derived from n=3 for each temperature group, n=25 measurements for esterase activity and mitochondrial polarization, and n=5 for ATP and CP level determination.
- Results
- Cardiomyocyte viability in extracted hearts. Live-dead assays and multiphoton microscopy (
FIG. 12 ) of cardiac biopsies performed immediately after extraction (control;FIG. 12A ) demonstrated robust green fluorescence (indicative of viable cells) but no red nuclear fluorescence (indicative of damaged cells). After 24-hour storage in Somah, with the exception of discoloration and visible loss of structural integrity in the 37° C. group, the gross morphology of DCD hearts was well preserved at all other temperature groups while the green fluorescence of live-dead assay in these groups was similar to that of controls. However, at 4° C., 10° C., and 37° C., the red nuclear fluorescence of damaged cells was also enhanced after 24-hour storage (FIG. 12B ) suggesting that hearts stored at all, but the subnormothermic temperature (21° C.) suffered some concurrent cellular damage. Upon simulated reperfusion of the stored hearts, there was a demonstrable decrease in green fluorescence in hearts that were stored at 4° C. and 37° C. (FIG. 12C ). - Esterase Activity Measurement. Prior to simulated perfusion, quantum yield of green fluorescence as a function of esterase activity was highest in the hearts stored at 21° C. and lowest at 37° C. (Table 3-1). After reperfusion, the esterase activity was unaltered in hearts stored at 21° C. but was variably decreased in hearts stored at 4° C., 10° C., and 37° C., although not significant in 10° C. group.
-
TABLE 3-1 Quantitative assessment of calcein fluorescence (esterase activity) in DCD hearts. 4° C. 10° C. 21° C. 37° C. Before 193.4 ± 6.7 202.8 ± 7.9 216.8 ± 8.4 130.5 ± 5.9 reperfusion After 165.8 ± 6.9 191.8 ± 6.7 220.4 ± 6.6 113.6 ± 5.8 reperfusion % change −14%b −5% 2% −13%b in CF Quantitation data (total fluorescence count) was obtained from analysis of images depicting esterase activity from 3 hearts donated after cardiocirculating death in each temperature group after 24 hours of storage in Somah solution and upon reperfusion. After 24 hours of storage (before reperfusion), the esterase activity was lowest in 37° C. and highest in 21° C. group hearts. Upon reperfusion, a significant decline in esterase activity was evident in hearts preserved at extreme hypothermic (4° C.) or normothermic (37° C.) temperatures but was unaltered in the 10° C. and 21° C. group hearts. CF = calcein fluorescence. a Arbitrary units ± standard error of means bSignificant change after perfusion - JC-1 Assay for Mitochondrial Polarization. In the freshly extracted DCD hearts, the polarized and depolarized states of mitochondria were in equilibrium (
FIG. 13 ). Irrespective of storage temperature, mitochondrial membranes in cardiomyocytes of DCD hearts remained polarized both after 24-hour storage and upon reperfusion, while the polarization ratio was not altered in any group after reperfusion. Furthermore, there was no significant difference in mitochondrial polarization status in the different groups before or after reperfusion. - High-Energy Phosphate Syntheses. Compared to controls, ATP/CP syntheses in hearts were significantly enhanced after 24-hour storage in Somah at 4° C., 10° C., and 21° C. (
FIG. 14 ). Upon reperfusion, ATP synthesis was significantly decreased in 4° C. group but was unchanged in the 10° C. group. In contrast, reperfusion resulted in a 400% increase in ATP synthesis in hearts stored at subnomiothermic temperature. Parallel to the ATP studies, CP synthesis was also significantly increased upon reperfusion in 21° C. group. - Protein Expression The structural viability of ex vivo stored hearts was determined by assessing the expression of proteins important for contractile function. Expression of myosin HC, actinin, actin, myosin LC and troponin C was well preserved in hearts stored in Somah for 24 hours at 21° C. (
FIG. 15 ). In contrast, these proteins were variably lost in other temperature groups either after 24-hour storage or upon reperfusion. - In conclusion, this example demonstrated for the first time that DCD hearts in static storage can be preserved in a viable state at subnormothermic temperature, beyond currently acceptable time of 4 to 5 hours of hypothermic storage, using the recently designed organ preservation solution, Somah.
- This Example evaluates the relative efficacy of Somah at 4 and 21° C. in preservation of optimum heart function after in vitro storage at subnormothermia.
- Materials and Methods
- Heart procurement surgery and cardioplegia. Ten female Yorkshire swine (45-54 Kg) were used in this comparative study. Hearts were divided into two groups of either 4° C. (n=5) or 21° C. cardioplegia (n=5), as per the protocol approved by an Animal Studies Committee (Institutional Animal Care and Use Committee). Hearts were extracted using mediastinal approach as described (Thatte H S, Rousou L, Hussaini B E, Lu X G, Treanor P R, Khuri S F: Development and evaluation of a novel solution, Somah, for the procurement and preservation of beating and non-beating donor hearts for transplantation. Circulation. 2009, 120: 1704-1713). The animals were bled from femoral vessels to collect blood for ex vivo experiments, and aorta was clamped when systolic pressure fell below 40 mmHg. 1000 ml of SOMAH cardioplegia (SOMAH (Thatte H S. Rousou L, Hussaini B E. Lu X G, Treanor P R, Khuri S F: Development and evaluation of a novel solution, Somah, for the procurement and preservation of beating and non-beating donor hearts for transplantation. Circulation. 2009, 120: 1704-1713) modified by addition of 20 mM K+, final concentration), at 4 or 21° C. was infused into the aortic root at a pressure of 75-100 mmHg at a flow rate of 300-400 ml/minute using roller pump and pressure transducer (Myothermnn Cardioplegia System, Medtronics, Minneapolis, Minn., USA) and the data was recorded using iWorks system (Dover, Nil, USA). After cardioplegic arrest, heart was dissected from all attachments and rinsed with normal saline before storing in SOMAH for 5-hours at 21° C. Hearts were transported to the lab within 15 minutes of excision.
- Extracorporeal storage of heart. Hearts were placed in sterile zip-lock bags containing 2 L of SOMAH in water-jacketed water bath at 21±2° C. The temperature of preservation solution was checked regularly during the entire storage period. Hearts were maintained in a non-contractile state by increasing SOMAH's plegia potential by supplementing the solution with 20 mM K+ complemented by 37 mM Mg2+(Fukuhiro Y, Wowk M, Ou R, Rosenfeldt F, Pepe S: Cardioplegic strategies for calcium control: low Ca2+, high Mg2+, citrate, or Na+/H+exchange inhibitor HOE-642. Circulation. 2000, 102 (19-3); Osaki S, Ishino K, Kotani Y, Honjo O, Suezawa T. Kanki K, Sano S: Resuscitation of non-beating donor hearts using continuous myocardial perfusion: the importance of controlled initial reperfusion. Ann Thorac Surg. 2006, 81: 2167-2171), during storage. Hearts in each group were weighed prior to and after 5-hour storage upon carefully emptying the heart chambers. Tissue punch biopsies (2×4 mm) were taken in the lab from the posterior wall of LV, 15 minutes into (0 hour; control) and after 5 hour storage for HEP assays.
- ATP and creatine phosphate assay. ATP and creatine phosphate (CP) were measured in tissue extracts as described (Thatte H S. Rousou L, Hussaini B E, Lu X G, Treanor P R, Khuri S F: Development and evaluation of a novel solution, Somah, for the procurement and preservation of beating and non-beating donor hearts for transplantation. Circulation. 2009, 120: 1704-1713; Bessho M. Ohsuzu F, Yanagida S, Sakata N, Aosaki N, Tajima T. Nakamura H: Differential extractability of creatine phosphate and ATP from cardiac muscle with ethanol and perchloric acid solution. Anal Biochem. 1991, 192: 117-124). In brief, tissue biopsies were flash frozen and stored at −80° C.; 20 mg of tissue was suspended in 400 μl of 0.4 M ice-cold perchloric acid and homogenized twice for 30 seconds. Homogenate was centrifuged at 1970 g for 10 minutes at 0° C. An aliquot of supernatant was neutralized with equal volume of ice-cold 0.4 M KHCO3 and centrifuged as above. The supernatant was stored at −80° C. for ATP and CP measurements. The pellet was dissolved in equal volume of 0.1 M NaOH, centrifuged and used for protein assay. ATP and CP were measured using a bioluminescent assay kit (Sigma-Aldrich and GloMax-Multi+Detection System, Promega), according to the protocol provided by the manufacturer.
- Preparation of heart for ex vivo resuscitation and functional studies. Aorta and pulmonary artery (PA) were separated. Aorta was cannulated (½-⅜inch tubing connector) and coronaries were gently flushed with 100 ml of SOMAH in both 4° C. and 21° C. cardioplegia groups at 40-50 mmHg pressure, carefully avoiding entry of air into the aorta. Pulmonary veins (PV) were separated and cannulated with ½-¼ inch tubing connector. PA was cannulated for sample collection while superior and inferior vena cavas were ligated.
- Preparation of blood for ex vivo studies. Systemically heparinized blood was collected intraoperatively, leukodepleted (Pall Leukoguard filter) and stored at 4° C. Prior to experiments, perfusate was prepared by adjusting the hematocrit of blood to 20% using SOMAH solution (1:1 ratio to reduce viscous strain on heart) and warmed to 21° C. The perfusate, pH, glucose, K+, Ca2+ and HCO3— were adjusted for swine blood levels (7.5; 100 mg/dl; 3.7, 1.38, and 32 mmol/l respectively), using 10% dextrose, KCl, CaCl2 and NaHCO3, respectively, as required.
- The SOMAH device. A custom-built apparatus was used for extra-corporeal reanimation of hearts (
FIG. 1 ). CDI monitor (Clinical DocumentationImprovement monitoring system 500, Terumo cardiovascular systems corporation. Ann Arbor, Mich.), was used for real-time monitoring of perfusate pH, temperature, pO2, pCO2, K+ and HCO3—. These parameters were also analyzed in inflow/outflow samples using i-STAT analyzer (Abaxis Ltd, Union city, CA). Pressures and flows were recorded at various points in the circuits (FIG. 16 ). A trans-esophageal echocardiography (TEE) probe was used to assess the contractile function of heart using the 2D-Echo system. 3-lead ECG was recorded during 2D Echo using brass crocodile leads immersed in the perfusate surrounding the heart. Pressures and flow data was acquired and monitored in real time using HMI software, specifically written for SOMAH Device (Comdel Inc, Wahpeton, N. Dak.). - Ex vivo functional studies. Hearts were attached to SOMAH Device and perfused through the aorta at 40-60 mmHg for 5 minutes, with 1-1.5 liters of SOMAH at 21° C. (pH 7.5), and then with perfusate, till pH, blood gases and electrolyte equilibrium was established. The perfusate pH, glucose, K+, Ca2+, HCO3— were adjusted for swine blood levels as mentioned above. Strong cardiac contractions were noted in both groups as the system temperature was gradually raised to 37° C. over a 30 minute period. Hemodynamic steady state (with respect to pH, blood gases, and electrolytes) was achieved within 40 minutes. Total duration of the experimental perfusion was approximately 180 minutes. Hearts were perfused through aortic root (no workload) until the system temperature reached 37° C., after which PV perfusion (full workload) proceeded until end of experiment. Corollary blood flow was determined during the initial antegrade perfusion by the amount of perfusate flowing to the heart through aorta per minute, and in the working heart by the amount of perfusate collected from pulmonary artery (both cavas ligated) per minute. Electroconversion (40-50 J) and/or epinephrine (1:50,000-1:100,000) were used if required (Lowalekar S K, Cao H, Lu X G, Treanor R, Thatte H S: Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant. 2014).
Epicardial 2D Echo was performed using TEE probe for functional assessment at 60 minutes (baseline) and at peak performance, approximately 90 minutes after initiation of perfusate perfusion in the two groups with hearts under full workload; and every 30 minutes thereafter. Peak cardiac performance was defined by the maximum contractile activity observed by 2D Echo. The data at peak performance was used for comparisons between the two groups. - Enzyme assays and blood chemistry. Quantitative levels of cardiac creatine kinase (CK), aspartate aminotransferase (AST), troponin-I (cTnI), lactate and gases (pO2/pCO2) were measured intra-operatively and in SOMAH samples taken at 10 minute, 2-hour and at end of 5-hour heart storage using Vetscan VS2 or iStat (Abaxis Ltd, Union City, Calif.). Inflow (aortic) and outflow (PA) samples were collected for enzyme assays and post perfusion assessment of myocardial O2 consumption (MVO2) and lactate levels using Vetscan VS2 or i-Stat System, at 5 and 90 minutes for enzyme assays, and at 60 minutes (baseline) and 90 minutes (peak performance) for MVO2 and lactate, after start of perfusate perfusion with Vetscan or iStat. MVO2 was calculated as described (Klabunde R: Cardiac function. Cardiovascular Physiology Concepts. 2011, Lippincott Williams & Wilkins, Baltimore, Md. USA, 84-88).
- Epicardial echocardiography. A trans-esophageal (TEE) probe was used for 2D echo evaluation of cardiac function intra-operatively and ex vivo using the Acuson Cypress system (Acuson, Mountain View, Calif.) and images were analyzed using Cypress viewer software provided with the system. Hearts were connected to SOMAH Device and suspended in a chamber containing 2 L of perfusate that covered ⅔rd surface of the heart. ECG was recorded during entire course of the experiment and 2D Echo acquisition was begun approximately 45-60 minute after perfusion, when good cardiac contractions were observed, and repeated at 30-minute intervals. Probe was placed in direct contact with heart and angle of probe and direction of pulse were adjusted as to obtain short-axis and long-axis views for calculations of cardiac functional parameters, and ventricular wall and septal thickness.
- Statistical analyses. Equal number of animals (n=5), were assigned to 4° C. and 21° C. cardioplegia groups for comparative analysis for biochemical, hemodynamic and functional measurements from each group. Statistical comparison for significant differences between the two groups was performed using SigmaPlot software. Paired t-test was used for all comparisons. P-value of <0.05 was considered significant. All values are expressed as mean±SEM. Flow diagram of the experimental design is shown in
FIG. 16 . - Results
- Intraoperative cardioplegia. Cardiac arrest was dependent on the temperature of cardioplegia and occurred within 10-15 seconds in 4° C. group and 20-25 seconds in the 21° C. group, likely because the hypothermic (4° C.) component of cardiac arrest was deliberately eliminated in the latter.
- Gross morphology, heart weights and release of enzymes during storage. Irrespective of temperature of cardioplegia, all hearts presented normal gross morphology without any discoloration. Hearts were pliable with no signs of hardening or stiffness. Weights of the hearts during 5-hour storage in the two groups were not altered between pre and post storage, demonstrating lack of storage-induced gross edema (not shown). A time dependent release of cardiac enzymes was minimally apparent in both groups that were not significantly different (not shown).
- Cardiac tissue HEP levels after arrest and during storage. As shown in
FIG. 17 , concentration of ATP. CP and total high-energy phosphates (HEP), within 15 minutes (control) of cardiac arrest were significantly greater in 4° C. as compared to 21° C. cardioplegia hearts (P<0.001) possibly due to the greater consumption of energy in 21° C. group hearts as they required approximately 10 seconds longer for total arrest. Both groups actively synthesized CP and ATP during storage, as shown inFIG. 17B . While the total concentrations of HEP at the end of storage were significantly greater in 4° C. hearts (P<0.01), normalization of values at 5 hour with respect to those at 0 hour demonstrated greater availability of HEP in 21° C. hearts than in 4° C. hearts at the end of storage, as shown inFIG. 17C . - Ex vivo cardiac functional studies—Coronary flow upon reperfusion. Coronary flow through the aorta, upon initial antegrade perfusion at similar perfusion pressures, was significantly greater in 21° C. hearts (P<0.05) than the 4° C. group (Table 4-1). The hearts in both groups demonstrated slow four chamber contractions immediately upon initiation of perfusion. Coronary flow decreased initially when system temperature was raised to 30° C., as the hearts started contracting vigorously. Both pressure and flow increased as system temperature was raised to 37° C. Coronary flow was highest in both groups at 37° C. (Table 4-1).
-
TABLE 4-1 Coronary flow (ml/min) in differential temperature cardioplegia hearts with the rise in system temperature of SOMAH Device Heart groups P1-21° C. F1-21° C. P2-30° C. F2-30° C. P3-37° C. F3-37° C. 4° C. 40 ± 1 312 ± 90 44 ± 2 297 ± 28 53 ± 4 621 ± 88 21° C. 40 ± 1 464 ± 65* 40 ± 2 348 ± 64 50 ± 3 619 ± 34 P1, P2, P3 - Aortic Root Pressures at respective temperatures. F1, F2, F3 - Coronary Flows at respective temperatures. *Significant from 4° C. - Release of enzymes upon reperfusion. Rate of CK. AST and cTnI release increased in 4° C. hearts during the perfusion period (
FIG. 18 ). Both CK and cTnI release increased significantly with the time of perfusion, but the AST did not. In contrast, there was a temporal decrease in release of these three enzymes in the 21° C. hearts during the same period (FIG. 18 ). However, release of CK and cTnI, but not the AST, was significantly greater by the 21° C. hearts upon initiation of perfusion than by the 4° C. hearts. - Metabolism in reperfused hearts. Consistent with previous observations (Lowalekar S K, Cao H, Lu X G, Treanor R, Thatte H S: Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant. 2014), there was a rapid switch in metabolism from anaerobic to aerobic upon reperfusion in both 4° C. and 21° C. cardioplegia groups, demonstrated by an increase in oxygen consumption and reversal of lactate ratios at peak performance, 90 minutes into reperfusion (
FIGS. 19A and 19B ). Oxygen extraction, lactate production and utilization, reached a steady state in both groups at peak performance that were not significantly different. However, upon reperfusion, 21° C. group hearts demonstrated robust synthesis of HEP in the working hearts. In contrast, production was attenuated in 4° C. hearts and the HEP continued to decline during course of the experiment. Ratios (post perfusion/pre perfusion) of ATP. CP and total HEP were 1.10, 1.97 and 1.17, respectively in 21° C. hearts which were significantly greater (p<0.01) than ratios of 0.47, 0.32 and 0.38 observed in the 4° C. hearts at end of experiment, when post perfusion biopsies were taken for HEP assays. - Functional revival upon reperfusion. Immediate spontaneous activity of both the atria and ventricles was apparent upon commencement of reperfusion in both groups. With increased temperature, force of ventricular contraction peaked at about 37° C. after a single cardioversion, which also established the normal electrical activity and electromechanical coupling in sinus rhythm in both groups. While 4 of the 5 hearts in 21° C. cardioplegia group reverted to sinus rhythm with a single cardioversion and none requiring further inotropic support, 2 of the 5 hearts in 4° C. cardioplegia group required additionally a single dose of epinephrine to maintain optimal function. Interestingly, hearts in both groups remained pliable throughout the experiment and did not show any edema at peak performance as indicated by unaltered thickness of LV and the septum, Table 4-2. The comparative data between 4 and 21° C. cardioplegia groups for cardiac functional parameters acquired by 2D Echo were similar to those observed in vivo (Table 4-2). Although hearts that received SOMAH cardioplegia at 21° C. appeared to have a better recovery, there were no significant differences in the functional parameters of the two groups.
-
TABLE 4-2 Cardiac functional parameters during surgery and at peak performance upon extracorporeal reperfusion in 4° C. and 21° C. SOMAH cardioplegia group hearts Parameters In vivo 4° C. hearts 21° C. hearts LV ant wall thickness (cm) 1.48 ± 0.07 1.55 ± 0.06 1.51 ± 0.04 Septal thickness (cm) 1.43 ± 0.12 1.61 ± 0.04 1.49 ± 0.07 Heart rate 98 ± 12 100 ± 10 110 ± 10 LV systolic pressure (mm Hg) 116 ± 8 100 ± 20 110 ± 10 LV diastolic pressure 68 ± 7 40 ± 10 55 ± 10 (mm Hg) Left atrial pressure (mm Hg) <10 0-5 0-5 Cardiac output 3300 ± 400 2500 ± 300 2640 ± 250 Fractional area change (%) >40 42 ± 13 51 ± 4 Ejection fraction (%) 65 ± 5 58 ± 4 66 ± 5 Stroke volume (ml) 29 ± 4 25 ± 2 24 ± 3 - This Example was undertaken to evaluate whether using crystalloid SOMAH at 21° C. instead of standard temperature of 4° (for cardioplegia could further improve the quality of hearts preserved at ambient temperature in SOMAH, and their eventual reanimation in vitro into optimal function.
- Myocardial edema has been reported in hearts arrested at perfusion pressures of cardioplegia as low as 50 mmHg (Mehlhorn U, Geissler H J, Laine G A, Allen S J: Myocardial fluid balance. Eur J Cardiothorac Surg. 2001, 20: 1220-1230). However, in present and past studies a crystalloid SOMAH cardioplegia infusion pressure of 100 mmHg has consistently been used irrespective of cardioplegia temperature, but edema was not seen in any of the hearts (Lowalekar S K, Cao H, Lu X G, Treanor P R, Thatte H S: Sub-normothermic preservation of donor hearts for transplantation using a novel solution, SOMAH: a comparative pre-clinical study. J Heart Lung Transplant. 2014, 33 (9): 963-970). SOMAH cardioplegia provides all the advantages of blood cardioplegia, in terms of protection from cardiac edema and provision of substrates for energy metabolism, and also provides clear surgical field. Additionally, provision of physiological concentrations of calcium in SOMAH solution, also prevents the likelihood of myocardial damage due to ‘calcium paradox’ (Yamamoto H, Yamamoto F: Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics. Gen Thorac Cardiovasc Surg. 2013, 61: 485-496. 10.1007/s 1748-013-0279-4). Furthermore, the disadvantages of blood such as the presence of leukocytes and platelets, culpable in reperfusion injury (Han S, Huang W. Liu Y, Pan S, Feng Z, Li S: Does leukocyte-depleted blood cardioplegia reduce myocardial reperfusion injury in cardiac surgery? A systematic review and meta-analysis. Perfusion. 2013, 28 (6): 474-483), are also averted. In contrast, the other crystalloid solutions (Celsior and UWS), when used for cardioplegia in recent studies did not prevent loss of high-energy phosphates in the stored hearts, edema upon reperfusion and potential high K+ mediated calcium overload and stiffness that resulted in non-functioning hearts (Lowalekar S K, Cao H, Lu X G, Treanor R, Thatte H S: Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant. 2014).
- In this study, HEP were conserved in 4° C. hearts because of rapid arrest, as a result total concentration of HEP was also greater in these hearts at the end of storage. In contrast, despite K+ concentration (20 mM) being equal in the two groups, the 21° C. hearts took longer for total arrest because of absence of the hypothermic component, resulting in depletion of HEP. Both groups synthesized HEP during storage in SOMAH, however, the functional availability of HEP was greater in 21° C. hearts than the 4° C. hearts at the end of 5 hour (
FIG. 3 ). Similarly, upon reperfusion, 21° C. hearts continued to synthesize HEP to meet the demands of the working heart, unlike the 4° C. hearts. At peak performance the available HEP in 21° C. hearts was significantly greater than 4° C. hearts, and continued to be so during course of the experiments. In contrast, 4° C. hearts were unable to synthesize HEP to keep with the energy demands, thus HEP continued to decrease in the working hearts. These results are in agreement with previous observations that, unlike in hearts preserved in SOMAH at ambient temperatures, exposure to severe hypothermia leads to attenuation of HEP synthesis upon reperfusion in these hearts (Lowalekar S K, Lu X G, Thatte H S: Further evaluation of somah: long-term preservation, temperature effect and prevention of ischemia-reperfusion injury in rat hearts harvested after cardiocirculatory death. Transplant Proc. 2013, 45 (9): 3192-3197). - Antegrade perfusion was significantly lower in the 4° C. heart than in 21° C. hearts, and remained diminished, even at higher perfusion pressures until the system temperature stabilized at 37° C. (Table 4-1). Without being bound to theory, it is plausible that sudden shock of encountering 4° C. cardioplegia by the normothermic beating heart leads to profound vasoconstriction that does not resolve during storage and only does so upon initiation of reperfusion and raising of temperature to 37° C. and potentially because of active release of vasodilators nitric oxide and prostacyclins (Thatte H S. Rousou L, Hussaini B E, Lu X G, Treanor P R, Khuri S F: Development and evaluation of a novel solution. Somah, for the procurement and preservation of beating and non-beating donor hearts for transplantation. Circulation. 2009, 120: 1704-1713). Increased vasodilation, greater coronary vascular patency and a favorable metabolic status provides for rapid nourishment and H+ washout, resulting in robust synthesis of HEP and swift recovery of function in the 21° C. hearts. These hearts reverted to sinus rhythm with a single cardioversion and rapidly attained cardiac and hemodynamic parameters approaching in vivo range (Table 4-2), not requiring any inotropic support. On the other hand, 4° C. hearts demonstrated strong contraction only when warmed to 37° C. some of the hearts requiring additional electroversion and/or inotropic intervention, albeit ten times less than that reported in human hearts in vitro (Hill A J, Laske T G, Coles J A, Sigg D C, Skadsberg N D, Vincent S A, Soule C L, Gallagher B A, Iaizzo P A: In vitro studies in human hearts. Am Thorac Surg. 2005, 79: 168-177) to maintain cardiac output.
- Release of cardiac enzymes was observed in both the groups upon reperfusion. An important mechanism of release of enzymes from the cardiomyocyte is by cytosol leakage during intracellular vesicular trafficking and incorporation (such as vesicles harboring glucose transporters; GLUT) into cell membrane, by a HEP dependent process, in response to external stimuli like insulin and increased metabolic demands in working hearts (Ferrera R, Benhabbouche S, Bopassa J C, Li B: One hour reperfusion is enough to assess function and infarct size with TIC staining in Langendorff rat model. Cardiovasc Drugs Ther. 2009, 23: 327-331). Therefore, release of cellular enzymes can occur even in absence of actual damage to the cardiomyocytes (enzyme paradox). Without being bound to theory, the initial burst of enzyme release in 21° C. cardioplegia group upon initiation of reperfusion likely resulted from greater availability of HEP at the end of storage for vesicular transport as the metabolic demands were ramped up with increase in system temperature and cardiac contractility (
FIG. 17 ). However, upon reaching metabolic steady state any further release of enzyme was temporally attenuated. In contrast, in the 4° C. hearts, the rate of release of enzymes increased with time as more HEP became available for these functions. Even though the present data does not differentiate between progressions of enzyme release, the fact that the cardiac functional parameters in both groups were similar and approach the physiological values observed in vivo (Table 4-2) indicate that the releases of enzymes by the SOMAH hearts is a marker of metabolism rather than tissue injury and hence these hearts would perform well upon transplant. - This Example was designed to evaluate the novel storage solution Somah in its ability to maintain phosphate synthesis of livers and halt progression of long-term static storage-dependent multicellular damage. The aim of this current pilot study was to evaluate the comparative efficacy of Somah with the currently clinically used University of Wisconsin solution (UWS) in their ability to preserve and potentiate recovery of DCD porcine livers in vitro during a 72 hour period of hypothermic storage. A limited extracorporeal hepatic reperfusion and functional evaluation of Somah-stored livers was also performed to test the feasibility for future transplant studies to evaluate graft function.
- Materials and Methods
- CoStorSol (UWS) (Preservation Solutions Inc, Elkhorn, Wis.) and Somah (Somahlution, LLC, Jupiter, Fla.), Table 5-1, was compared for storage properties. All other chemicals were obtained from Sigma-Aldrich (SL Louis, Mo.). VetScan iStat, VetScan VS2, CG4+, CG8+, Large Animal Profile. Comprehensive Diagnostic Profile cartridges for measuring blood gases, electrolytes, lactate, glucose, aspartate transaminase (AST), alanine transaminase (ALT) and creatine kinase (CK) enzymes were purchased from Abaxis Inc (Union City, Calif.).
-
TABLE 5-1 Composition of Somah Organ Preservation solution (pH 7.5) and University of Wisconsin Solution (UWS; pH 7.8). Components Concentration (mM) Distilled water 1.00 L Calcium 1.30 chloride 7.00 Potassium phosphate (monobasic) 0.44 Magnesium chloride (hexahydrate) 0.50 Magnesium sulfate (heptahydrate) 0.50 Sodium chloride 125.00 Sodium bicarbonate 5.00 Sodium phosphate(dibasic; heptahydrate) 0.19 D-glucose 11.00 Glutathione (reduced) 1.50 Ascorbic acid 1.00 L-arginine 5.00 L-citrulline malate 1.00 Adenosine 2.00 Creatine orotate 0.50 Creatine monohydrate 2.00 L-carnosine 10.00 L-carnitine 10.00 Dichloroacetate 0.50 Insulin (10 mg/ml) 1.00 ml/L Composition of University of Wisconsin (UWS), (pH 7.8) Lactobionic Acid 105 Potassium Dihydrogen Phosphate 25 Potassium Hydroxide (56%) 100 Sodium Hydroxide (40%) 27 Magnesium Sulfate (heptahydrate) 5 Raffinose (pentahydrate) 30 Adenosine 5 Glutathione 3 Allopurinol 1 Hydroxyethyl Starch (Pentafraction) 50 g/L Insulin 4.0 mg/L - Liver storage and procurement of samples. The study was conducted in fourteen female swines, each weighing 40-50 Kg in accordance with protocol approved by an Animal Studies Subconunittee (IACUC), VA Boston Healthcare System. The animals were divided into two groups of seven animals each. Whole livers were dissected out 60±10 minutes after cardiac death and extraction of heart. The livers were stored in UWS (UWS livers) or Somah solution (Somah livers) for 72 hours at 4° C. The solutions were not replaced during storage. Liver biopsies were obtained at 0, 6, 24 and 72 hours for imaging and biochemical assessment of viability. UWS and Somah solutions were sampled at 1, 6, 24 and 72 hours for metabolic monitoring and for other assays and compounds relevant to liver function.
- Surgical procedure. General anesthesia was induced with i.m. injections of telazol 4-6 mg/kg and
xylazine 2 mg/kg. After intubation, animals were maintained with i.v. propofol (10 mg/kg/hour), remifentanyl (40-60 μg/hr) and nimbex (cisatracurium) 10-20 mg, and mechanically ventilated. Aorta was cross-clamped, heart arrested, and heart-lung block was extracted for other experiments as described ((Lowalekar S K, Cao H, Lu X G, Treanor R, Thatte H S: Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant 2014). After median laparotomy, suprahepatic aorta was cannulated, and abdominal organs lushed with 2 L of ice cold UWS or Somah solution at a pressure and flow rate of 100 mmHg and 300 ml/min respectively, till the perfusate returning through the suprahepatic inferior vena cava (IVC) was clear. The harvest was concluded with a total hepatectomy. Livers were transferred to plastic bags containing preservative solutions maintained at 4° C. in an icebox, and transported within 30 minutes to the lab for further analysis. Livers were transferred to storage box containing preservative solutions and stored at 4° C. for another 72 hours. - ATP and creatine phosphate assay. ATP and creatine phosphate (CP) were measured in liver tissue extracts. In brief, 20 mg of hepatic tissue was suspended in 400 μl of 0.4 M ice-cold perchloric acid and homogenized twice for 30 sec. Homogenate was centrifuged at 1970 g for 10 mins at 0° C. An aliquot of supernatant was neutralized with equal volume of ice-cold 0.4 M KHCO1 solution and centrifuged as mentioned above. The supernatant was stored at −80° C. for ATP and CP measurements. The pellet was dissolved in equal volume of 0.1 M NaOH and centrifuged and used for protein assay. ATP and CP were measured using a bioluminescent assay kit (Sigma-Aldrich and GloMax-Multi+ Detection System, Promega) according to the protocol provided by manufacturer.
- Preparation of blood for Ex vivo studies. Systemically heparinized blood was collected intraoperatively, leukodepleted and stored at 4° C. Prior to the commencement of experiments, the hematocrit was adjusted to 20% using Somah solution (now perfusate). The perfusate, pH, glucose, K+, Ca2+ and HCO3— were adjusted for swine blood levels (7.5; 100 mg/dl; 3.7, 1.38, and 32 mmol/l respectively), using 10% dextrose, KCl, CaCl2 and NaHCO3, respectively; gases were adjusted as required.
- Ex vivo perfusion. Livers were stored in Somah for 72 hours at 4° C. (n=3). Hepatic artery and portal vein were identified and cannulated. The livers were kept in a polypropylene perfusion chamber attached to a custom built Somah Device used for ex vivo reanimation of hearts. An oxygenator, heat exchanger, clinical documentation improvement (CDI) monitor and data acquisition device with custom written software (Comdel inc. Wahpeton, N. Dak.) were incorporated into the system for real-time monitoring of changes in perfusate pH, temperature, pO2, pCO2, K+ and HCO3-apop, pressure and flow rates. Somah device reservoir was filled with 2 L perfusate. Livers were gently flushed through the portal vein with 2 L of cold Somah, and then connected to Somah device via the hepatic artery (HA) and portal vein (PV). The reservoir outlet was diverted into two circuits: in the first circuit, the perfusate drained by gravity into the PV at a pressure of 8-10 mmHg (adjusted by changing the height of the reservoir). In the second circuit, perfusate was diverted through a pump to the HA (at pressures of 80-100 mmHg) via the oxygenator and heat exchanger. Temperature of perfusate was raised to 37° C. over a 20 min period and the perfusate was circulated through the liver for next 2 hours, the liver perfusate drained into a chamber through hepatic veins (HV) and was returned to the reservoir by another pump. Perfusate draining from the HV was temporally sampled for albumin, liver enzymes and other metabolites as mentioned below. Because of damage to the DCD livers stored in UWS, this functional assessment was performed only in Somah-livers.
- Analysis of metabolites and liver enzymes. Blood parameters were assessed in perfusate inflow (HA) and outflow (HV). CDI monitor, VetScan iStat and VetScan VS2 were employed to determine biochemical parameters, blood gas, albumin synthesis and liver enzymes including alkaline phosphatase (ALP), Alanine aminotransferase (ALT). Aspartate aminotransferase (AST), γ-glutamyl transpepstidase (GGT) and creatine kinase (CK).
- Histopathology. Tissue biopsies of livers stored either in Somah or UWS were taken at 0, 6, 24 and 72 hour storage time points, fixed in 10% formalin and processed for histopathology (10μ sections; Hematoxylin and Eosin stain). The images were acquired and analyzed using Olympus microscope and image analyzer system (BX51TRF; Olympus America Inc, USA). Images were assessed blindly for histopathology by three independent observers. Statistical analyses: The measurements and data extraction were performed in a blinded fashion. Comparison within the two groups (UWS vs. Somah, n=7 in each group; static storage) was conducted to evaluate the effect of the two solutions on organ function. The quantified initial values of various assays were compared to subsequent time points within each group using one-way analysis-of-variance (ANOVA), followed by Dunnett's multiple comparison test and t-test for comparative analysis between paired groups. Statistical significance was accepted at 95% confidence level (P<0.05). All values used were mean±SEM unless otherwise indicated. All analyses were performed using GraphPad Prism 6 (version 6.1), using a 0.05 significance level.
- Results
- Gross appearance: Upon storage in UWS at 4° C., the gross appearance of livers was rapidly altered to a discolored state within the first hour of storage and subsequently continued to temporally deteriorate (not shown). In contrast, livers stored in Somah maintained their color similar to freshly extracted livers (control), even after extended 72 hour storage at 4° C. (
FIG. 20 ). Furthermore, there was no weight gain by the Somah livers during storage (not shown) - Hepatocytes: Nuclear chromatin condensation and pyknotic changes of hepatocytes in numerous low power fields were seen in livers stored in UWS but not in Somah. Binucleate and polyploid hepatocytic nuclei were consistently seen in sections obtained from both UWS and Somah-preserved livers. Furthermore, in Somah livers, cellular boundaries between adjacent hepatocytes were visibly intact, and no cholestasis or bile canalicular dilatations were apparent upon careful scan of multiple fields. In sections obtained from UWS livers at 72 hrs, degeneration of hepatocytes associated with extensive vacuolation was evident, but not in Somah livers (
FIG. 21 ). - Biliary ducts and ductules: Nuclei lining both bile ductules and larger bile ducts in the portal triad appeared intensely pyknotic, suggesting apoptosis or necrosis of cholangiocytes in UWS livers. In contrast, the bile ducts and ductules were uniform in appearance with regularly placed nuclei and well preserved nuclear heterogeneity in Somah livers after 72 hrs of storage (
FIG. 21 ). Furthermore, in UWS livers, there was denudation of bile ductular epithelium and sloughing of the mucosa along with disorganization of the basally placed nuclei of the ductules as early as 6 hr time point (FIG. 22 ). In contrast, such denudation of bile ductular epithelium was not visible in Somah livers even after 72 hours of storage (FIGS. 21 and 22 ). - Metabolism in stored livers. While the starting pH for freshly reconstituted UWS and Somah was alkaline (UWS pH being higher than Somah), it was more acidic (6.8-7.0) in Somah compared to UWS (7.3-7.8) during all storage time points. There was a greater increase in lactate in UWS despite a lesser decrease in pH. Production of lactate did not correspond with sharp drop in solution pH, perhaps due to high buffering capacity of both the solutions. There was 1.5-fold increase in lactate levels in the UWS in comparison to Somah solution, which was significantly different at 24 and 72 hours, respectively (p<0.05) (
FIGS. 23A and 23B ). - As shown in
FIG. 23 (lower panel), there was a comparable increase in glucose concentration in both UWS and Somah solution. Glucose concentration in UWS increased from 0 mg/dl to as high as 140 mg/dl at the end of 72 hour storage. Similarly, the glucose levels in Somah increased by 1.72 fold to 320 mg/dl over baseline levels of 180 mg/dl during the same time period, indicating greater glycogen breakdown than glucose reuptake. Oxidative phosphorylation is attenuated by hypothermia. Since in an open system, the solubility of atmospheric oxygen in water is inversely related to temperature, both Somah and UWS were supersaturated with oxygen at 4° C., with a pO2 of 200±13 mmHg at the start of storage. Therefore, utilization of oxygen by the livers during extended temporal hypothermic storage cannot be clearly demonstrated, as oxygen consumption, if any, follows zero order kinetics. - On the contrary, while the pCO2, an indicator of dissolved CO2, does not change in Somah or UWS solution in the absence of organs (not shown), the present studies demonstrated a significant increase in pCO2 in Somah with stored liver during the 72 hour storage period, indicating oxidative metabolic turnover in Somah-stored DCD livers. In contrast, CO2 levels were significantly lower and remained unaltered in UWS with stored liver during the 72 hour period. In UWS, pCO2 measured at 30 minutes (6.30±0.38 mmHg) after the immersion of the liver and transfer to the lab increased insignificantly to only 7.33±0.48 mmHg over 24 hours and 9.27±0.89 mmHg at 72 hours storage. In contrast in Somah, the pCO2 increased significantly from 10.8±1.13 mmHg within 30 minutes after initial immersion of the liver to 15±1.45 mm Hg at 1 hour, to 27±1.14 mmHg at the end of 72 hours, indicating temporal increase in metabolism. The greater pCO2 in Somah than UWS at 30 minutes is indicative of active metabolism from the start of storage. Probability of bicarbonates present in Somah contributing to this increase in pCO2 was negated by the fact that HCO3— concentration remained mostly unaltered (4.23 mM/L) during the 72 hour storage. Conversely, HCO3— concentration decreased from 7.30 to 5.33 mM/L in UWS during the 72 hour storage, which, without being bound to theory, may have contributed to the non-significant increase in pCO2 that was observed in UWS during the storage period (
FIG. 25 ). Another possibility to be considered is that anaerobic glycolysis, through lactate production, may have contributed to the rise of pCO2 in Somah (as well as the mild rise in UWS stored livers). These data indicate that at least cellular metabolism was kept intact. - Measurement of phosphates in stored livers. ATP. CP and total phosphate concentrations decreased significantly (p<0.05) in UWS livers during the 72 hour storage (
FIG. 25 ). The total phosphate decreased temporally in UWS livers during storage, resulting in 32% drop in the first 6 hours, followed by a 50% decrease by the end of 72 hours. In contrast, ATP, CP and total phosphate levels did not change appreciably in Somah livers during the entire course of preservation. An increase in total phosphate concentration at 72 hours in Somah livers was observed (FIG. 25 ), analogous with metabolic production of CO2. - Release of Liver Enzymes during Storage. A time dependent release of ALT, AST and CK enzymes was observed in storage solutions as markers of liver tissue injury. Release of all three enzymes was significantly elevated (P<0.05) when livers were stored in UWS, in comparison to livers stored in Somah (
FIG. 26 ). - Functional evaluation of somah livers. Somah stored livers (72 hours) were reperfused with blood (perfusate) for 2 hours at 37° C. for functional evaluation. Oxygen consumption by the reperfused livers increased significantly by 38% and 64% (p<0.05) at 30 and 120 min, respectively. Concomitantly, lactate concentration released in the perfusate decreased by 11% and 41% at 30 min and at the end of 2 hours, indicating anaerobic to aerobic metabolic switch.
- There was no significant difference in temporal release of liver enzymes during reperfusion (
FIG. 27 ). Both ALP (15.33±0.96) and γ-GT (17.5±1.06 U/L) were within physiological concentrations at the end of 2 hours. However, AST (2151±81), ALT (228±32) and CK (1428±205 U/L) concentrations were elevated in the perfusate at the end of reperfusion. There was a significant increase in synthesis and release of albumin by the Somah livers within 30 min after reperfusion (p<0.03), which increased temporally over the 2 hour period (p<0.01) (FIG. 28 ). Synthesis and release of bile was also increased temporally in perfused Somah livers (data not shown). - The objective of this Example was to compare “Somah” and UWS solution for extended temporal extracorporeal preservation of porcine DCD livers. In this study, evidence of efficient storage properties with of Somah over UWS to functionally salvage DCD livers is provided. Without being bound to theory, it was hypothesized that the unique formulation of Somah temporally maintains and/or augments energy state of an organ during extracorporeal storage, resulting in enhanced cellular homeostasis and structural integrity, thereby, effectively improving the overall repair and recovery of excised organ during the storage period.
- The results of the present study reveal that progressive histological injury of DCD livers is potentially preventable, depending upon the composition of storage solution. The karyopyknosis in hepatocytes and reactive changes of biliary epithelial cells were visible as early as 6 hrs in UWS-livers, but not in Somah-livers at 72 hour time point. Furthermore, this study provides detailed findings of different kinds of biliary injury, earlier only scantily reported (Kochhar et al., 2013, World J. Gasterenterol., 19:2841-46). DCD livers stored in UWS showed degenerative changes in both small and large bile ducts, a potential cause of non-anastomotic biliary stricture and biliary dysfunction.
- This has been reported to result in poor post-transplant graft functioning (Kochhar et al., 2013. World J. Gasterenterol., 19:2841-46) and greater morbidity (Yan et al., 2011, J. Surg. Res., 169:117-124). Without being bound to theory, the higher K+ levels and ischemia may have augmented cellular damage in UWS-livers (Lowalekar S K, Cao H, Lu X G, Treanor P R. Thatte H S. Subnormothermic preservation in somah: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant. 2014; 14:2253-62). Furthermore, while acidic pH is reported to be constitutively beneficial to hepatocytes and sinusoidal epithelial cells (Lowalekar S K, Cao H, Lu X G, Treanor P R, Thatte H S: Sub-normothermic preservation of donor hearts for transplantation using a novel solution. SOMAH: a comparative pre-clinical study. J Heart Lung Transplant. 2014, 33 (9): 963-970), the pH of Somah, compared to UWS remained relatively acidic throughout the preservation period. The enzyme assay studies showed significantly diminished hepatocellular injury of livers stored in Somah in contrast to UWS.
- While during hypothermic perfused organ storage, glycolysis appears to be the primary energy source at a pO2 of 150 mmHg (Opie L H, Lopaschuk G D (2004) Fuels: aerobic and anaerobic metabolism. In: Opie L H, ed. Heart Physiology: From Cell to Circulation. 4th ed. Philadelphia, Pa.: Lippincott, Williams and Wilkins 306-354), the dichloroacetate (DCA) in Somah likely diverts the pyruvate generated by glycolysis into Krebs cycle, thus further enhancing ATP synthesis and maintenance of phosphates (
FIG. 25 ). Furthermore, the DCA, by enhancing oxidative metabolism of pyruvate, also prevents build-up of lactate in Somah stored livers. Moreover, insulin, which enhances the entry of glucose into cells, is a hepatotrophic factor and is essential for maintenance of hepatic ultrastructure and regenerative ability. Somah solution exploits this ability of insulin by providing it in a concentration of 100 U/L, 2.5 folds higher than that in UWS. Thus, the greater lactate accumulation above threshold levels in the absence of DCA and the lower insulin concentration in UWS-livers contributes to the comparative changes in this group. - Loss in phosphates in the explanted organs during storage leads to irreversible degenerative changes in the organ. Despite an equivalent increase in glycogenolysis-dependent glucose concentration in both UWS and Somah solution livers during storage, there was a depletion of phosphate stores in UWS, in contrast to enhancement in Somah. Without being bound to theory, this suggests that UWS livers are in fact in a catabolic state, resulting in loss of phosphates. In contrast, by promoting oxidative phosphorylation of glucose in Somah-livers, a 15 folds greater amount of phosphates are generated (for equivalent glucose molecules) than by anaerobic glycolysis alone (Brown, Biochem J. 1992, 284:1-13). Furthermore, during hypothermic perfusion, livers having greater ATP levels demonstrate lower oxidative stress upon re-warming (Belzer F, Southard J H, Transplantation. 1988 April; 45(4):673-6).
- Static organ preservation has always been recognized as critical component in maintaining liver explants prior to transplantation (Pegg et al., Translpantation, 1981, 32:437-43). Limited studies have addressed the deleterious effect of storage of livers in UWS solution (Startzl et al., Hepatology, 2010, 5:1869-84). However, this does not appear to occur in DCD livers preserved in Somah. Preliminary functional studies indicate that there is a rapid switchover to aerobic from anaerobic metabolism, supported by similar observations in the heart (Lowalekar S K. Cao H, Lu X G. Treanor R, Thatte H S: Subnormothermic preservation in SOMAH: a novel approach for enhanced functional resuscitation of donor hearts for transplant. Am J Transplant. 2014). Similarly, there was a significant increase in synthesis of albumin, and release of bile in the reperfused Somah livers, indicating that metabolism and function are preserved after prolonged storage. UWS-stored livers were not evaluated for functional recovery because of gross damage to these organs.
- The biliary system in Somah livers remains patent and intact, demonstrating lack of frank damage. It is well known that hepatocytes can repair or regenerate, especially if the energy state of the organ can be preserved. It is the failure of biliary system that leads to PNF and DGF (Kochhar et al., 2013. World J. Gasterenterol., 19:2841-46). Biliary dysfunction may be prevented by ex vivo storage in Somah.
- Eighty-six of every hundred patients requiring renal transplant last year, did not get one, adding to the ever mounting waitlist for transplantrequiring individuals [National Kidney Foundation; http://www.kidney.org]. This is despite tremendous progress in solid organ transplantations in last several decades and availability of renal replacement therapy (Hemodialysis and Peritoneal dialysis) which are not only associated with severely debilitating and/or life-threatening complications but hinder routine lifestyle of patients due to frequent requirements for hospital visits, imparting a huge financial burden on society.
- In 2015, 14000 patients in US received renal transplant, 2500 patients are added to renal transplant waitlist each month, with around 100,000 patients awaiting kidney transplantation at the time of writing this paper; the average waiting time being three to five years. Although, 65% of renal grafts are procured from deceased (DCD; Donation after Cardiac Death) donors, these grafts are twice as likely to develop delayed graft function (DGF) compared to standard-criteria donors, an increased incidence of primary non-function (PNF), and halved overall graft survival. Whereas grafts exposure to warm and/or cold ischemia is an obligate inevitability of solid organ transplant, the resulting cellular/tissue damage during this period is consequential of the less than desired post-transplant operative renal function. The above data indicate an enormous potential to improve quality of DCD kidneys for transplantation by making advances in preservation technology, and thus more desirable long-term patient outcomes.
- This Example evaluated the ability of novel organ preservation solution Somah compared to University of Wisconsin (UW) solution for extended storage of DCD kidneys.
- Materials and Methods
- Surgical procurement of kidneys. Female Yorkshire Swine weighing 40-50 Kgs were used as per protocol approved by institutional animal studies committee. Swine were sedated with telazol 4-6 mg/kg i.m. and
xylazine 2 mg/kg i.m., intubated and connected to ventilator. Anesthesia was maintained using i.v. propofol (10 mg/kg/hr) and remifentanyl (40-60 μg/hr). Cis-atracurium (10-20 mg i.v.), a paralytic agent, was administered ten minutes prior to surgery. Upon midline sternotomy, animals were systemically heparinized (300 mg/Kg) and aortic root cannulated. Ice cold cardioplegia (20 mM K+) was infused after aortic clamping to stop the heart which was then excised for other experiments as described [6,7]. Time of complete cessation of heart contraction was recorded as the beginning of warm ischemia of other body organs. Post median laparotomy, suprahepatic aorta was cannulated and abdominal organs flushed with 2 L of ice cold UW (CoStorSol; Preservation Solutions Inc., Elkhorn, Wis.) or Somah solution (Somahlution Inc., Jupiter, Fla.), at 100 mmHg pressure and a flow of 300 ml/min, till perfusate returning through inferior vena cava (IVC) was clear. Abdominal organ harvest was concluded first with hepatectomy for use in other experiments, and subsequent total bilateral nephrectomy after carefully dissecting the renal pedicles. Kidneys were immediately transferred to Somah or UW solution (Table 6-1) at 4° C. and static stored for 72 hours. Kidney biopsies were obtained for histopathology, HEP and Western blot assays attime Time 0 corresponds to 1 hour in storage; time required to transport kidneys from animal research facility to lab before first biopsy. -
TABLE 6-1 Composition of Somah and UW solutions. SOMAH (pH 7.5) mmol/L* Potassium Phosphate (monobasic) 0.44 Potassium Choloride 7.00 Sodium Chloride 125.00 Sodium Bicarbonate 5.00 Calcium Chloride 1.30 Sodium Phosphate (dibasic; heptahydrate) 0.19 Magnesium Chloride (hexahydrate) 0.50 Magnesium Sulfate (heptahydrate) 0.50 D-Glucose 11.00 Glutathione (reduced) 1.50 Ascorbic Acid 1.00 L-Arginine 5.00 L-Citrulline Malate 1.00 Adenosine 2.00 Creatine Orotate 0.50 Creatine Monohydrate 2.00 L-Carnosine 10.00 L-Carnitine 10.00 Dichloroacetate 0.50 Insulin 10 mg/L UW SOLUTION (pH 7.4) Lactobionic Acid 105.00 Potassium Dihydrogen Phosphate 25.00 Potassium Hydroxide (56%) 100.00 Sodium Hydroxide (40%) 27.00 Magnesium Sulfate (heptahydrate) 5.00 Raffinose (pentahydrate) 30.00 Adenosine 5.00 Glutathione 3.00 Allopurinol 1.00 Hydroxyethyl Starch (Pentafraction) 50 g/L Insulin 4.0 mg/L - Histopathology. Tissue was fixed in formalin and embedded in paraffin before cutting 10μ thin sections that were melted onto glass slides for further processing. Tissue sections were dried in sequentially increasing ethanol concentrations and then subjected to hematoxylin and eosin staining after which slides were immersed in xylazine clearing agent, covered with cover slip and examined under microscope. Images were acquired and analyzed using Olympus microscope and image analyzer system (BX51TRF; Olympus America Inc. USA) and assessed in blind fashion by independent observers.
- ATP and creatine phosphate assay. ATP and creatine phosphate (CP) were measured in kidney tissue extracts as described [4-7,10]. In brief, 20 mg of renal tissue was suspended in 400 μl of 0.4 M ice-cold perchloric acid and homogenized twice for 30 secs. Homogenate was centrifuged at 1970 g for 10 mins at 0° C. An aliquot of supernatant was neutralized with equal volume of ice cold 0.4 M KHCO3 solution and centrifuged as above. Supernatant was stored at −80° C. for ATP/CP measurements. The pellet was dissolved in equal volume of 0.1 M NaOH and centrifuged and used for protein assay. ATP/CP was measured using a bioluminescent assay kit (Sigma-Aldrich and GloMax Multi+Detection System. Promega) according to manufacturer's protocol.
- Western blotting. 20 mg of kidney tissue was suspended in extraction buffer containing a protease inhibitor cocktail. Tissue was homogenized for 30 sees, centrifuged at 16,100×g for 10 mins and supernatant was collected. Equal amounts of total protein (30 μg) from different samples were mixed with Laemmli sample buffer containing 5% β-Mercaptoethanol, and heated at 100° C. for 3 mins. Proteins were resolved on 10% SDS-PAGE, and electro-blotted onto nitrocellulose membrane; proteins were identified using antibodies (anti-Caveolin, eNOS, vWF, and EPO) and chemiluminescence assays and band densities were normalized to betaactin as described [4].
- Metabolic analysis. Changes in pH and lactate, glucose metabolism, oxygen and carbondioxide concentrations (pO2 and pCO2) in Somah and UW were assessed at 0 (1 hour, vide supra), 6, 24 and 72-hour time-points during storage using VetScan iStat and VetScan VS2.
- Statistical analysis. The measurements and data extraction were performed in blinded fashion. Comparison within two groups (UW vs. Somah, n=7 in each group) was conducted to evaluate effects of the two solutions. Quantified initial values of various assays were compared to subsequent time points within each group using one-way analysis-of-variance (ANOVA), followed by Dunnett's multiple comparison test, and t-test for comparative analysis between groups. Statistical significance was accepted at 95% confidence level (p<0.05). All values used were mean±SEM unless otherwise indicated. All analyses were performed using GraphPad Prism 6 (v6.1). The authors had access to and take full responsibility for integrity of data. All authors have read and agree to the manuscript as written.
- Results
- Gross morphology of kidneys. Kidneys were examined during 1-3 days of immersion static storage at 4° C. Kidneys stored in UW showed dusky and mottled appearance (
FIG. 1a ), indicative of organ congestion. In contrast, kidneys stored in Somah appeared healthy, of uniform color and morphologically unaltered after 3 days storage (FIG. 1d ). - Histomorphology of kidneys. Irrespective of storage solution, there was no evident interstitial edema in all DCD kidneys at observed time-points, with well preserved overall structure of renal tissue (
FIGS. 1b,1c,1e and 1f ). The normal amorphous collection in tubular lumen was observed in proximal convoluted tubules (PCT) at all time-points and not increased with storage duration. Distal convoluted tubules (DCT) remained mostly clear of any debris at all time-points except at 72 hour where a minimal to moderate epithelial denudation was apparent in both UW and Somah-preserved kidneys (FIGS. 1c and 1f ). Renal glomeruli exhibited normal cellularity with normal appearing Bowman's space and continuous parietal epithelium at all time-points, in both solutions (FIGS. 1b,1c,1e and 1f ). - A gradual time-dependent loss of tubular epithelial nuclear heterogeneity with increased hyperchromaticity and occasional loss of cellular margins was observed in both UW and Somah-stored kidneys, indicative of tubular epithelial injury (
FIGS. 1c and 1f ). However, extent of these changes were significantly greater in UW-stored kidneys (p<0.05). On an average 3.5%, 24.4%, 39.7% and 37% in UW kidneys, and 4.4%, 6.2%, 10.9% and 11.6% in Somah kidneys, of the epithelial cell nuclei (of PCT/DCT's) were severely hyperchromatic, attime - Metabolism in stored kidneys. DCD kidneys were evaluated for physiological/biochemical viability by assessing metabolic functions during extracorporeal storage; demonstrating differentially active metabolism in UW and Somah groups. While freshly reconstituted solutions started off with a more alkaline pH (moreso in UW), a time-dependent fall in pH was apparent in Somah, but remained more acidic (6.8-7.2) compared to UW (7.5-7.4) (
FIG. 30A ). While there was a temporal increase in glucose levels in UW solution, suggesting glycogenolysis, there was a comparative significant fall (p<0.05) in glucose levels in Somah, at and beyond 6 hour time-points, suggesting utilization of glucose present in Somah by kidney tissue/cells (FIG. 2B ). Inversely, compared to Somah, there was a significantly greater (p<0.05) rise in lactate levels in UW at 72 hour time-point (FIG. 30C ). - Since in an open experimental system as ours, the solubility of atmospheric oxygen in solution is inversely related to temperature, and since oxygen consumption follows zero-order kinetics, and as Somah and UW both were supersaturated with oxygen at 4° C., with a pO2 of 200±13 mmHg at all times (
FIG. 30D ), oxygen utilization by kidneys could not be clearly demonstrated. However, in contrast to UW, in which pCO2 was significantly lower than in Somah throughout storage (7.28±0.40 mmHg at 1-hour and 7.50±0.48 mmHg at 72 hours), a significant initial increase in pCO2 was observed in Somah (p<0.01) (from 5.8±1.15 mmHg after initial immersion of kidney to 17.00±0.45 mmHg) within 1 hour of DCD kidney storage, and remained consistently high during 72 hour period, indicating oxidative metabolic turnover right from the start of storage period (FIG. 30E ). It must be noted that pCO2, an indicator of dissolved CO2, does not change in Somah or UW solution in the absence of organs (not shown). Probability of bicarbonates present in Somah contributing to increase in pCO2 was negated by the fact that HCO3— concentration remained mostly unaltered (4.86 mM/L) during 72 hour storage. Conversely, HCO3— concentration decreased from 6.30 to 4.33 mM/L in UW during 72 hour storage that may have contributed to the non-significant increase in pCO2 (FIG. 30E ). - High-energy phosphates in stored kidneys. The UW kidney tissue ATP. Creatine Phosphate (CP) and total HEP concentrations decreased linearly and significantly (p<0.05) during hypothermic storage. HEP dropped by 20% within six hours (
FIG. 31 ), with a net decrease of 45% at the end of 72 hour storage. In contrast, ATP, CP and total HEP levels did not change appreciably in Somah kidneys, and any decrease in ATP was compensated with a parallel increase in CP concentration, thus maintaining superior total energy levels in renal tissue during storage. - Markers of vascular endothelial function. The expression of caveolin, eNOS, vWF and EPO was well preserved in DCD kidneys preserved in Somah, during the entire storage period (
FIG. 32 ). In contrast, while expression of caveolin protein was unaltered in UW-preserved kidneys as well, there was time-dependent decrease in expression of eNOS, vWF and EPO, indicative of possible renal tissue damage. - Being one of the most resistant internal organs to ischemia, use of kidneys from deceased (DCD) donors for transplantation has been commonly practiced worldwide (Being one of the most resistant internal organs to ischemia, use of kidneys from deceased (DCD) donors for transplantation has been commonly practiced worldwide (Morrissey P E, Monaco A P (2014) Donation after circulatory death: Current practices, ongoing challenges, and potential improvements. Transplantation 97: 258-264). While DCD pool of kidneys is still highly underutilized, prognosis of DCD kidneys upon transplantation is associated with an observably increased incidence of DOF, PNF and lowered graft life expectancy in recipients. Without being bound to theory, the results of the present study suggest that by maintaining energy levels in DCD kidneys during storage using Somah, subtle damage at cellular levels can be avoided.
- The results show that UW-preserved kidneys display patchy areas of discoloration within a few minutes of organ perfusion with UW, upon harvesting, and did not resolve during 72 hour storage. In contrast, Somah-preserved kidneys remained uniform in their external morphology at all time-points. While Somah has a viscosity close to that of normal saline, UW is characterized by a much higher viscosity due to hydroxyl-ethyl starch (HES: Table 6-1) (Collins G M, Wicomb W N (1992) New organ preservation solutions. Kidney Int Suppl 38: S197-S202). While HES helps to prevent organ edema during storage, it increases solution density that can interfere with perfusion of all parts of the organ. Although gross morphology is not the best indicator of organ viability, it is probable that an uneven perfusion of kidneys during harvesting, despite copious use of solution for perfusion, could have resulted in patchy discoloration of kidneys, due to greater UW viscosity (
FIG. 29 ). - Renal histopathology showed no gross ultrastructural changes in either cortical or medullary regions of UW or Somah-stored kidneys. However, higher magnifications revealed subtle changes in cellular nuclei, especially in tubular epithelial cells, characterized by loss of nuclear heterochromacity with increased hyperchromacity, significantly greater in UW-stored kidneys. This is consistent with an inadequacy of UW to reach all parts of kidneys (vide supra), while Somah reached effectively and provided necessary nutrients to tissues in their entirety during harvesting and extracorporeal storage, thus avoiding development of minor lesions and may potentially improve the post-transplant outcomes. Despite better endurance of renal tissue in Somah, Somah pH was more acidotic, compared to UW, at all time-points. While acidic pH is reported to be constitutively beneficial to hepatocytes, sinusoidal epithelial cells as well as cardiomyocytes (Lemasters J J, Bond J M, Currin R T, Nieminen A L, Caldwell-Kenkel (1993) Reperfusion Injury to Heart and Liver Cell: Protection by acidosis during ischemia and a ‘pH paradox’ during reperfusion. In: Hochachka P W, Lutz P L, Sick TJ, Rosenthal M (eds) Surviving Hypoxia: Mechanisms of Control and Adaptation. CRC Press, Inc, Florida 495-508), this is the first report showing advantage of a relatively acidic environment in extracorporeal kidney preservation.
- Glucose, an important energy source for highly metabolic renal tissue, was excluded from kidney preservation solutions used in current practice as it was thought to cause edema by enhanced lactate accumulation, a product of anaerobic metabolism during extracorporeal storage (Kallerhoff M, Holscher M, Kehrer G, Klab G, Bretschneider H J (1985) Effects of preservation conditions and temperature on tissue acidification in canine kidneys. Transplantation 485-489). UW, a commonly used solution for renal storage, does not contain any glucose either. However, that glucose is an important energy source during extracorporeal renal storage was demonstrated by an endogenous increase in glucose levels in UW, likely due to renal glycogenolysis, and a corresponding fall in glucose levels in Somah, which innately contains high concentration of glucose (Table 6-1). However, even after prolonged storage of kidneys in Somah, development of edema was not observed by gross or histological examination, contrary to previous studies involving other solutions (Kallerhoff M. Blech M. Kehrer G, Kleinert H, Langheinrich M, et al. (1987) Effects of glucose in protected ischemic kidneys. Urol Res 15: 215-222).
- After 72 hour kidney storage, UW demonstrated substantial rise in deleterious lactate levels that remained low at all time-points in Somah (
FIG. 30C ), despite metabolism (anaerobic and aerobic) of glucose, leading to corresponding maintenance of tissue HEP in Somah kidneys (FIG. 31 ). Aerobic oxidative phosphorylation activity in Somah kidneys was confirmed by observed increase in metabolic CO2 in Somah during storage. This was an expected result; as Somah also contains dichloroacetate (DCA), a compound that increases the activity of pyruvate dehydrogenase complex thus enhancing conversion of pyruvate to acetyl-CoA, preventing accumulation of lactate (Shangraw R E, Winter R. Hromco J, Robinson S T, Gallaher E J (1994) Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. Anesthesiology 81: 1127-1138) confirming observations in hearts and livers stored in Somah (Thatte H S, Rousou L. Hussaini B E, Lu X G, Treanor P R, et al. (2009) Development and evaluation of a novel solution, Somah, for the procurement and preservation of beating and non-beating donor hearts for transplantation. Circulation 20: 1704-1713). Furthermore, without being bound to theory, DCA, by virtue of its vessel-preservation abilities, may help prevent development of post-transplant renal artery stenosis, and further improve prognosis of transplanted DCD kidneys (Deuse T, Hua X, Wang D, Maegdefessel L. Heeren J, et al. (2014) Dicholoroacetate prevents restenosis in preclinical animal models of vessel injury. Nature 509: 641-644). - A significant loss of energy state (HEP) in explanted organs during storage leads to irreversible degenerative changes in the organ (Vajdova K, Graf R, Clavien P A (2002) ATP-supplies in the coldpreserved liver: a long-neglected factor of organ viability. Hepatology 36: 1543-1551). It is thus imperative for preservative solution to maintain organ in homeostasis and/or allow it to recover during extended storage by modulating organs metabolic pathways. Despite potential glycogenolysis-dependent increase in glucose concentration in UW during storage (
FIG. 30B ), a significant depletion of renal HEP stores was apparent, in contrast to obvious preservation of energy state in Somah kidneys (FIG. 31 ). This suggests that UW kidneys were highly catabolic, leading to loss of HEP's and tissue injury, (FIG. 29 ). In contrast, greater oxidative phosphorylation of glucose in Somah-stored kidneys, facilitates greater HEP generation (for equivalent glucose molecules), than by anaerobic glycolysis alone thus enhancing the organs energy state during storage. Without being bound to theory, the low HEP levels observed in DCD UW-kidneys, could predictably result in delayed graft function (DGF) at the least, and even primary non-function (PNF). Therefore, despite the predominant use as preservation solution for explanted kidneys, UW may not provide optimal conditions for extended storage of DCD (or BHD) kidneys. In contrast, preservation in Somah may provide a viable alternative. - The blood vessels (capillaries) form the bulk of renal cortical tissue while tubular structures predominate in renal medulla. While glomerular tuft collapse within 6 hour storage in Ilistidine-Tryptophan-Ketoglutarate (IITK) solution has been reported (Kallerhoff M, Blech M, Kehrer G, Kleinert H, Langheinrich M, et al. (1987) Effects of glucose in protected ischemic kidneys. Urol Res 15: 215-222), such drastic glomerular change was not observed in either Somah or UW stored kidneys, at any timepoint (
FIG. 29 ). However, a steady decline in expression of eNOS (important in vasomotor function), von-Willebrands factor (vWF; marker for blood vessel endothelium) and erythropoietin (EPO; marker of specialized peritubular epithelial cells), during 72 hour DCD kidney storage in UW, suggests subtle damage to both vascular and tubular structures (FIG. 32 ). This is consistent with histological findings of increase in tubular nuclear hyperchromacity observed in UWstored kidneys. In contrast, the expression of all investigated proteins including caveolin, eNOS, vWF and EPO were unaltered during the same periods of observation in Somrah-preserved kidneys suggesting both cortical and tubular renal tissue preservation. - This Example provides evidence that use of Somah for static preservation of DCD kidneys may potentially decrease the incidence of DGF, PNF and improve graft life upon transplantation.
Claims (32)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/735,089 US20190082678A1 (en) | 2015-06-09 | 2016-06-09 | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562173184P | 2015-06-09 | 2015-06-09 | |
PCT/US2016/036738 WO2016201126A1 (en) | 2015-06-09 | 2016-06-09 | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures |
US15/735,089 US20190082678A1 (en) | 2015-06-09 | 2016-06-09 | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190082678A1 true US20190082678A1 (en) | 2019-03-21 |
Family
ID=57504230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/735,089 Abandoned US20190082678A1 (en) | 2015-06-09 | 2016-06-09 | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures |
Country Status (9)
Country | Link |
---|---|
US (1) | US20190082678A1 (en) |
EP (1) | EP3310161A4 (en) |
JP (1) | JP2018521027A (en) |
CN (1) | CN108366552A (en) |
AU (1) | AU2016274769A1 (en) |
BR (1) | BR112017026671A2 (en) |
CA (1) | CA2988974A1 (en) |
HK (1) | HK1251947A1 (en) |
WO (1) | WO2016201126A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114052008A (en) * | 2021-11-23 | 2022-02-18 | 中山大学附属第三医院(中山大学肝脏病医院) | Preserving fluid and application thereof |
WO2023201038A1 (en) * | 2022-04-15 | 2023-10-19 | Marizyme, Inc. | Powder formulations and use thereof in medical and/or surgical procedures |
WO2023224887A1 (en) * | 2022-05-16 | 2023-11-23 | Marizyme, Inc. | Use of cytoprotectant formulations in cell or tissue transport and/or storage |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107509722B (en) * | 2017-08-30 | 2020-11-10 | 迈克生物股份有限公司 | Specimen preservation solution |
WO2020122928A1 (en) * | 2018-12-14 | 2020-06-18 | National Taiwan University | A stable cardioplegic solution for cardiac surgery |
TWI781262B (en) * | 2018-12-14 | 2022-10-21 | 國立臺灣大學 | A stable cardioplegic solution for cardiac surgery |
CN109486747A (en) * | 2018-12-24 | 2019-03-19 | 成都清科生物科技有限公司 | A kind of mescenchymal stem cell recovery protection liquid, preparation method and method for resuscitation |
EP3920846A4 (en) * | 2019-02-06 | 2022-11-09 | The Board and Trustees of the Leland Stanford Junior University | Biologically modified vascular grafts for improved bypass surgery outcomes |
WO2020168191A1 (en) * | 2019-02-14 | 2020-08-20 | North Grove Investments, Inc. | Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof |
WO2023162065A1 (en) * | 2022-02-24 | 2023-08-31 | Blue Industries株式会社 | Biological sample preservative, production method of biological sample preservative, preservation method of biological sample, and kit for preserving biological sample |
KR102463256B1 (en) * | 2022-05-02 | 2022-11-07 | 주식회사 프롬바이오 | Composition for Low-temperatuer Preservation or Cryopreservation of Fat Tissue Using Caffeine, etc. and the Preservation Method of Fat Tissue Using the Same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611830B2 (en) * | 2000-04-10 | 2009-11-03 | The United States Of America As Represented By The Department Of Veteran's Affairs | Device to lavage a blood vessel |
JP2008519830A (en) * | 2004-11-12 | 2008-06-12 | ドールザンド・エアドライブ・ビー.ブイ. | Composition for cold preservation and perfusion of organs |
CN105123670B (en) * | 2007-02-17 | 2018-12-14 | 哈佛学院董事会 | For carrying out the composition and method of tissue preserration |
AU2015201137B2 (en) * | 2007-02-17 | 2016-07-14 | President And Fellows Of Harvard College | Compositions and method for tissue preservation |
PE20151426A1 (en) * | 2012-12-31 | 2015-09-18 | Somahlution Llc | SOLUTION TO PRESERVE VASCULAR DUCTS |
-
2016
- 2016-06-09 JP JP2017563995A patent/JP2018521027A/en active Pending
- 2016-06-09 WO PCT/US2016/036738 patent/WO2016201126A1/en unknown
- 2016-06-09 US US15/735,089 patent/US20190082678A1/en not_active Abandoned
- 2016-06-09 AU AU2016274769A patent/AU2016274769A1/en not_active Abandoned
- 2016-06-09 EP EP16808306.1A patent/EP3310161A4/en not_active Withdrawn
- 2016-06-09 BR BR112017026671A patent/BR112017026671A2/en not_active Application Discontinuation
- 2016-06-09 CA CA2988974A patent/CA2988974A1/en not_active Abandoned
- 2016-06-09 CN CN201680046574.XA patent/CN108366552A/en active Pending
-
2018
- 2018-09-03 HK HK18111279.9A patent/HK1251947A1/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114052008A (en) * | 2021-11-23 | 2022-02-18 | 中山大学附属第三医院(中山大学肝脏病医院) | Preserving fluid and application thereof |
WO2023201038A1 (en) * | 2022-04-15 | 2023-10-19 | Marizyme, Inc. | Powder formulations and use thereof in medical and/or surgical procedures |
WO2023224887A1 (en) * | 2022-05-16 | 2023-11-23 | Marizyme, Inc. | Use of cytoprotectant formulations in cell or tissue transport and/or storage |
Also Published As
Publication number | Publication date |
---|---|
EP3310161A1 (en) | 2018-04-25 |
AU2016274769A1 (en) | 2018-01-18 |
CA2988974A1 (en) | 2016-12-15 |
CN108366552A (en) | 2018-08-03 |
JP2018521027A (en) | 2018-08-02 |
HK1251947A1 (en) | 2019-05-03 |
EP3310161A4 (en) | 2019-02-20 |
BR112017026671A2 (en) | 2018-08-14 |
WO2016201126A1 (en) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190082678A1 (en) | Compositions and methods for tissue preservation at ambient or subnormothermic temperatures | |
US8288084B2 (en) | Composition and method for flushing and cold/cryo preserving organs, tissues, and cells | |
Hicks et al. | Organ preservation | |
US9603354B2 (en) | Protective solutions for organs | |
US9060507B2 (en) | Perfusion solution | |
EP3128836B1 (en) | Modulation of calcium ion homeostasis in harvested transplantable hearts | |
US11033021B2 (en) | Composition and solution with controlled calcium ion level, and related method and use for reperfusion | |
Lowalekar et al. | Sub-normothermic preservation of donor hearts for transplantation using a novel solution, SOMAH: a comparative pre-clinical study | |
US20240090494A1 (en) | Perfusion solution | |
Lowalekar et al. | Subnormothermic preservation in somah: a novel approach for enhanced functional resuscitation of donor hearts for transplant | |
Finger | Organ preservation | |
AU2015336862A1 (en) | Novel composition and solution with controlled calcium ion level, and related method and use for reperfusion | |
US20100311035A1 (en) | Preservation solution for organs and biological tissues | |
KR100304594B1 (en) | Composition for the Preservation of Organs and Blood Cells | |
Kraft et al. | CPA toxicity screening of cryoprotective solutions in rat hearts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHU Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THATTE, HEMANT S.;REEL/FRAME:045769/0525 Effective date: 20170622 Owner name: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THATTE, HEMANT S.;REEL/FRAME:045769/0525 Effective date: 20170622 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |